JP6276762B2 - キナーゼ阻害剤として活性な置換ピロール類 - Google Patents
キナーゼ阻害剤として活性な置換ピロール類 Download PDFInfo
- Publication number
- JP6276762B2 JP6276762B2 JP2015524721A JP2015524721A JP6276762B2 JP 6276762 B2 JP6276762 B2 JP 6276762B2 JP 2015524721 A JP2015524721 A JP 2015524721A JP 2015524721 A JP2015524721 A JP 2015524721A JP 6276762 B2 JP6276762 B2 JP 6276762B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyrrole
- chloro
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003233 pyrroles Chemical class 0.000 title description 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 756
- 238000000034 method Methods 0.000 claims description 275
- -1 1H-pyrazolo [3,4-d] pyrimidin-4-yl Chemical group 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 53
- 125000006239 protecting group Chemical group 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 38
- 150000001412 amines Chemical class 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 238000005859 coupling reaction Methods 0.000 claims description 17
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- JGAJIFPYCFEXCC-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(N)C=2)N1 JGAJIFPYCFEXCC-UHFFFAOYSA-N 0.000 claims description 7
- QLTOLEGOZASZTK-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(N)C=2)N1 QLTOLEGOZASZTK-UHFFFAOYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- DCECDNWVAPZULO-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3CCNC=3N=CN=2)=C1 DCECDNWVAPZULO-UHFFFAOYSA-N 0.000 claims description 6
- OLROTZLJQKXALJ-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3C=CNC=3N=CN=2)=C1 OLROTZLJQKXALJ-UHFFFAOYSA-N 0.000 claims description 6
- AQIROXWVNRWNRS-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2N=CN=C(NC)C=2)=C1 AQIROXWVNRWNRS-UHFFFAOYSA-N 0.000 claims description 6
- GIRPYPOYZZTUCA-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3CCNC=3N=CN=2)=C1 GIRPYPOYZZTUCA-UHFFFAOYSA-N 0.000 claims description 6
- ZMEBQCWGPNPVIQ-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2C=3NC=NC=3N=CN=2)=CN1C1=CC(C(F)(F)F)=CC=C1Cl ZMEBQCWGPNPVIQ-UHFFFAOYSA-N 0.000 claims description 6
- LSPIMHPSWRNVOM-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2C=3C=CNC=3N=CN=2)=CN1C1=CC(C(F)(F)F)=CC=C1Cl LSPIMHPSWRNVOM-UHFFFAOYSA-N 0.000 claims description 6
- MKQFWNKDBIRKBB-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C=3C=CNC=3N=CN=2)N1 MKQFWNKDBIRKBB-UHFFFAOYSA-N 0.000 claims description 6
- BZBJYYHYWHLUBK-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(NC)C=2)N1 BZBJYYHYWHLUBK-UHFFFAOYSA-N 0.000 claims description 6
- URLRGLNLWAAQBP-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-n-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2C=3C=CNC=3N=CN=2)N1 URLRGLNLWAAQBP-UHFFFAOYSA-N 0.000 claims description 6
- XBTXHNPXZFHTCK-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-n-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2N=CN=C(NC)C=2)N1 XBTXHNPXZFHTCK-UHFFFAOYSA-N 0.000 claims description 6
- JTSNOEPPKSJTRM-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NC=C2)C JTSNOEPPKSJTRM-UHFFFAOYSA-N 0.000 claims description 6
- LTPXTDBFKQWZGD-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(Cl)C=2)C)=N1 LTPXTDBFKQWZGD-UHFFFAOYSA-N 0.000 claims description 6
- WBDBHDDZPYVBEA-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2C=3C=CNC=3N=CN=2)NC=1C1=CC(C(F)(F)F)=CC=C1Cl WBDBHDDZPYVBEA-UHFFFAOYSA-N 0.000 claims description 6
- CTIWZQQLUVHPMM-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(C=2)C(F)(F)F)Cl)=N1 CTIWZQQLUVHPMM-UHFFFAOYSA-N 0.000 claims description 6
- MHMDWDJIIHJUDF-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C=3C=CNC=3N=CN=2)N1 MHMDWDJIIHJUDF-UHFFFAOYSA-N 0.000 claims description 6
- RJOWGBLWKKDTDG-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(NC)C=2)N1 RJOWGBLWKKDTDG-UHFFFAOYSA-N 0.000 claims description 6
- PTDTVIAKMSNLIE-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-n-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(=O)NC)C=C(C=2C=3C=CNC=3N=CN=2)N1 PTDTVIAKMSNLIE-UHFFFAOYSA-N 0.000 claims description 6
- FVPNPZLCSGCTTC-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-n-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(=O)NC)C=C(C=2N=CN=C(NC)C=2)N1 FVPNPZLCSGCTTC-UHFFFAOYSA-N 0.000 claims description 6
- GUSLOEWIZUYDTG-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C=3C=CNC=3N=CN=2)N1 GUSLOEWIZUYDTG-UHFFFAOYSA-N 0.000 claims description 6
- PEZCZVVGBCSRDD-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)NC(C=2C=3C=CNC=3N=CN=2)=C1 PEZCZVVGBCSRDD-UHFFFAOYSA-N 0.000 claims description 6
- ZYYHRQWVJBHYER-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-n-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)NC(C=2C=3C=CNC=3N=CN=2)=C1 ZYYHRQWVJBHYER-UHFFFAOYSA-N 0.000 claims description 6
- LEVQVJSXOOHXKL-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)NC(C=2C=3C=CNC=3N=CN=2)=C1 LEVQVJSXOOHXKL-UHFFFAOYSA-N 0.000 claims description 6
- NGFDNYMTMUQQGJ-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-n-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(C=2C=3C=CNC=3N=CN=2)=CC=1C1=CC(Cl)=CC=C1C NGFDNYMTMUQQGJ-UHFFFAOYSA-N 0.000 claims description 6
- XMVJNAGLHNAYFM-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)NC(C=2C=3C=CNC=3N=CN=2)=C1 XMVJNAGLHNAYFM-UHFFFAOYSA-N 0.000 claims description 6
- RKUFUTNRBJSUDP-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=CN(C=2C=3C=CNC=3N=CN=2)C=C1C(N)=O RKUFUTNRBJSUDP-UHFFFAOYSA-N 0.000 claims description 6
- SFODGATVPKMEPG-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-(5-chloro-2-ethylphenyl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2N=CN=C(N)C=2)=C1 SFODGATVPKMEPG-UHFFFAOYSA-N 0.000 claims description 6
- FMMZEGNEDFXJGY-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C(N)=O)=CC(C=2N=CN=C(N)C=2)=C1 FMMZEGNEDFXJGY-UHFFFAOYSA-N 0.000 claims description 6
- XTXFMIZIDJTEIT-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)C=C(C=2N=CN=C(N)C=2)N1 XTXFMIZIDJTEIT-UHFFFAOYSA-N 0.000 claims description 6
- JZMMLUAZRAWSND-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-hydroxyethyl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C(N1CCO)=C(C(N)=O)C=C1C1=CC(N)=NC=N1 JZMMLUAZRAWSND-UHFFFAOYSA-N 0.000 claims description 6
- VXKNGQTXNFKVEX-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2N=CN=C(N)C=2)NC=1C1=CC(C(F)(F)F)=CC=C1Cl VXKNGQTXNFKVEX-UHFFFAOYSA-N 0.000 claims description 6
- LWBXZXZAHVCFLN-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(N)C=2)N1 LWBXZXZAHVCFLN-UHFFFAOYSA-N 0.000 claims description 6
- DFCSTASJIDSDPI-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(=O)NC)C=C(C=2N=CN=C(N)C=2)N1 DFCSTASJIDSDPI-UHFFFAOYSA-N 0.000 claims description 6
- KQXFSYYJWUNORW-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2N=CN=C(N)C=2)N1 KQXFSYYJWUNORW-UHFFFAOYSA-N 0.000 claims description 6
- ARPAPRSMYXHOTK-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(C=2NC(=C(C(N)=O)C=2)C=2C(=CC=C(C=2)C(F)(F)F)C)=N1 ARPAPRSMYXHOTK-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 6
- HQOVYDWBZKNRFQ-UHFFFAOYSA-N n-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C=3C=CNC=3N=CN=2)NC=1C1=CC(C(F)(F)F)=CC=C1C HQOVYDWBZKNRFQ-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- PJWBRBZXFHTCLK-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1-(2-hydroxyethyl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)N(CCO)C(C=2N=CN=C(N)C=2)=C1 PJWBRBZXFHTCLK-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- OYFHYNGYRZEOJP-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3C=CNC=3N=CN=2)=C1 OYFHYNGYRZEOJP-UHFFFAOYSA-N 0.000 claims description 3
- UWLNMZKXFIIUBR-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-n-methyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(=O)NC)NC(C=2C=3C=CNC=3N=CN=2)=C1 UWLNMZKXFIIUBR-UHFFFAOYSA-N 0.000 claims description 3
- GVCLNACSYKYUHP-UHFFFAOYSA-N 4-amino-7-(2-hydroxyethoxymethyl)pyrrolo[2,3-d]pyrimidine-5-carbothioamide Chemical compound C1=NC(N)=C2C(C(=S)N)=CN(COCCO)C2=N1 GVCLNACSYKYUHP-UHFFFAOYSA-N 0.000 claims description 3
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 claims description 3
- 102000042838 JAK family Human genes 0.000 claims description 3
- 108091082332 JAK family Proteins 0.000 claims description 3
- 238000011319 anticancer therapy Methods 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000004952 protein activity Effects 0.000 claims description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 3
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000006315 carbonylation Effects 0.000 claims 1
- 238000005810 carbonylation reaction Methods 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 164
- 238000005481 NMR spectroscopy Methods 0.000 description 162
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 116
- 239000000243 solution Substances 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 94
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 85
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- LQSJUQMCZHVKES-UHFFFAOYSA-N 6-iodopyrimidin-4-amine Chemical compound NC1=CC(I)=NC=N1 LQSJUQMCZHVKES-UHFFFAOYSA-N 0.000 description 73
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 72
- 239000011541 reaction mixture Substances 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 62
- 239000011734 sodium Substances 0.000 description 62
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 239000002904 solvent Substances 0.000 description 39
- 238000003818 flash chromatography Methods 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
- 229910052786 argon Inorganic materials 0.000 description 31
- 239000012267 brine Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- 238000003756 stirring Methods 0.000 description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 29
- 101100441092 Danio rerio crlf3 gene Proteins 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- WZVLJUBTIWFTIE-UHFFFAOYSA-N 6-chloro-n-methylpyrimidin-4-amine Chemical compound CNC1=CC(Cl)=NC=N1 WZVLJUBTIWFTIE-UHFFFAOYSA-N 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- DPPLCQFHORWGCK-UHFFFAOYSA-N 4-chloro-7-[(4-methoxyphenyl)methyl]-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(OC)=CC=C1CN1C(N=CN=C2Cl)=C2CC1 DPPLCQFHORWGCK-UHFFFAOYSA-N 0.000 description 23
- ONTLBVKRDUFQFP-UHFFFAOYSA-N 4-chloropyrrolo[2,1-f][1,2,4]triazine Chemical compound ClC1=NC=NN2C=CC=C12 ONTLBVKRDUFQFP-UHFFFAOYSA-N 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- OECXPHCYXVJWRZ-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-2-carboxylate Chemical compound CCOC(=O)c1c(ccn1S(=O)(=O)c1ccccc1)-c1cc(ccc1Cl)C(F)(F)F OECXPHCYXVJWRZ-UHFFFAOYSA-N 0.000 description 20
- NHTIHPIJNHNKMF-UHFFFAOYSA-N 5-bromo-2-[2-chloro-5-(trifluoromethyl)phenyl]-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound C[Si](C)(C)CCOCN1C(Br)=CC(C#N)=C1C1=CC(C(F)(F)F)=CC=C1Cl NHTIHPIJNHNKMF-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 18
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 17
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000010410 layer Substances 0.000 description 17
- YWBDBLXIRAQZIH-UHFFFAOYSA-N 2-[(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1Cl YWBDBLXIRAQZIH-UHFFFAOYSA-N 0.000 description 16
- RFNFCCVFHGFRAA-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(C=2C(=CNC=2)C#N)=C1 RFNFCCVFHGFRAA-UHFFFAOYSA-N 0.000 description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- NHUNXJZNNPIVCF-UHFFFAOYSA-N 4-bromo-1-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(N2C(=CC(Br)=C2)C#N)=C1 NHUNXJZNNPIVCF-UHFFFAOYSA-N 0.000 description 14
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 11
- JQNLSVGJRUOZMR-UHFFFAOYSA-N 6-chloro-9-[(4-methoxyphenyl)methyl]purine Chemical compound C1=CC(OC)=CC=C1CN1C2=NC=NC(Cl)=C2N=C1 JQNLSVGJRUOZMR-UHFFFAOYSA-N 0.000 description 11
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 11
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 11
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- ICFKRRZWSUVSMH-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxylate Chemical compound CCOC(=O)c1c(ccn1S(=O)(=O)c1ccccc1)-c1cc(ccc1C)C(F)(F)F ICFKRRZWSUVSMH-UHFFFAOYSA-N 0.000 description 11
- YMIPWMDLRUKHCC-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-phenylpyrrole-2-carboxylate Chemical compound CCOC(=O)C1=C(C=2C=CC=CC=2)C=CN1S(=O)(=O)C1=CC=CC=C1 YMIPWMDLRUKHCC-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 150000002367 halogens Chemical group 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 10
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- YAASWOUUIIRMAA-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=CN1COCC[Si](C)(C)C YAASWOUUIIRMAA-UHFFFAOYSA-N 0.000 description 9
- HJYIKRLPDIITKV-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)O HJYIKRLPDIITKV-UHFFFAOYSA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 101150003085 Pdcl gene Proteins 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 102000001253 Protein Kinase Human genes 0.000 description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- GPGRARCBCBBBFH-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxylate Chemical compound CCOC(=O)C1=C(C=2C(=CC=C(C=2)C(F)(F)F)CC)C=CN1S(=O)(=O)C1=CC=CC=C1 GPGRARCBCBBBFH-UHFFFAOYSA-N 0.000 description 9
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 9
- 239000004533 oil dispersion Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 108060006633 protein kinase Proteins 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 8
- VTXFSTRBQFCMOI-UHFFFAOYSA-N 4-bromo-1-(5-chloro-2-ethylphenyl)pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1N1C(C#N)=CC(Br)=C1 VTXFSTRBQFCMOI-UHFFFAOYSA-N 0.000 description 8
- OTNCLKVFAAYVBB-UHFFFAOYSA-N 4-bromo-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(Br)=C1 OTNCLKVFAAYVBB-UHFFFAOYSA-N 0.000 description 8
- SJWYIFAILOWQTO-UHFFFAOYSA-N 4-bromo-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(Br)=C1 SJWYIFAILOWQTO-UHFFFAOYSA-N 0.000 description 8
- KLTHGFVAJMWMPP-UHFFFAOYSA-N 4-bromo-1-phenylpyrrole-2-carbonitrile Chemical compound C1=C(Br)C=C(C#N)N1C1=CC=CC=C1 KLTHGFVAJMWMPP-UHFFFAOYSA-N 0.000 description 8
- ZHZVGDWSCRDCRJ-UHFFFAOYSA-N 5-bromo-2-(5-chloro-2-ethylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound BrC1=CC(=C(N1COCC[Si](C)(C)C)C1=C(C=CC(=C1)Cl)CC)C#N ZHZVGDWSCRDCRJ-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RNUCFBHSNVDALQ-UHFFFAOYSA-N ethyl 5-(6-aminopyrimidin-4-yl)-1-(benzenesulfonyl)-3-(5-chloro-2-methylphenyl)pyrrole-2-carboxylate Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C(C(=O)OCC)=C(C=2C(=CC=C(Cl)C=2)C)C=C1C1=CC(N)=NC=N1 RNUCFBHSNVDALQ-UHFFFAOYSA-N 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- LIIJWRRSLMDWPN-UHFFFAOYSA-N methyl 1-(benzenesulfonyl)-2-(5-chloro-2-ethylphenyl)pyrrole-3-carboxylate Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)OC)C=CN1S(=O)(=O)C1=CC=CC=C1 LIIJWRRSLMDWPN-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- BVFZVCUVMMWSOL-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound Cc1ccc(Cl)cc1-c1c(cc(B2OC(C)(C)C(C)(C)O2)n1COCC[Si](C)(C)C)C#N BVFZVCUVMMWSOL-UHFFFAOYSA-N 0.000 description 7
- ZPCYOBGUULWTRD-UHFFFAOYSA-N 2-[(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)N=CC2=C1Cl ZPCYOBGUULWTRD-UHFFFAOYSA-N 0.000 description 7
- DGGPFZCXEMWEJF-UHFFFAOYSA-N 4-bromo-1-(5-chloro-2-methylphenyl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1N1C(C#N)=CC(Br)=C1 DGGPFZCXEMWEJF-UHFFFAOYSA-N 0.000 description 7
- PIJFKYPWDFYYCA-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2N=CN=C(N)C=2)N1 PIJFKYPWDFYYCA-UHFFFAOYSA-N 0.000 description 7
- PLTAYJYXBYZMAW-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C(N1COCC[Si](C)(C)C)=C(C#N)C=C1C1=CC(N)=NC=N1 PLTAYJYXBYZMAW-UHFFFAOYSA-N 0.000 description 7
- NUKVKJNOZRDQHY-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1h-pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)NC(C=2N=CN=C(N)C=2)=C1 NUKVKJNOZRDQHY-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 0 CC1(C)OB(c2c(C)c(C(*)=O)c(*)[n]2*)OC1(C)C Chemical compound CC1(C)OB(c2c(C)c(C(*)=O)c(*)[n]2*)OC1(C)C 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- NXNQJSRXYYMOJP-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-(5-chloro-2-ethylphenyl)pyrrole-2-carboxylate Chemical compound CCOC(=O)C1=C(C=2C(=CC=C(Cl)C=2)CC)C=CN1S(=O)(=O)C1=CC=CC=C1 NXNQJSRXYYMOJP-UHFFFAOYSA-N 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- QYSNJZIFFSQORI-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrole-2-carbonitrile Chemical compound CC1(C)OB(OC1(C)C)c1cc(C#N)n(c1)-c1cc(ccc1Cl)C(F)(F)F QYSNJZIFFSQORI-UHFFFAOYSA-N 0.000 description 6
- MKXFVYLKTGXZES-UHFFFAOYSA-N 2-iodopyrimidin-4-amine Chemical compound NC1=CC=NC(I)=N1 MKXFVYLKTGXZES-UHFFFAOYSA-N 0.000 description 6
- PMNLSKBKSYEQRH-UHFFFAOYSA-N 5-bromo-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=C(Br)N1COCC[Si](C)(C)C PMNLSKBKSYEQRH-UHFFFAOYSA-N 0.000 description 6
- CHUQSUOLNQXNTO-UHFFFAOYSA-N 5-bromo-2-[2-methyl-5-(trifluoromethyl)phenyl]-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=C(Br)N1COCC[Si](C)(C)C CHUQSUOLNQXNTO-UHFFFAOYSA-N 0.000 description 6
- QFWPQIGPNUXCLZ-UHFFFAOYSA-N 5-bromo-2-phenyl-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound C[Si](C)(C)CCOCN1C(Br)=CC(C#N)=C1C1=CC=CC=C1 QFWPQIGPNUXCLZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- ZTNVCLBNCFGIHR-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-2-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrole-3-carboxylate Chemical compound C=1C=CC=CC=1S(=O)(=O)N1C(C=2C=CC=CC=2)=C(C(=O)OCC)C=C1B1OC(C)(C)C(C)(C)O1 ZTNVCLBNCFGIHR-UHFFFAOYSA-N 0.000 description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- IKJSKQYLSATHPY-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=CNC=C1C#N IKJSKQYLSATHPY-UHFFFAOYSA-N 0.000 description 5
- RPLFDDTUHBRVGN-UHFFFAOYSA-N 4-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CNC=C1C#N RPLFDDTUHBRVGN-UHFFFAOYSA-N 0.000 description 5
- BMMCNKYHQAKJBN-UHFFFAOYSA-N 4-phenyl-1h-pyrrole-3-carbonitrile Chemical compound N#CC1=CNC=C1C1=CC=CC=C1 BMMCNKYHQAKJBN-UHFFFAOYSA-N 0.000 description 5
- RYVXWZJVZPFCEE-UHFFFAOYSA-N 6-[5-(5-chloro-2-methylphenyl)-1h-pyrrol-3-yl]pyrimidin-4-amine Chemical compound CC1=CC=C(Cl)C=C1C1=CC(C=2N=CN=C(N)C=2)=CN1 RYVXWZJVZPFCEE-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008482 dysregulation Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- WBGURWAKCQAEQW-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C3=CC=CN3N=CN=2)=C1 WBGURWAKCQAEQW-UHFFFAOYSA-N 0.000 description 4
- PLNFZFIIWPZOJR-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2C=3C=NNC=3N=CN=2)=CN1C1=CC(C(F)(F)F)=CC=C1Cl PLNFZFIIWPZOJR-UHFFFAOYSA-N 0.000 description 4
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 4
- GXKCDKVSMGKKQG-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C#N)C=CN1 GXKCDKVSMGKKQG-UHFFFAOYSA-N 0.000 description 4
- LPKIJBLZODYRKV-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C=3C=CNC=3N=CC=2)N1 LPKIJBLZODYRKV-UHFFFAOYSA-N 0.000 description 4
- QSKJARKJVYIWIV-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CNC=C1C#N QSKJARKJVYIWIV-UHFFFAOYSA-N 0.000 description 4
- DRBOMSUDAODGRK-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2N=CN=C(N)C=2)N1 DRBOMSUDAODGRK-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- UHIDBPFJCZEHMM-UHFFFAOYSA-N tert-butyl 4-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)pyrrole-1-carboxylate Chemical compound Cc1ccc(Cl)cc1-c1cc(cn1C(=O)OC(C)(C)C)-c1cc(N)ncn1 UHIDBPFJCZEHMM-UHFFFAOYSA-N 0.000 description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 3
- PSZMTRRKARIKBT-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-(5-chloro-2-methylphenyl)pyrrole-3-carbonitrile Chemical compound NC1=CC(=NC=N1)N1C=C(C(=C1)C1=C(C=CC(=C1)Cl)C)C#N PSZMTRRKARIKBT-UHFFFAOYSA-N 0.000 description 3
- VTJXILNURWFKQV-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-(5-chloro-2-ethylphenyl)pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C#N)C=CN1S(=O)(=O)C1=CC=CC=C1 VTJXILNURWFKQV-UHFFFAOYSA-N 0.000 description 3
- HFEJENUTWBNNAD-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=CNC=C1C#N HFEJENUTWBNNAD-UHFFFAOYSA-N 0.000 description 3
- LSNFZRYSTREMDT-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2N=CN=C(N)C=2)=C1 LSNFZRYSTREMDT-UHFFFAOYSA-N 0.000 description 3
- LQNNJVRJHRFWIK-UHFFFAOYSA-N 4-chloro-1-ethyl-2-iodobenzene Chemical compound CCC1=CC=C(Cl)C=C1I LQNNJVRJHRFWIK-UHFFFAOYSA-N 0.000 description 3
- ZPEUDOWPJSXIPI-UHFFFAOYSA-N 5-bromo-2-(5-chloro-2-methylphenyl)-1-(2-trimethylsilylethoxymethyl)pyrrole-3-carbonitrile Chemical compound BrC1=CC(=C(N1COCC[Si](C)(C)C)C1=C(C=CC(=C1)Cl)C)C#N ZPEUDOWPJSXIPI-UHFFFAOYSA-N 0.000 description 3
- DDYTVUGYXUWXGN-UHFFFAOYSA-N 5-chloro-2-methylbenzaldehyde Chemical compound CC1=CC=C(Cl)C=C1C=O DDYTVUGYXUWXGN-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 108010010057 TYK2 Kinase Proteins 0.000 description 3
- 102000015774 TYK2 Kinase Human genes 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 102000036693 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- NNCJVJCTTLQQKA-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-3-(5-chloro-2-methylphenyl)pyrrole-2-carboxylate Chemical compound CCOC(=O)C1=C(C=2C(=CC=C(Cl)C=2)C)C=CN1S(=O)(=O)C1=CC=CC=C1 NNCJVJCTTLQQKA-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- QVJVLNUYSIEYEO-UHFFFAOYSA-N tert-butyl 2-(5-chloro-2-ethylphenyl)-4-iodopyrrole-1-carboxylate Chemical compound CCc1ccc(Cl)cc1-c1cc(I)cn1C(=O)OC(C)(C)C QVJVLNUYSIEYEO-UHFFFAOYSA-N 0.000 description 3
- GSRYFXMYOKWUMT-UHFFFAOYSA-N tert-butyl 2-[2-ethyl-5-(trifluoromethyl)phenyl]-4-iodopyrrole-1-carboxylate Chemical compound CCc1ccc(cc1-c1cc(I)cn1C(=O)OC(C)(C)C)C(F)(F)F GSRYFXMYOKWUMT-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- YRJOEPZAAQARFR-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3C=NNC=3N=CN=2)=C1 YRJOEPZAAQARFR-UHFFFAOYSA-N 0.000 description 2
- YIXYHFYBXPQGGF-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(7h-purin-6-yl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3NC=NC=3N=CN=2)=C1 YIXYHFYBXPQGGF-UHFFFAOYSA-N 0.000 description 2
- JVQOMNPLAVRLAJ-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2C=3C=CNC=3N=CN=2)=C1 JVQOMNPLAVRLAJ-UHFFFAOYSA-N 0.000 description 2
- XXKUYXPJFLRXEO-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=C2C(=NC=C1)NC=C2)C(=O)N)C XXKUYXPJFLRXEO-UHFFFAOYSA-N 0.000 description 2
- VUGMRWKRIYBHIM-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3C=NNC=3N=CN=2)=C1 VUGMRWKRIYBHIM-UHFFFAOYSA-N 0.000 description 2
- GXXMUASSRQBURG-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(7h-purin-6-yl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2C=3NC=NC=3N=CN=2)=C1 GXXMUASSRQBURG-UHFFFAOYSA-N 0.000 description 2
- DFBJUFDCBMYZJV-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2C=3C=CNC=3N=CN=2)=C1 DFBJUFDCBMYZJV-UHFFFAOYSA-N 0.000 description 2
- RPUKSLQLGFJALK-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carboxamide Chemical compound C1=NC(NC)=CC(C2=CN(C(C(N)=O)=C2)C=2C(=CC=C(Cl)C=2)C)=N1 RPUKSLQLGFJALK-UHFFFAOYSA-N 0.000 description 2
- LCPNDRXSKAUPSE-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N)C LCPNDRXSKAUPSE-UHFFFAOYSA-N 0.000 description 2
- MPXWPRMVXNYYDG-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N MPXWPRMVXNYYDG-UHFFFAOYSA-N 0.000 description 2
- GYDJNIUEBAEADW-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)N2C=C(C(=C2)C2=C(C=CC(=C2)C(F)(F)F)CC)C(=O)N GYDJNIUEBAEADW-UHFFFAOYSA-N 0.000 description 2
- XIWJWTCUENPILW-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)N2C=C(C(=C2)C2=C(C=CC(=C2)C(F)(F)F)C)C(=O)N XIWJWTCUENPILW-UHFFFAOYSA-N 0.000 description 2
- FWXZMZQRLPQFEY-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-phenylpyrrole-3-carbonitrile Chemical compound C1(=CC=CC=C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N FWXZMZQRLPQFEY-UHFFFAOYSA-N 0.000 description 2
- DTPDMSNDXUBGCH-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-phenylpyrrole-3-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)N2C=C(C(=C2)C2=CC=CC=C2)C(=O)N DTPDMSNDXUBGCH-UHFFFAOYSA-N 0.000 description 2
- XMRXGQBGIYANDV-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-(5-chloro-2-ethylphenyl)pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=CN(C=2N=CN=C(N)C=2)C=C1C#N XMRXGQBGIYANDV-UHFFFAOYSA-N 0.000 description 2
- FMHOMUDGGBYDNS-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-(5-chloro-2-methylphenyl)pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)N1C=C(C(=C1)C1=C(C=CC(=C1)Cl)C)C(=O)N FMHOMUDGGBYDNS-UHFFFAOYSA-N 0.000 description 2
- ZLWZUWVVMGZZAD-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound NC1=CC(=NC=N1)N1C=C(C(=C1)C1=C(C=CC(=C1)C(F)(F)F)Cl)C#N ZLWZUWVVMGZZAD-UHFFFAOYSA-N 0.000 description 2
- IRXJOAWOYMTRJZ-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)N1C=C(C(=C1)C1=C(C=CC(=C1)C(F)(F)F)Cl)C(=O)N IRXJOAWOYMTRJZ-UHFFFAOYSA-N 0.000 description 2
- XHSXYLWHAWTJGE-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CN(C=2N=CN=C(N)C=2)C=C1C#N XHSXYLWHAWTJGE-UHFFFAOYSA-N 0.000 description 2
- SJNAYKPQKOYZEU-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=CN(C=2N=CN=C(N)C=2)C=C1C(N)=O SJNAYKPQKOYZEU-UHFFFAOYSA-N 0.000 description 2
- ZFOYZHYNUGGMRB-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CN(C=2N=CN=C(N)C=2)C=C1C#N ZFOYZHYNUGGMRB-UHFFFAOYSA-N 0.000 description 2
- LESVOWQLJIMXOG-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=CN(C=2N=CN=C(N)C=2)C=C1C(N)=O LESVOWQLJIMXOG-UHFFFAOYSA-N 0.000 description 2
- BJNONRZUXYEXDH-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-phenylpyrrole-2-carbonitrile Chemical compound C1=NC(N)=CC(N2C(=CC(=C2)C=2C=CC=CC=2)C#N)=N1 BJNONRZUXYEXDH-UHFFFAOYSA-N 0.000 description 2
- WFXIINGFGNDXAO-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-4-phenylpyrrole-3-carboxamide Chemical compound NC(=O)C1=CN(C=2N=CN=C(N)C=2)C=C1C1=CC=CC=C1 WFXIINGFGNDXAO-UHFFFAOYSA-N 0.000 description 2
- ADPFCBOAGONWTC-UHFFFAOYSA-N 1-(benzenesulfonyl)-2-(5-chloro-2-ethylphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrole-3-carbonitrile Chemical compound CCc1ccc(Cl)cc1-c1c(cc(B2OC(C)(C)C(C)(C)O2)n1S(=O)(=O)c1ccccc1)C#N ADPFCBOAGONWTC-UHFFFAOYSA-N 0.000 description 2
- XBZJRNOJVSDTRZ-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-(5-chloro-2-ethylphenyl)pyrrole-2-carboxylic acid Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(O)=O)N(S(=O)(=O)C=2C=CC=CC=2)C=C1 XBZJRNOJVSDTRZ-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- XFPGJVFZNXREMJ-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N XFPGJVFZNXREMJ-UHFFFAOYSA-N 0.000 description 2
- ASRHEFMFBLHXTI-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(N2C(=CC(=C2)C=2C=3NC=NC=3N=CN=2)C#N)=C1 ASRHEFMFBLHXTI-UHFFFAOYSA-N 0.000 description 2
- ZNWHLGJQPUMRIN-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(N2C(=CC(=C2)C=2C=3C=CNC=3N=CN=2)C#N)=C1 ZNWHLGJQPUMRIN-UHFFFAOYSA-N 0.000 description 2
- AMZBOSKSWODSEE-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C(=O)N AMZBOSKSWODSEE-UHFFFAOYSA-N 0.000 description 2
- VHQMOTBXWLSZHS-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N VHQMOTBXWLSZHS-UHFFFAOYSA-N 0.000 description 2
- UAZQNWRNQVUKRW-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C#N UAZQNWRNQVUKRW-UHFFFAOYSA-N 0.000 description 2
- SXLDQRSHWYRDNN-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C(=O)N SXLDQRSHWYRDNN-UHFFFAOYSA-N 0.000 description 2
- UFHAKIDMTREDNF-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NC=C2)C#N UFHAKIDMTREDNF-UHFFFAOYSA-N 0.000 description 2
- CWCXAVDCSMJKIP-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N CWCXAVDCSMJKIP-UHFFFAOYSA-N 0.000 description 2
- RIOIGPOQLXXNLB-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(C=2C=3NC=NC=3N=CN=2)=C1 RIOIGPOQLXXNLB-UHFFFAOYSA-N 0.000 description 2
- XLLUKPQANVCDLD-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C(N)=O)=CC(C=2C=3NC=NC=3N=CN=2)=C1 XLLUKPQANVCDLD-UHFFFAOYSA-N 0.000 description 2
- UMYSCGGAEYNSQT-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C(=O)N UMYSCGGAEYNSQT-UHFFFAOYSA-N 0.000 description 2
- VGILJLDEWTWOIB-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C(=O)N VGILJLDEWTWOIB-UHFFFAOYSA-N 0.000 description 2
- LQVQYLOZDMLXAU-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NC=C2)C#N LQVQYLOZDMLXAU-UHFFFAOYSA-N 0.000 description 2
- USYOXOPJMLDSQM-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N USYOXOPJMLDSQM-UHFFFAOYSA-N 0.000 description 2
- VWBXUAKCBVLGQP-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1C(C(N)=O)=CC(C=2C=3NC=NC=3N=CN=2)=C1 VWBXUAKCBVLGQP-UHFFFAOYSA-N 0.000 description 2
- MMHIZRLYTQUIGJ-UHFFFAOYSA-N 1-[6-(methylamino)pyrimidin-4-yl]-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CNC1=CC(=NC=N1)N1C(=CC(=C1)C1=C(C=CC(=C1)C(F)(F)F)C)C#N MMHIZRLYTQUIGJ-UHFFFAOYSA-N 0.000 description 2
- XOWRJWNOUZQTTR-UHFFFAOYSA-N 1-[6-(methylamino)pyrimidin-4-yl]-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CNC1=CC(=NC=N1)N1C=C(C(=C1)C1=C(C=CC(=C1)C(F)(F)F)C)C(=O)N XOWRJWNOUZQTTR-UHFFFAOYSA-N 0.000 description 2
- WUKVYDHKDZHISC-UHFFFAOYSA-N 1-[6-(methylamino)pyrimidin-4-yl]-4-phenylpyrrole-3-carbonitrile Chemical compound C1=NC(NC)=CC(N2C=C(C(C#N)=C2)C=2C=CC=CC=2)=N1 WUKVYDHKDZHISC-UHFFFAOYSA-N 0.000 description 2
- GHVQEHPFELHFNI-UHFFFAOYSA-N 1-[6-(methylamino)pyrimidin-4-yl]-4-phenylpyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(N2C=C(C(C(N)=O)=C2)C=2C=CC=CC=2)=N1 GHVQEHPFELHFNI-UHFFFAOYSA-N 0.000 description 2
- IHHXYTIKYUHTQU-UHFFFAOYSA-N 1-ethyl-4-(trifluoromethyl)benzene Chemical compound CCC1=CC=C(C(F)(F)F)C=C1 IHHXYTIKYUHTQU-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SEMVYXBPOVCBCP-UHFFFAOYSA-N 1-phenyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carboxamide Chemical compound C1(=CC=CC=C1)N1C(=CC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N SEMVYXBPOVCBCP-UHFFFAOYSA-N 0.000 description 2
- XSYCSWLOHOSSQK-UHFFFAOYSA-N 1-phenyl-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound C1(=CC=CC=C1)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N XSYCSWLOHOSSQK-UHFFFAOYSA-N 0.000 description 2
- PCYWMDGJYQAMCR-UHFFFAOYSA-N 1h-pyrrole-3-carbonitrile Chemical compound N#CC=1C=CNC=1 PCYWMDGJYQAMCR-UHFFFAOYSA-N 0.000 description 2
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 2
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 2
- FXKASOSOVAVXTA-UHFFFAOYSA-N 2-(2-iodoethoxy)oxane Chemical compound ICCOC1CCCCO1 FXKASOSOVAVXTA-UHFFFAOYSA-N 0.000 description 2
- BWPOJCBOVVZPKP-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C1=C2C(=NC=N1)NN=C2)CC BWPOJCBOVVZPKP-UHFFFAOYSA-N 0.000 description 2
- VESMTKRNWWLUED-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NCC2)CC VESMTKRNWWLUED-UHFFFAOYSA-N 0.000 description 2
- UJWDWSSGZYIXAL-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NCC2)CC UJWDWSSGZYIXAL-UHFFFAOYSA-N 0.000 description 2
- PEXIMIHOGDFCJR-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(7h-purin-6-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C=3NC=NC=3N=CN=2)N1 PEXIMIHOGDFCJR-UHFFFAOYSA-N 0.000 description 2
- UHEHDCAXYVURDU-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2)CC UHEHDCAXYVURDU-UHFFFAOYSA-N 0.000 description 2
- CBIVVUSCQNNNBS-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-N-methyl-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-1-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1N(C=C(C1)C1=NC=NC(=C1)NC)C(=O)NC)CC CBIVVUSCQNNNBS-UHFFFAOYSA-N 0.000 description 2
- OREYNGKUHGWZPQ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=CN1 OREYNGKUHGWZPQ-UHFFFAOYSA-N 0.000 description 2
- HYEABGKSVFEMNB-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=C2C(=NC=N1)NN=C2)C HYEABGKSVFEMNB-UHFFFAOYSA-N 0.000 description 2
- ZXTZCFGIGCWGOJ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=C2C(=NC=C1)NC=C2)C ZXTZCFGIGCWGOJ-UHFFFAOYSA-N 0.000 description 2
- RXZGOTNGIKMIIP-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C=3C=NNC=3N=CN=2)N1 RXZGOTNGIKMIIP-UHFFFAOYSA-N 0.000 description 2
- QAZULEUSBWRAMM-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NCC2)C QAZULEUSBWRAMM-UHFFFAOYSA-N 0.000 description 2
- UEVUVSTWRNJVRS-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NCC2)C UEVUVSTWRNJVRS-UHFFFAOYSA-N 0.000 description 2
- GRVBQPFSRAESRZ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(7h-purin-6-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)C=C(C=2C=3NC=NC=3N=CN=2)N1 GRVBQPFSRAESRZ-UHFFFAOYSA-N 0.000 description 2
- PJDXSARFTRPZOP-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2)C PJDXSARFTRPZOP-UHFFFAOYSA-N 0.000 description 2
- UJTKVYIOVVTKQN-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2)C UJTKVYIOVVTKQN-UHFFFAOYSA-N 0.000 description 2
- ZTACQMWCNBLPPQ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-N-methyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-1-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1N(C=C(C1)C=1C2=C(N=CN1)NC=C2)C(=O)NC)C ZTACQMWCNBLPPQ-UHFFFAOYSA-N 0.000 description 2
- FVGDOKDFHPXUQC-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-N-methyl-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-1-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1N(C=C(C1)C1=NC=NC(=C1)NC)C(=O)NC)C FVGDOKDFHPXUQC-UHFFFAOYSA-N 0.000 description 2
- NVFLHNAIBIAMLN-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NC=C2)C NVFLHNAIBIAMLN-UHFFFAOYSA-N 0.000 description 2
- QIDQEYMQSPMOSE-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C1=NC=NC(=C1)NC)C QIDQEYMQSPMOSE-UHFFFAOYSA-N 0.000 description 2
- XZIRRBIOVUGENX-UHFFFAOYSA-N 2-[(4-chloropyrrolo[2,3-b]pyridin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1Cl XZIRRBIOVUGENX-UHFFFAOYSA-N 0.000 description 2
- RYRGMFCNKHVADH-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=C2C(=NC=N1)NN=C2 RYRGMFCNKHVADH-UHFFFAOYSA-N 0.000 description 2
- HHLIMTMJTIZXQB-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NCC2 HHLIMTMJTIZXQB-UHFFFAOYSA-N 0.000 description 2
- LNVCDNCVEVDMFN-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NCC2 LNVCDNCVEVDMFN-UHFFFAOYSA-N 0.000 description 2
- CRPRNBQGGBJKGN-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7h-purin-6-yl)-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2C=3NC=NC=3N=CN=2)NC=1C1=CC(C(F)(F)F)=CC=C1Cl CRPRNBQGGBJKGN-UHFFFAOYSA-N 0.000 description 2
- BWRIWNOYVFYMHC-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NC=C2 BWRIWNOYVFYMHC-UHFFFAOYSA-N 0.000 description 2
- UGYAEPFCJAHHQT-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C1=C(C=CC(=C1)C(F)(F)F)Cl UGYAEPFCJAHHQT-UHFFFAOYSA-N 0.000 description 2
- YGUYAGGKVQOTGY-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C1=NC=NN2C1=CC=C2 YGUYAGGKVQOTGY-UHFFFAOYSA-N 0.000 description 2
- BHIMDJBHJNMVOV-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=C2C(=NC=N1)NN=C2 BHIMDJBHJNMVOV-UHFFFAOYSA-N 0.000 description 2
- BZZNPXIYLJFEQH-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(7h-purin-6-yl)-1h-pyrrole-3-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C=3NC=NC=3N=CN=2)N1 BZZNPXIYLJFEQH-UHFFFAOYSA-N 0.000 description 2
- NVKJUDGZHMEJQT-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-1-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1N(C=C(C1)C=1C2=C(N=CN1)NC=C2)C(=O)NC NVKJUDGZHMEJQT-UHFFFAOYSA-N 0.000 description 2
- WNXANKBKBYMTAT-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-1-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1N(C=C(C1)C1=NC=NC(=C1)NC)C(=O)NC WNXANKBKBYMTAT-UHFFFAOYSA-N 0.000 description 2
- NHJMOIWKYNPXKA-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C1=NC=NN2C1=CC=C2 NHJMOIWKYNPXKA-UHFFFAOYSA-N 0.000 description 2
- BCYDGZOQEIPLJG-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=C2C(=NC=N1)NN=C2 BCYDGZOQEIPLJG-UHFFFAOYSA-N 0.000 description 2
- BESYGXNPZRTTIS-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7h-purin-6-yl)-1h-pyrrole-3-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)C=C(C=2C=3NC=NC=3N=CN=2)N1 BESYGXNPZRTTIS-UHFFFAOYSA-N 0.000 description 2
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- FPPFSMHSBXPQRL-UHFFFAOYSA-N 2-phenyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound C1(=CC=CC=C1)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2 FPPFSMHSBXPQRL-UHFFFAOYSA-N 0.000 description 2
- CMAQRDCPSACAOG-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N)CC CMAQRDCPSACAOG-UHFFFAOYSA-N 0.000 description 2
- GMQSUWZGJOPUNK-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)NC)CC GMQSUWZGJOPUNK-UHFFFAOYSA-N 0.000 description 2
- QMPXJGZFSXKLPX-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)NC(C=2N=CN=C(NC)C=2)=C1 QMPXJGZFSXKLPX-UHFFFAOYSA-N 0.000 description 2
- HRDYECDTOCNZTB-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N)CC HRDYECDTOCNZTB-UHFFFAOYSA-N 0.000 description 2
- FALDUFKVISOBRE-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C(=O)NC)CC FALDUFKVISOBRE-UHFFFAOYSA-N 0.000 description 2
- XUWRIWFGRUHMFA-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-3-(2,2-diethoxyethylamino)prop-2-enenitrile Chemical compound CCOC(OCC)CNC(=CC#N)C1=CC(Cl)=CC=C1C XUWRIWFGRUHMFA-UHFFFAOYSA-N 0.000 description 2
- LFLDQXUMPKWFDR-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N)C LFLDQXUMPKWFDR-UHFFFAOYSA-N 0.000 description 2
- RRHUTOHTOFXGRN-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)NC)C RRHUTOHTOFXGRN-UHFFFAOYSA-N 0.000 description 2
- FKTGOYBFEOHYPL-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C(=O)N)C FKTGOYBFEOHYPL-UHFFFAOYSA-N 0.000 description 2
- HDVPZUKSBQFJNA-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N)C HDVPZUKSBQFJNA-UHFFFAOYSA-N 0.000 description 2
- VSEMIWZGLDUSDO-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-n-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(C=2N=CN=C(NC)C=2)=CC=1C1=CC(Cl)=CC=C1C VSEMIWZGLDUSDO-UHFFFAOYSA-N 0.000 description 2
- VAYHLMRDINKTPO-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)prop-2-enenitrile Chemical compound Cc1ccc(Cl)cc1C=CC#N VAYHLMRDINKTPO-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- DADQPWXLRMEBHN-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N DADQPWXLRMEBHN-UHFFFAOYSA-N 0.000 description 2
- MJAOVCSFLLFPGW-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)NC MJAOVCSFLLFPGW-UHFFFAOYSA-N 0.000 description 2
- BCTWRKQVVHWDIZ-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N BCTWRKQVVHWDIZ-UHFFFAOYSA-N 0.000 description 2
- XBNAREOKHKCPHP-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)NC XBNAREOKHKCPHP-UHFFFAOYSA-N 0.000 description 2
- BISNZGTUZWWINN-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C(=O)NC BISNZGTUZWWINN-UHFFFAOYSA-N 0.000 description 2
- NWYNMZQMKGYJME-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)NC NWYNMZQMKGYJME-UHFFFAOYSA-N 0.000 description 2
- XPJFHTDMWQVNMP-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)NC(C=2N=CN=C(NC)C=2)=C1 XPJFHTDMWQVNMP-UHFFFAOYSA-N 0.000 description 2
- NKYGOEGZTDQACO-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)NC NKYGOEGZTDQACO-UHFFFAOYSA-N 0.000 description 2
- XRPYJPWSEDKGOU-UHFFFAOYSA-N 3-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N XRPYJPWSEDKGOU-UHFFFAOYSA-N 0.000 description 2
- SRKAHCUSLVUBGC-UHFFFAOYSA-N 3-phenyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound C1(=CC=CC=C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)N SRKAHCUSLVUBGC-UHFFFAOYSA-N 0.000 description 2
- JUQVXXJJMIJHPU-UHFFFAOYSA-N 3-phenyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound C1(=CC=CC=C1)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N JUQVXXJJMIJHPU-UHFFFAOYSA-N 0.000 description 2
- QPBDIRLKRKQOEX-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C(=O)N)CC QPBDIRLKRKQOEX-UHFFFAOYSA-N 0.000 description 2
- VBXYGKDBUBYWNB-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C#N)CC VBXYGKDBUBYWNB-UHFFFAOYSA-N 0.000 description 2
- UHNXPQNGFWCRNX-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=CN(C=2C=3C=CNC=3N=CN=2)C=C1C(N)=O UHNXPQNGFWCRNX-UHFFFAOYSA-N 0.000 description 2
- BKMGQGBEWLTHKG-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=NC=NC(=C1)NC)C#N)CC BKMGQGBEWLTHKG-UHFFFAOYSA-N 0.000 description 2
- UGHUGHAZMUYAIS-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=CN(C=2N=CN=C(NC)C=2)C=C1C(N)=O UGHUGHAZMUYAIS-UHFFFAOYSA-N 0.000 description 2
- DSEIONSAVKVMJK-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C#N)CC DSEIONSAVKVMJK-UHFFFAOYSA-N 0.000 description 2
- WSCGVBWZUXUNQA-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=C2C(=NC=N1)NN=C2)C#N)C WSCGVBWZUXUNQA-UHFFFAOYSA-N 0.000 description 2
- OSCWCBQLERBKEX-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=C2C(=NC=C1)NC=C2)C#N)C OSCWCBQLERBKEX-UHFFFAOYSA-N 0.000 description 2
- SYOWMDKPFHRWIJ-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=C2C(=NC=C1)NC=C2)C(=O)N)C SYOWMDKPFHRWIJ-UHFFFAOYSA-N 0.000 description 2
- ZQWGWZSVZODELB-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=CN(C=2C=3C=NNC=3N=CN=2)C=C1C(N)=O ZQWGWZSVZODELB-UHFFFAOYSA-N 0.000 description 2
- AHGFZUJKGCSAHK-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N)C AHGFZUJKGCSAHK-UHFFFAOYSA-N 0.000 description 2
- PIYYMPWMYBAFOB-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C(=O)N)C PIYYMPWMYBAFOB-UHFFFAOYSA-N 0.000 description 2
- FLLOCNFFOIIXBD-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(7h-purin-6-yl)pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=CN(C=2C=3NC=NC=3N=CN=2)C=C1C#N FLLOCNFFOIIXBD-UHFFFAOYSA-N 0.000 description 2
- XJTNPOQPKVRPLR-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(7h-purin-6-yl)pyrrole-3-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=CN(C=2C=3NC=NC=3N=CN=2)C=C1C(N)=O XJTNPOQPKVRPLR-UHFFFAOYSA-N 0.000 description 2
- WWJNWSWLCSQEBC-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C(=O)N)C WWJNWSWLCSQEBC-UHFFFAOYSA-N 0.000 description 2
- DMQMNFUXHJFNDP-UHFFFAOYSA-N 4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)C=2C=C(N(C2)C2=C(C=CC(=C2)C(F)(F)F)CC)C(=O)N DMQMNFUXHJFNDP-UHFFFAOYSA-N 0.000 description 2
- HYADADFZRZVBBF-UHFFFAOYSA-N 4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C#N HYADADFZRZVBBF-UHFFFAOYSA-N 0.000 description 2
- WBVXUEJOBKYHGH-UHFFFAOYSA-N 4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)C=2C=C(N(C2)C2=C(C=CC(=C2)C(F)(F)F)C)C(=O)N WBVXUEJOBKYHGH-UHFFFAOYSA-N 0.000 description 2
- HQAFZJJJBYAVEA-UHFFFAOYSA-N 4-(6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidin-4-yl)-1-phenylpyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2C=3CCNC=3N=CN=2)=CN1C1=CC=CC=C1 HQAFZJJJBYAVEA-UHFFFAOYSA-N 0.000 description 2
- GVOUWKWXTFNERU-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-(5-chloro-2-ethylphenyl)pyrrole-3-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1N1C=C(C=2N=CN=C(N)C=2)C(C(N)=O)=C1 GVOUWKWXTFNERU-UHFFFAOYSA-N 0.000 description 2
- KZJLFVSFVDUMIS-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)pyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1N1C(C(N)=O)=CC(C=2N=CN=C(N)C=2)=C1 KZJLFVSFVDUMIS-UHFFFAOYSA-N 0.000 description 2
- RGAHQPSLTLDDDU-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2N=CN=C(N)C=2)=CN1C1=CC(C(F)(F)F)=CC=C1Cl RGAHQPSLTLDDDU-UHFFFAOYSA-N 0.000 description 2
- NEKBJJBNAVLZNH-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(C=2N=CN=C(N)C=2)=C1 NEKBJJBNAVLZNH-UHFFFAOYSA-N 0.000 description 2
- NDBKXPMLZRSUQL-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1C(C(N)=O)=CC(C=2N=CN=C(N)C=2)=C1 NDBKXPMLZRSUQL-UHFFFAOYSA-N 0.000 description 2
- MIPZCJMIVQGEMA-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-phenylpyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2N=CN=C(N)C=2)=CN1C1=CC=CC=C1 MIPZCJMIVQGEMA-UHFFFAOYSA-N 0.000 description 2
- JJCAJMTUEJEHQJ-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-N-methylpyrrole-1-carboxamide Chemical compound NC1=CC(=NC=N1)C=1C=C(N(C1)C(=O)NC)C1=C(C=CC(=C1)Cl)C JJCAJMTUEJEHQJ-UHFFFAOYSA-N 0.000 description 2
- VCYUJDQEBUQVHX-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methylpyrrole-1-carboxamide Chemical compound NC1=CC(=NC=N1)C=1C=C(N(C1)C(=O)NC)C1=C(C=CC(=C1)C(F)(F)F)CC VCYUJDQEBUQVHX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- URLOKDNCGMDGQL-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N URLOKDNCGMDGQL-UHFFFAOYSA-N 0.000 description 2
- RQPPHSUQDYMEEC-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C(=O)N RQPPHSUQDYMEEC-UHFFFAOYSA-N 0.000 description 2
- VIJQNEBAPAMTNZ-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C(=O)N VIJQNEBAPAMTNZ-UHFFFAOYSA-N 0.000 description 2
- YSQGZZJIANXYHF-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NC(=C1)NC)C(=O)N YSQGZZJIANXYHF-UHFFFAOYSA-N 0.000 description 2
- BJIWSKRHZMHLPF-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C(=O)N BJIWSKRHZMHLPF-UHFFFAOYSA-N 0.000 description 2
- ISQIQEGKNAEESG-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NC(=C1)NC)C(=O)N ISQIQEGKNAEESG-UHFFFAOYSA-N 0.000 description 2
- IHVHUOBVJNWBRX-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C=C(N(C1)C1=NC=NN2C1=CC=C2)C#N IHVHUOBVJNWBRX-UHFFFAOYSA-N 0.000 description 2
- PGVMJBDJVUBETG-UHFFFAOYSA-N 4-[2-methyl-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C#N PGVMJBDJVUBETG-UHFFFAOYSA-N 0.000 description 2
- CAMUXLODSVCZSY-UHFFFAOYSA-N 4-[2-methyl-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C(=O)N CAMUXLODSVCZSY-UHFFFAOYSA-N 0.000 description 2
- IUEBVTDYTNWAGH-UHFFFAOYSA-N 4-[2-methyl-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C#N IUEBVTDYTNWAGH-UHFFFAOYSA-N 0.000 description 2
- AIADOYKLNISUKC-UHFFFAOYSA-N 4-[6-(methylamino)pyrimidin-4-yl]-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carboxamide Chemical compound CNC1=CC(=NC=N1)C=1C=C(N(C1)C1=C(C=CC(=C1)C(F)(F)F)C)C(=O)N AIADOYKLNISUKC-UHFFFAOYSA-N 0.000 description 2
- OONNZMCLGSRPOP-UHFFFAOYSA-N 4-chloro-1-ethyl-2-nitrobenzene Chemical compound CCC1=CC=C(Cl)C=C1[N+]([O-])=O OONNZMCLGSRPOP-UHFFFAOYSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- IBAKZUHOEWYQRB-UHFFFAOYSA-N 4-phenyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carboxamide Chemical compound C1(=CC=CC=C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C(=O)N IBAKZUHOEWYQRB-UHFFFAOYSA-N 0.000 description 2
- AHQUONZCASBCJF-UHFFFAOYSA-N 4-phenyl-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound C=1N(C=2C3=CC=CN3N=CN=2)C(C#N)=CC=1C1=CC=CC=C1 AHQUONZCASBCJF-UHFFFAOYSA-N 0.000 description 2
- BMTDEJAZFFSOIM-UHFFFAOYSA-N 4-phenyl-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound NC(=O)c1cn(cc1-c1ccccc1)-c1ncnn2cccc12 BMTDEJAZFFSOIM-UHFFFAOYSA-N 0.000 description 2
- IBBIMVPFNKSYKO-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NCC2 IBBIMVPFNKSYKO-UHFFFAOYSA-N 0.000 description 2
- JKEPOXZPBIIWGA-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C=1C2=C(N=CN1)NCC2 JKEPOXZPBIIWGA-UHFFFAOYSA-N 0.000 description 2
- ZNNJQLQTDVOKSQ-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)NC ZNNJQLQTDVOKSQ-UHFFFAOYSA-N 0.000 description 2
- CIWZVCDMJPEJTL-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N CIWZVCDMJPEJTL-UHFFFAOYSA-N 0.000 description 2
- NDVJMOYKFXTRQO-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NCC2 NDVJMOYKFXTRQO-UHFFFAOYSA-N 0.000 description 2
- KFMRGEQEGOZNBF-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-2-phenyl-1H-pyrrole-3-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)C1=CC(=C(N1)C1=CC=CC=C1)C(=O)NC KFMRGEQEGOZNBF-UHFFFAOYSA-N 0.000 description 2
- JNHZWPISSJJGNG-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-3-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)NC JNHZWPISSJJGNG-UHFFFAOYSA-N 0.000 description 2
- JYTPHRYCOQUKLV-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-3-phenyl-1H-pyrrole-2-carboxamide Chemical compound N1=CN=C(C2=C1NCC2)C2=CC(=C(N2)C(=O)NC)C2=CC=CC=C2 JYTPHRYCOQUKLV-UHFFFAOYSA-N 0.000 description 2
- JWROEWMVEVRHHB-UHFFFAOYSA-N 5-(6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidin-4-yl)-3-phenyl-1h-pyrrole-2-carboxamide Chemical compound NC(=O)C=1NC(C=2C=3CCNC=3N=CN=2)=CC=1C1=CC=CC=C1 JWROEWMVEVRHHB-UHFFFAOYSA-N 0.000 description 2
- MVIXKCOFSPBCHP-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-(2,2,2-trifluoroethyl)pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1CC(F)(F)F)C1=C(C=CC(=C1)Cl)C)C(=O)N MVIXKCOFSPBCHP-UHFFFAOYSA-N 0.000 description 2
- DNSXXJZFCAJFIJ-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-ethylpyrrole-3-carboxamide Chemical compound CCN1C(C=2N=CN=C(N)C=2)=CC(C(N)=O)=C1C1=CC(Cl)=CC=C1C DNSXXJZFCAJFIJ-UHFFFAOYSA-N 0.000 description 2
- RNJWXGDSMRJQOS-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-1-methylpyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1C)C1=C(C=CC(=C1)Cl)C)C(=O)N RNJWXGDSMRJQOS-UHFFFAOYSA-N 0.000 description 2
- XHKHESSTNWADJM-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-methylphenyl)-n-methyl-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2N=CN=C(N)C=2)NC=1C1=CC(Cl)=CC=C1C XHKHESSTNWADJM-UHFFFAOYSA-N 0.000 description 2
- ZNHJNUIHFHSMNE-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C1=C(C=CC(=C1)C(F)(F)F)Cl)C(=O)NC ZNHJNUIHFHSMNE-UHFFFAOYSA-N 0.000 description 2
- JSFDPKMIYQOHMR-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-phenyl-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2N=CN=C(N)C=2)NC=1C1=CC=CC=C1 JSFDPKMIYQOHMR-UHFFFAOYSA-N 0.000 description 2
- KPTZNGFVZMIRNM-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-ethylphenyl)-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(N)=O)NC(C=2N=CN=C(N)C=2)=C1 KPTZNGFVZMIRNM-UHFFFAOYSA-N 0.000 description 2
- ZBPPGRYCFNXHHQ-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-ethylphenyl)-n-methyl-1h-pyrrole-2-carboxamide Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)NC)NC(C=2N=CN=C(N)C=2)=C1 ZBPPGRYCFNXHHQ-UHFFFAOYSA-N 0.000 description 2
- ZWNXQQXXTMCGEY-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1-(2,2,2-trifluoroethyl)pyrrole-2-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1CC(F)(F)F)C(=O)N)C1=C(C=CC(=C1)Cl)C ZWNXQQXXTMCGEY-UHFFFAOYSA-N 0.000 description 2
- IFYJYMGJZVZCLA-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1-ethylpyrrole-2-carboxamide Chemical compound NC(=O)C=1N(CC)C(C=2N=CN=C(N)C=2)=CC=1C1=CC(Cl)=CC=C1C IFYJYMGJZVZCLA-UHFFFAOYSA-N 0.000 description 2
- NGYBSJGZJSEBAL-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1-methylpyrrole-2-carboxamide Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(N)=O)N(C)C(C=2N=CN=C(N)C=2)=C1 NGYBSJGZJSEBAL-UHFFFAOYSA-N 0.000 description 2
- MFWZAWVZLZYRTN-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-n-methyl-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(C=2N=CN=C(N)C=2)=CC=1C1=CC(Cl)=CC=C1C MFWZAWVZLZYRTN-UHFFFAOYSA-N 0.000 description 2
- OMULYWNKTPDEOD-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-chloro-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)N)C1=C(C=CC(=C1)C(F)(F)F)Cl OMULYWNKTPDEOD-UHFFFAOYSA-N 0.000 description 2
- RARVOTHLZJZICO-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-chloro-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-2-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)NC)C1=C(C=CC(=C1)C(F)(F)F)Cl RARVOTHLZJZICO-UHFFFAOYSA-N 0.000 description 2
- WLZMBRCWUHJJHG-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C1=C(C=CC(=C1)C(F)(F)F)C)C(=O)NC WLZMBRCWUHJJHG-UHFFFAOYSA-N 0.000 description 2
- QTTOJNQQNMDPIB-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-n-methyl-3-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(C=2N=CN=C(N)C=2)=CC=1C1=CC(C(F)(F)F)=CC=C1C QTTOJNQQNMDPIB-UHFFFAOYSA-N 0.000 description 2
- ZWXBQWKMZNOOKW-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-n-methyl-3-phenyl-1h-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(C=2N=CN=C(N)C=2)=CC=1C1=CC=CC=C1 ZWXBQWKMZNOOKW-UHFFFAOYSA-N 0.000 description 2
- GMQQHPPOQUQRBC-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-3-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound CNC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)N)C1=C(C=CC(=C1)C(F)(F)F)C GMQQHPPOQUQRBC-UHFFFAOYSA-N 0.000 description 2
- BQRIFMIMUYMLAZ-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-3-phenyl-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC)=CC(C=2NC(=C(C=2)C=2C=CC=CC=2)C(N)=O)=N1 BQRIFMIMUYMLAZ-UHFFFAOYSA-N 0.000 description 2
- GXMFLLVURQXDPD-UHFFFAOYSA-N 5-chloro-2-ethylaniline Chemical compound CCC1=CC=C(Cl)C=C1N GXMFLLVURQXDPD-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- YFIHGQNGWOKBKJ-UHFFFAOYSA-N C1=CC=C(C=C1)N2C=CC(=C2C#N)C3=C4C=NNC4=NC=N3 Chemical compound C1=CC=C(C=C1)N2C=CC(=C2C#N)C3=C4C=NNC4=NC=N3 YFIHGQNGWOKBKJ-UHFFFAOYSA-N 0.000 description 2
- WLDPEXDLWAIACT-UHFFFAOYSA-N CCC1=C(C=C(C=C1)Cl)C2=C(C=CN2C(=O)NC)C3=C4C=CNC4=NC=N3 Chemical compound CCC1=C(C=C(C=C1)Cl)C2=C(C=CN2C(=O)NC)C3=C4C=CNC4=NC=N3 WLDPEXDLWAIACT-UHFFFAOYSA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- DEQPXLOTTFSGLX-UHFFFAOYSA-N N-methyl-2-[2-methyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C1=NC=NN2C1=CC=C2 DEQPXLOTTFSGLX-UHFFFAOYSA-N 0.000 description 2
- IQXIMCXBFNYYKD-UHFFFAOYSA-N N-methyl-3-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(=CC1C1=C(C=CC(=C1)C(F)(F)F)C)C=1C2=C(N=CN1)NC=C2 IQXIMCXBFNYYKD-UHFFFAOYSA-N 0.000 description 2
- BACQIZLSISILNI-UHFFFAOYSA-N N-methyl-3-[2-methyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(=CC1C1=C(C=CC(=C1)C(F)(F)F)C)C1=NC=NN2C1=CC=C2 BACQIZLSISILNI-UHFFFAOYSA-N 0.000 description 2
- CSJBTWHEZMBAIE-UHFFFAOYSA-N N-methyl-3-phenyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(=CC1C1=CC=CC=C1)C=1C2=C(N=CN1)NC=C2 CSJBTWHEZMBAIE-UHFFFAOYSA-N 0.000 description 2
- CIGAOUXUCGXFEN-UHFFFAOYSA-N N-methyl-3-phenyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(=CC1C1=CC=CC=C1)C1=NC=NN2C1=CC=C2 CIGAOUXUCGXFEN-UHFFFAOYSA-N 0.000 description 2
- WRSBDJJWYWSUNW-UHFFFAOYSA-N N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C1=C(C=CC(=C1)C(F)(F)F)C WRSBDJJWYWSUNW-UHFFFAOYSA-N 0.000 description 2
- ATOKBYMEDMMCKI-UHFFFAOYSA-N N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-3-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound CNC(=O)C=1NC(=CC1C1=C(C=CC(=C1)C(F)(F)F)C)C1=NC=NC(=C1)NC ATOKBYMEDMMCKI-UHFFFAOYSA-N 0.000 description 2
- MVWIRGGMFSZZMP-UHFFFAOYSA-N N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-3-phenyl-1H-pyrrole-2-carboxamide Chemical compound CNC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)NC)C1=CC=CC=C1 MVWIRGGMFSZZMP-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002942 anti-growth Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DGVCSBGHKPAQTR-UHFFFAOYSA-N ethyl 1-(benzenesulfonyl)-2-phenylpyrrole-3-carboxylate Chemical compound CCOC(=O)C=1C=CN(S(=O)(=O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 DGVCSBGHKPAQTR-UHFFFAOYSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- ISBKZHUQXJKCKP-UHFFFAOYSA-N methyl 2-bromo-5-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(C(F)(F)F)=CC=C1Br ISBKZHUQXJKCKP-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- GZDYCKLIQUPOIR-UHFFFAOYSA-N n-(2,2-diethoxyethyl)acetamide Chemical compound CCOC(OCC)CNC(C)=O GZDYCKLIQUPOIR-UHFFFAOYSA-N 0.000 description 2
- DGPLVKVFSPWWHC-UHFFFAOYSA-N n-methyl-2-phenyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2C=3C=CNC=3N=CN=2)NC=1C1=CC=CC=C1 DGPLVKVFSPWWHC-UHFFFAOYSA-N 0.000 description 2
- VERCQLOBLOLFMW-UHFFFAOYSA-N n-methylpyrimidin-4-amine Chemical compound CNC1=CC=NC=N1 VERCQLOBLOLFMW-UHFFFAOYSA-N 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000003277 telomerase inhibitor Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- GHOBPGCJYCNQTH-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C#N)CC GHOBPGCJYCNQTH-UHFFFAOYSA-N 0.000 description 1
- RGLFITCFJAOPQM-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C#N)CC RGLFITCFJAOPQM-UHFFFAOYSA-N 0.000 description 1
- WZMVHBMOGUCTKF-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2C=3NC=NC=3N=CN=2)=C1 WZMVHBMOGUCTKF-UHFFFAOYSA-N 0.000 description 1
- PMARJESQXHSTMY-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C#N)CC PMARJESQXHSTMY-UHFFFAOYSA-N 0.000 description 1
- ZSNKISFRNJVOGJ-UHFFFAOYSA-N 1-(5-chloro-2-ethylphenyl)-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N)CC ZSNKISFRNJVOGJ-UHFFFAOYSA-N 0.000 description 1
- ULXZDNPJIDLMIF-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C#N)C ULXZDNPJIDLMIF-UHFFFAOYSA-N 0.000 description 1
- JBNPEYXGEJFVAK-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=C2C(=NC=C1)NC=C2)C#N)C JBNPEYXGEJFVAK-UHFFFAOYSA-N 0.000 description 1
- RUWSCDCKASFXEL-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1N1C(C#N)=CC(B2OC(C)(C)C(C)(C)O2)=C1 RUWSCDCKASFXEL-UHFFFAOYSA-N 0.000 description 1
- NHQIJLTUYUWGJT-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C#N)C NHQIJLTUYUWGJT-UHFFFAOYSA-N 0.000 description 1
- VVZSIHJSCHAABI-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2C=3NC=NC=3N=CN=2)=C1 VVZSIHJSCHAABI-UHFFFAOYSA-N 0.000 description 1
- ISAYTOLMDWRGAA-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C#N)C ISAYTOLMDWRGAA-UHFFFAOYSA-N 0.000 description 1
- WXBWDRZKVXRNJU-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound ClC=1C=CC(=C(C1)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N)C WXBWDRZKVXRNJU-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- XJNODIASYGKTPM-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N XJNODIASYGKTPM-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- ISKVXISQGNSOKW-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C#N ISKVXISQGNSOKW-UHFFFAOYSA-N 0.000 description 1
- YXUJKIHKNJGUHZ-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C#N YXUJKIHKNJGUHZ-UHFFFAOYSA-N 0.000 description 1
- YIJRICFTOUWCFJ-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C#N YIJRICFTOUWCFJ-UHFFFAOYSA-N 0.000 description 1
- IJKGYBUUXLZIRR-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-[9-[(4-methoxyphenyl)methyl]purin-6-yl]pyrrole-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1CN1C2=NC=NC(C3=CN(C(C#N)=C3)C=3C(=CC=C(C=3)C(F)(F)F)Cl)=C2N=C1 IJKGYBUUXLZIRR-UHFFFAOYSA-N 0.000 description 1
- AQCJUVCWQCRCHB-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound NC(=O)C1=CC(C=2C3=CC=CN3N=CN=2)=CN1C1=CC(C(F)(F)F)=CC=C1Cl AQCJUVCWQCRCHB-UHFFFAOYSA-N 0.000 description 1
- RHYFEGGCSGRQLL-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-[6-(methylamino)pyrimidin-4-yl]pyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NC(=C1)NC)C#N RHYFEGGCSGRQLL-UHFFFAOYSA-N 0.000 description 1
- UESPOIRMFKKZKL-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N UESPOIRMFKKZKL-UHFFFAOYSA-N 0.000 description 1
- IDWVPLPMVGMNNS-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N IDWVPLPMVGMNNS-UHFFFAOYSA-N 0.000 description 1
- OVRDMNCZIBGACY-UHFFFAOYSA-N 1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-3-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C=C(C=C1)C#N OVRDMNCZIBGACY-UHFFFAOYSA-N 0.000 description 1
- BKFWYQBTVNPHTP-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=C2C(=NC=N1)NN=C2)C#N BKFWYQBTVNPHTP-UHFFFAOYSA-N 0.000 description 1
- MCVXNTBAPZFPQQ-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(C=2C=3NC=NC=3N=CN=2)=C1 MCVXNTBAPZFPQQ-UHFFFAOYSA-N 0.000 description 1
- FBBCXUAHSLBNOS-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N FBBCXUAHSLBNOS-UHFFFAOYSA-N 0.000 description 1
- DGQORWGKYXHCEU-UHFFFAOYSA-N 1-[2-methyl-5-(trifluoromethyl)phenyl]-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N DGQORWGKYXHCEU-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- CEWDRCQPGANDRS-UHFFFAOYSA-N 1-ethenyl-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(C=C)C=C1 CEWDRCQPGANDRS-UHFFFAOYSA-N 0.000 description 1
- RZKOZYMLAGQISR-UHFFFAOYSA-N 1-ethyl-2-iodo-4-(trifluoromethyl)benzene Chemical compound CCC1=CC=C(C(F)(F)F)C=C1I RZKOZYMLAGQISR-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WUGRTUQBZXXGBF-UHFFFAOYSA-N 1-phenyl-4-(7h-purin-6-yl)pyrrole-2-carbonitrile Chemical compound N#CC1=CC(C=2C=3NC=NC=3N=CN=2)=CN1C1=CC=CC=C1 WUGRTUQBZXXGBF-UHFFFAOYSA-N 0.000 description 1
- FPJSBDNLTAFCLE-UHFFFAOYSA-N 1-phenyl-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound N#CC1=CC(C=2C=3C=CNC=3N=CN=2)=CN1C1=CC=CC=C1 FPJSBDNLTAFCLE-UHFFFAOYSA-N 0.000 description 1
- OJMCOXLAMRDKBR-UHFFFAOYSA-N 1-phenyl-4-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-2-carbonitrile Chemical compound C1(=CC=CC=C1)N1C(=CC(=C1)C1=NC=NN2C1=CC=C2)C#N OJMCOXLAMRDKBR-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- BAJCRPRPWGNRKM-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)pyrimidine Chemical class C1=CNC(C=2N=CC=CN=2)=C1 BAJCRPRPWGNRKM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- WROHQABQNMBRRC-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=C2C(=NC=N1)NN=C2)CC WROHQABQNMBRRC-UHFFFAOYSA-N 0.000 description 1
- UOXCLGNYRPWUMJ-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NCC2)CC UOXCLGNYRPWUMJ-UHFFFAOYSA-N 0.000 description 1
- YFMPQAVQXXFSRZ-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2)CC YFMPQAVQXXFSRZ-UHFFFAOYSA-N 0.000 description 1
- YQWQEWAHVUXFIR-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-(7h-purin-6-yl)-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2C=3NC=NC=3N=CN=2)N1 YQWQEWAHVUXFIR-UHFFFAOYSA-N 0.000 description 1
- WUJYLNYFSCSLSC-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C=1)C=1NC(=CC=1C#N)C1=NC=NC(=C1)NC)CC WUJYLNYFSCSLSC-UHFFFAOYSA-N 0.000 description 1
- SQMUYTBJZLSACN-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2)CC SQMUYTBJZLSACN-UHFFFAOYSA-N 0.000 description 1
- FOXOKMLWHIQVBF-UHFFFAOYSA-N 2-(5-chloro-2-ethylphenyl)-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C1=NC=NN2C1=CC=C2)CC FOXOKMLWHIQVBF-UHFFFAOYSA-N 0.000 description 1
- QPEFFSGFJRUPJD-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NCC2)C QPEFFSGFJRUPJD-UHFFFAOYSA-N 0.000 description 1
- GMELECYCNFVJJZ-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2)C GMELECYCNFVJJZ-UHFFFAOYSA-N 0.000 description 1
- LSXGBWSSKYGAAB-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-(7h-purin-6-yl)-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=C(C#N)C=C(C=2C=3NC=NC=3N=CN=2)N1 LSXGBWSSKYGAAB-UHFFFAOYSA-N 0.000 description 1
- FSAYCNAGVKUERL-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C#N)C1=NC=NC(=C1)NC)C FSAYCNAGVKUERL-UHFFFAOYSA-N 0.000 description 1
- JOOBOKNOIMLNGX-UHFFFAOYSA-N 2-(5-chloro-2-methylphenyl)-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1NC(=CC1C(=O)NC)C1=NC=NN2C1=CC=C2)C JOOBOKNOIMLNGX-UHFFFAOYSA-N 0.000 description 1
- QPSSNRBRLJOBHV-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(C2=C(C=CN2)C#N)=C1 QPSSNRBRLJOBHV-UHFFFAOYSA-N 0.000 description 1
- VKOCFMHGBLVVID-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C1=C2C(=NC=N1)NN=C2 VKOCFMHGBLVVID-UHFFFAOYSA-N 0.000 description 1
- MAOYSSYPGYWFCP-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC=1C#N)C=1C2=C(N=CN=1)NCC2 MAOYSSYPGYWFCP-UHFFFAOYSA-N 0.000 description 1
- FGJCDNDAKLNAPC-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2 FGJCDNDAKLNAPC-UHFFFAOYSA-N 0.000 description 1
- CNKKPZWUIKRSCQ-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-(7h-purin-6-yl)-1h-pyrrole-3-carbonitrile Chemical compound FC(F)(F)C1=CC=C(Cl)C(C2=C(C=C(N2)C=2C=3NC=NC=3N=CN=2)C#N)=C1 CNKKPZWUIKRSCQ-UHFFFAOYSA-N 0.000 description 1
- CWPDELYREDVNBE-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C1=NC=NC(=C1)NC CWPDELYREDVNBE-UHFFFAOYSA-N 0.000 description 1
- IRVNSEPHCUMQHV-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2 IRVNSEPHCUMQHV-UHFFFAOYSA-N 0.000 description 1
- FFUXWOAZCMQHOL-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2 FFUXWOAZCMQHOL-UHFFFAOYSA-N 0.000 description 1
- JWLVGBDPVPTFLA-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=CN1 JWLVGBDPVPTFLA-UHFFFAOYSA-N 0.000 description 1
- ASOKGEAUZQQJGS-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2 ASOKGEAUZQQJGS-UHFFFAOYSA-N 0.000 description 1
- VTVOOFPWHHBCMZ-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carbonitrile Chemical compound CNC1=CC(=NC=N1)C1=CC(=C(N1)C1=C(C=CC(=C1)C(F)(F)F)CC)C#N VTVOOFPWHHBCMZ-UHFFFAOYSA-N 0.000 description 1
- RTOCSLJROLVZNN-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2 RTOCSLJROLVZNN-UHFFFAOYSA-N 0.000 description 1
- SJKWPRFVUQFRPS-UHFFFAOYSA-N 2-[2-ethyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2 SJKWPRFVUQFRPS-UHFFFAOYSA-N 0.000 description 1
- CHRUHSFCVHNVMO-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=CN1 CHRUHSFCVHNVMO-UHFFFAOYSA-N 0.000 description 1
- MMEWGKAKTAKTAC-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2 MMEWGKAKTAKTAC-UHFFFAOYSA-N 0.000 description 1
- AEXOTZJWBGTDJE-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carbonitrile Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C#N)C1=NC=NN2C1=CC=C2 AEXOTZJWBGTDJE-UHFFFAOYSA-N 0.000 description 1
- WJMVZJFPPIZSEH-UHFFFAOYSA-N 2-[2-methyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2 WJMVZJFPPIZSEH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- REBQGRPKXYIJDC-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1Br REBQGRPKXYIJDC-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- WLXRKCGYQAKHSJ-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1Cl WLXRKCGYQAKHSJ-UHFFFAOYSA-N 0.000 description 1
- NTXLUXJCQVIFDB-UHFFFAOYSA-N 2-chloro-7-[(4-methoxyphenyl)methyl]-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound ClC=1N=CC2=C(N=1)N(CC2)CC1=CC=C(C=C1)OC NTXLUXJCQVIFDB-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- MOJQDGQMSMYUDN-UHFFFAOYSA-N 2-ethyl-5-(trifluoromethyl)aniline Chemical compound CCC1=CC=C(C(F)(F)F)C=C1N MOJQDGQMSMYUDN-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- STJUSBSLJXOSDU-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)benzoic acid Chemical compound CC1=CC=C(C(F)(F)F)C=C1C(O)=O STJUSBSLJXOSDU-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- SRTONGWZJVFIHQ-UHFFFAOYSA-N 2-phenyl-1h-pyrrole-3-carbonitrile Chemical compound C1=CNC(C=2C=CC=CC=2)=C1C#N SRTONGWZJVFIHQ-UHFFFAOYSA-N 0.000 description 1
- ZWVFLWBYBIWHKX-UHFFFAOYSA-N 2-phenyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-3-carbonitrile Chemical compound C1(=CC=CC=C1)C=1NC(=CC1C#N)C=1C2=C(N=CN1)NC=C2 ZWVFLWBYBIWHKX-UHFFFAOYSA-N 0.000 description 1
- SCJSMBGMVRRJGF-UHFFFAOYSA-N 2-phenyl-5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2C=3C=CNC=3N=CN=2)NC=1C1=CC=CC=C1 SCJSMBGMVRRJGF-UHFFFAOYSA-N 0.000 description 1
- YWFOLJNSPFOBFT-UHFFFAOYSA-N 2-phenyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound C1(=CC=CC=C1)C=1NC(=CC1C(=O)N)C1=NC=NN2C1=CC=C2 YWFOLJNSPFOBFT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- LLXPPMBFCUHQGM-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)O)CC LLXPPMBFCUHQGM-UHFFFAOYSA-N 0.000 description 1
- BPDGNTJFIGKZOT-UHFFFAOYSA-N 3-(5-chloro-2-ethylphenyl)-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)NC)CC BPDGNTJFIGKZOT-UHFFFAOYSA-N 0.000 description 1
- ZIJJZPWAHFFITN-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-3-oxopropanenitrile Chemical compound CC1=CC=C(Cl)C=C1C(=O)CC#N ZIJJZPWAHFFITN-UHFFFAOYSA-N 0.000 description 1
- IVAMJZWZOGFWKT-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C=1C2=C(N=CN1)NC=C2)C(=O)O)C IVAMJZWZOGFWKT-UHFFFAOYSA-N 0.000 description 1
- VHGPXQWNZJNMBX-UHFFFAOYSA-N 3-(5-chloro-2-methylphenyl)-N-methyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC=1C=CC(=C(C1)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)NC)C VHGPXQWNZJNMBX-UHFFFAOYSA-N 0.000 description 1
- SKMKJBYBPYBDMN-RYUDHWBXSA-N 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine Chemical compound C1=C(OC(F)F)C(N)=NC=C1C1=CC(N2[C@H]3C[C@H](OC3)C2)=NC(N2CC(F)(F)CC2)=N1 SKMKJBYBPYBDMN-RYUDHWBXSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- QFQCTVFXOBCQPJ-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C(=O)N QFQCTVFXOBCQPJ-UHFFFAOYSA-N 0.000 description 1
- GKRFYLHZQITAOT-UHFFFAOYSA-N 3-[2-chloro-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N GKRFYLHZQITAOT-UHFFFAOYSA-N 0.000 description 1
- RNYIVACDDNINGE-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N RNYIVACDDNINGE-UHFFFAOYSA-N 0.000 description 1
- KIZJDWQFIFDVKY-UHFFFAOYSA-N 3-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NC(=C1)NC)C(=O)NC KIZJDWQFIFDVKY-UHFFFAOYSA-N 0.000 description 1
- ZVHQSGYVEFXBNB-UHFFFAOYSA-N 3-[2-methyl-5-(trifluoromethyl)phenyl]-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-2-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C(=O)N ZVHQSGYVEFXBNB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- DIDJRRXYSWWMOQ-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NCC2)C#N)CC DIDJRRXYSWWMOQ-UHFFFAOYSA-N 0.000 description 1
- GTECJFYQYLRTCT-UHFFFAOYSA-N 4-(5-chloro-2-ethylphenyl)-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C(=O)N)CC GTECJFYQYLRTCT-UHFFFAOYSA-N 0.000 description 1
- HHNVINFAYJQNGS-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(6-chloropyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound CC1=CC=C(Cl)C=C1C1=CN(C=2N=CN=C(Cl)C=2)C=C1C#N HHNVINFAYJQNGS-UHFFFAOYSA-N 0.000 description 1
- DTNYUWZSDSLSPZ-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C#N)C DTNYUWZSDSLSPZ-UHFFFAOYSA-N 0.000 description 1
- BXKSUIBNJJORTO-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carbonitrile Chemical compound C1=NC(NC)=CC(N2C=C(C(C#N)=C2)C=2C(=CC=C(Cl)C=2)C)=N1 BXKSUIBNJJORTO-UHFFFAOYSA-N 0.000 description 1
- NRKKGAQGWMSKRH-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(N2C=C(C(C(N)=O)=C2)C=2C(=CC=C(Cl)C=2)C)=N1 NRKKGAQGWMSKRH-UHFFFAOYSA-N 0.000 description 1
- AGRIULXVJBARKY-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-[7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]pyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C=1C2=C(N=CN1)N(C=C2)COCC[Si](C)(C)C)C#N)C AGRIULXVJBARKY-UHFFFAOYSA-N 0.000 description 1
- LJHNKFFRKOGXGO-UHFFFAOYSA-N 4-(5-chloro-2-methylphenyl)-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carbonitrile Chemical compound ClC=1C=CC(=C(C1)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C#N)C LJHNKFFRKOGXGO-UHFFFAOYSA-N 0.000 description 1
- QEWJBJOXVOIJQZ-UHFFFAOYSA-N 4-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-[2-ethyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)N1C(=CC(=C1)C=1C2=C(N=CN1)NCC2)C#N QEWJBJOXVOIJQZ-UHFFFAOYSA-N 0.000 description 1
- HBJIIDHYVKJEPX-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-(5-chloro-2-ethylphenyl)pyrrole-2-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1N1C(C#N)=CC(C=2N=CN=C(N)C=2)=C1 HBJIIDHYVKJEPX-UHFFFAOYSA-N 0.000 description 1
- YPJOZLQOTVLLEJ-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-chloro-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound NC1=CC(=NC=N1)C=1C=C(N(C1)C1=C(C=CC(=C1)C(F)(F)F)Cl)C#N YPJOZLQOTVLLEJ-UHFFFAOYSA-N 0.000 description 1
- VKWKKVJWRNFYQK-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1N1C(C#N)=CC(C=2N=CN=C(N)C=2)=C1 VKWKKVJWRNFYQK-UHFFFAOYSA-N 0.000 description 1
- AFCLSFRZPYVAOJ-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-1-phenylpyrrole-2-carbonitrile Chemical compound C1=NC(N)=CC(C2=CN(C(C#N)=C2)C=2C=CC=CC=2)=N1 AFCLSFRZPYVAOJ-UHFFFAOYSA-N 0.000 description 1
- IPKOFPXGTPVICS-UHFFFAOYSA-N 4-(6-aminopyrimidin-4-yl)-2-(5-chloro-2-ethylphenyl)-N-methylpyrrole-1-carboxamide Chemical compound NC1=CC(=NC=N1)C=1C=C(N(C1)C(=O)NC)C1=C(C=CC(=C1)Cl)CC IPKOFPXGTPVICS-UHFFFAOYSA-N 0.000 description 1
- PJLBFBQHQJYVPF-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C#N PJLBFBQHQJYVPF-UHFFFAOYSA-N 0.000 description 1
- ZPSCJKDMLHWAQR-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-[6-(methylamino)pyrimidin-4-yl]pyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NC(=C1)NC)C#N ZPSCJKDMLHWAQR-UHFFFAOYSA-N 0.000 description 1
- FWYGJXBBTBASPD-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carbonitrile Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C#N FWYGJXBBTBASPD-UHFFFAOYSA-N 0.000 description 1
- XYIRHNYUTMMQHY-UHFFFAOYSA-N 4-[2-chloro-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound ClC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C(=O)N XYIRHNYUTMMQHY-UHFFFAOYSA-N 0.000 description 1
- JIDNNROAZWMEER-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-3-carbonitrile Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C=1C2=C(N=CN1)NC=C2)C#N JIDNNROAZWMEER-UHFFFAOYSA-N 0.000 description 1
- OEPMQWVOFXRBMN-UHFFFAOYSA-N 4-[2-ethyl-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C(=O)N OEPMQWVOFXRBMN-UHFFFAOYSA-N 0.000 description 1
- FRIGTXISHDYCPI-UHFFFAOYSA-N 4-[2-methyl-5-(trifluoromethyl)phenyl]-1-pyrrolo[2,1-f][1,2,4]triazin-4-ylpyrrole-3-carboxamide Chemical compound CC1=C(C=C(C=C1)C(F)(F)F)C=1C(=CN(C1)C1=NC=NN2C1=CC=C2)C(=O)N FRIGTXISHDYCPI-UHFFFAOYSA-N 0.000 description 1
- QTYGJBIAFDWCSG-UHFFFAOYSA-N 4-[6-(methylamino)pyrimidin-4-yl]-1-[2-methyl-5-(trifluoromethyl)phenyl]pyrrole-2-carbonitrile Chemical compound CNC1=CC(=NC=N1)C=1C=C(N(C1)C1=C(C=CC(=C1)C(F)(F)F)C)C#N QTYGJBIAFDWCSG-UHFFFAOYSA-N 0.000 description 1
- NMXUULZUESOFSG-UHFFFAOYSA-N 4-[6-(methylamino)pyrimidin-4-yl]-1-phenylpyrrole-2-carbonitrile Chemical compound C1=NC(NC)=CC(C2=CN(C(C#N)=C2)C=2C=CC=CC=2)=N1 NMXUULZUESOFSG-UHFFFAOYSA-N 0.000 description 1
- VKGTUZSMVWITRU-UHFFFAOYSA-N 4-[6-(methylamino)pyrimidin-4-yl]-1-phenylpyrrole-2-carboxamide Chemical compound C1=NC(NC)=CC(C2=CN(C(C(N)=O)=C2)C=2C=CC=CC=2)=N1 VKGTUZSMVWITRU-UHFFFAOYSA-N 0.000 description 1
- DLGZLIXYVSQGOX-UHFFFAOYSA-N 4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide Chemical compound C1CN(C(C)(C)C)CCN1C(C=C1)=CC=C1NC(C1=NC=NN11)=NC=C1C1=COC(C(N)=O)=C1 DLGZLIXYVSQGOX-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- IBOJUVQGALOUBG-MDZDMXLPSA-N 4-chloro-1-methyl-2-[(e)-2-(4-methylphenyl)sulfonylethenyl]benzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)\C=C\C1=CC(Cl)=CC=C1C IBOJUVQGALOUBG-MDZDMXLPSA-N 0.000 description 1
- ZIOGCIPQDRCAKY-UHFFFAOYSA-N 4-chloro-2-iodo-1-methylbenzene Chemical compound CC1=CC=C(Cl)C=C1I ZIOGCIPQDRCAKY-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OUVUXCBBKYHSLC-UHFFFAOYSA-N 4-ethyl-3-nitroaniline Chemical compound CCC1=CC=C(N)C=C1[N+]([O-])=O OUVUXCBBKYHSLC-UHFFFAOYSA-N 0.000 description 1
- UHQXKNWVBJJGSI-UHFFFAOYSA-N 4-phenyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrole-2-carbonitrile Chemical compound C1(=CC=CC=C1)C=1C=C(N(C1)C=1C2=C(N=CN1)NC=C2)C#N UHQXKNWVBJJGSI-UHFFFAOYSA-N 0.000 description 1
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 1
- AVPFOCLWDPYEIC-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-3-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C=1NC(=CC1C(=O)NC)C=1C2=C(N=CN1)NCC2 AVPFOCLWDPYEIC-UHFFFAOYSA-N 0.000 description 1
- WTYKNXQJVXABAE-UHFFFAOYSA-N 5-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound C(C)C1=C(C=C(C=C1)C(F)(F)F)C1=C(NC(=C1)C=1C2=C(N=CN1)NCC2)C(=O)N WTYKNXQJVXABAE-UHFFFAOYSA-N 0.000 description 1
- TYMXIJNOZMUSTR-UHFFFAOYSA-N 5-(6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidin-4-yl)-2-phenyl-1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=C(C=2C=3CCNC=3N=CN=2)NC=1C1=CC=CC=C1 TYMXIJNOZMUSTR-UHFFFAOYSA-N 0.000 description 1
- WIVYMDBLJSKAQQ-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-1-(benzenesulfonyl)-2-(5-chloro-2-ethylphenyl)pyrrole-3-carbonitrile Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1S(=O)(=O)C1=CC=CC=C1)C1=C(C=CC(=C1)Cl)CC)C#N WIVYMDBLJSKAQQ-UHFFFAOYSA-N 0.000 description 1
- TUJQYDDLNSMOAK-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-chloro-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbonitrile Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C1=C(C=CC(=C1)C(F)(F)F)Cl)C#N TUJQYDDLNSMOAK-UHFFFAOYSA-N 0.000 description 1
- NAGOBIWVRXENAR-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-ethyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=C(C=2N=CN=C(N)C=2)N1 NAGOBIWVRXENAR-UHFFFAOYSA-N 0.000 description 1
- KNLQHDFIHOZRFC-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-3-carbonitrile Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C#N)C=C(C=2N=CN=C(N)C=2)N1 KNLQHDFIHOZRFC-UHFFFAOYSA-N 0.000 description 1
- UTVFJGLYYQTUGE-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-phenyl-1h-pyrrole-3-carbonitrile Chemical compound C1=NC(N)=CC(C=2NC(=C(C#N)C=2)C=2C=CC=CC=2)=N1 UTVFJGLYYQTUGE-UHFFFAOYSA-N 0.000 description 1
- PNSOXJRREZNIGL-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-2-phenyl-1h-pyrrole-3-carboxylic acid Chemical compound C1=NC(N)=CC(C=2NC(=C(C(O)=O)C=2)C=2C=CC=CC=2)=N1 PNSOXJRREZNIGL-UHFFFAOYSA-N 0.000 description 1
- VUXHQDVEUKROLS-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-ethylphenyl)-1H-pyrrole-2-carboxylic acid Chemical compound CCc1ccc(Cl)cc1-c1cc([nH]c1C(O)=O)-c1cc(N)ncn1 VUXHQDVEUKROLS-UHFFFAOYSA-N 0.000 description 1
- FRLYEWFNNRVEKD-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-(5-chloro-2-methylphenyl)-1h-pyrrole-2-carboxylic acid Chemical compound CC1=CC=C(Cl)C=C1C1=C(C(O)=O)NC(C=2N=CN=C(N)C=2)=C1 FRLYEWFNNRVEKD-UHFFFAOYSA-N 0.000 description 1
- ZWJPOQFDXWHJIW-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)N)C1=C(C=CC(=C1)C(F)(F)F)CC ZWJPOQFDXWHJIW-UHFFFAOYSA-N 0.000 description 1
- ISQSNBXEADZSRP-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxylic acid Chemical compound CCc1ccc(cc1-c1cc([nH]c1C(O)=O)-c1cc(N)ncn1)C(F)(F)F ISQSNBXEADZSRP-UHFFFAOYSA-N 0.000 description 1
- RBLWNGOJITXCTA-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-N-methyl-1H-pyrrole-2-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)NC)C1=C(C=CC(=C1)C(F)(F)F)CC RBLWNGOJITXCTA-UHFFFAOYSA-N 0.000 description 1
- UHTSXGRYYZVJKH-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-[2-methyl-5-(trifluoromethyl)phenyl]-1h-pyrrole-2-carboxamide Chemical compound CC1=CC=C(C(F)(F)F)C=C1C1=C(C(N)=O)NC(C=2N=CN=C(N)C=2)=C1 UHTSXGRYYZVJKH-UHFFFAOYSA-N 0.000 description 1
- KZBNPFNJOXOXKF-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-3-phenyl-1h-pyrrole-2-carboxamide Chemical compound NC(=O)C=1NC(C=2N=CN=C(N)C=2)=CC=1C1=CC=CC=C1 KZBNPFNJOXOXKF-UHFFFAOYSA-N 0.000 description 1
- AJVLPLYXFIUFBC-UHFFFAOYSA-N 5-(6-aminopyrimidin-4-yl)-N-methyl-2-phenyl-1H-pyrrole-3-carboxamide Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C1=CC=CC=C1)C(=O)NC AJVLPLYXFIUFBC-UHFFFAOYSA-N 0.000 description 1
- INDRYZSGYQPWSJ-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-2-[2-methyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbonitrile Chemical compound CNC1=CC(=NC=N1)C1=CC(=C(N1)C1=C(C=CC(=C1)C(F)(F)F)C)C#N INDRYZSGYQPWSJ-UHFFFAOYSA-N 0.000 description 1
- WROVMMLMSXEEQJ-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-2-phenyl-1h-pyrrole-3-carbonitrile Chemical compound C1=NC(NC)=CC(C=2NC(=C(C#N)C=2)C=2C=CC=CC=2)=N1 WROVMMLMSXEEQJ-UHFFFAOYSA-N 0.000 description 1
- LUYYDUGEYCIQGE-UHFFFAOYSA-N 5-[6-(methylamino)pyrimidin-4-yl]-2-phenyl-1h-pyrrole-3-carboxamide Chemical compound C1=NC(NC)=CC(C=2NC(=C(C(N)=O)C=2)C=2C=CC=CC=2)=N1 LUYYDUGEYCIQGE-UHFFFAOYSA-N 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- SCPGYEAMUCKJRC-UHFFFAOYSA-N 5-bromo-2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carbonitrile Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C#N)C=C(Br)N1 SCPGYEAMUCKJRC-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- WKSLUZTZBSDWDE-UHFFFAOYSA-N 5-chloro-2-methylbenzoyl chloride Chemical compound CC1=CC=C(Cl)C=C1C(Cl)=O WKSLUZTZBSDWDE-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- AYWIJMUSAAWSCA-UHFFFAOYSA-N 6-chloro-5-(2-chloroethyl)-N-[(4-methoxyphenyl)methyl]pyrimidin-4-amine Chemical compound ClC1=C(C(=NC=N1)NCC1=CC=C(C=C1)OC)CCCl AYWIJMUSAAWSCA-UHFFFAOYSA-N 0.000 description 1
- NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 101150064299 AUR1 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100381333 Arabidopsis thaliana AUR2 gene Proteins 0.000 description 1
- 101000995861 Arabidopsis thaliana Regulatory protein NPR1 Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- WINCOSHADVNIPX-UHFFFAOYSA-N B1(OC(C(O1)(C)C)(C)C)C2=CC(=CN2S(=O)(=O)C3=CC=CC=C3)C4=C(C=CC(=C4)Cl)C Chemical compound B1(OC(C(O1)(C)C)(C)C)C2=CC(=CN2S(=O)(=O)C3=CC=CC=C3)C4=C(C=CC(=C4)Cl)C WINCOSHADVNIPX-UHFFFAOYSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- REKLHDWXWAMLQT-UHFFFAOYSA-N BrC1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-].C(=C)C1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-] Chemical compound BrC1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-].C(=C)C1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-] REKLHDWXWAMLQT-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- REDAEAIGJPBWDX-UHFFFAOYSA-N C(=C)C1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-].C(C)C1=C(N)C=C(C=C1)C(F)(F)F Chemical compound C(=C)C1=C(C=C(C=C1)C(F)(F)F)[N+](=O)[O-].C(C)C1=C(N)C=C(C=C1)C(F)(F)F REDAEAIGJPBWDX-UHFFFAOYSA-N 0.000 description 1
- JHWOCPAGHMELIN-UHFFFAOYSA-N C(=O)(N1C=NC=C1)N1C=NC=C1.N1C=NC=C1.O=C(CC(=O)OCC)C1=CC=CC=C1 Chemical compound C(=O)(N1C=NC=C1)N1C=NC=C1.N1C=NC=C1.O=C(CC(=O)OCC)C1=CC=CC=C1 JHWOCPAGHMELIN-UHFFFAOYSA-N 0.000 description 1
- JMCHVJYCOZETQL-UHFFFAOYSA-N C(C)C1=CC=C(N)C=C1.C(C)C1=C(C=C(N)C=C1)[N+](=O)[O-] Chemical compound C(C)C1=CC=C(N)C=C1.C(C)C1=C(C=C(N)C=C1)[N+](=O)[O-] JMCHVJYCOZETQL-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- ATFBLHRTBCSBAT-UHFFFAOYSA-N C1CNC2=NC=NC(=C21)C3=C(N(C=C3)C4=CC=CC=C4)C#N Chemical compound C1CNC2=NC=NC(=C21)C3=C(N(C=C3)C4=CC=CC=C4)C#N ATFBLHRTBCSBAT-UHFFFAOYSA-N 0.000 description 1
- JWQVTSVHYYOKJD-UHFFFAOYSA-N CC1=C(C=C(C=C1)Cl)C2=CN(C=C2)C3=NC=NC4=C3C=CN4COCC[Si](C)(C)C Chemical compound CC1=C(C=C(C=C1)Cl)C2=CN(C=C2)C3=NC=NC4=C3C=CN4COCC[Si](C)(C)C JWQVTSVHYYOKJD-UHFFFAOYSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- PEGHXXGQDVKXGV-UHFFFAOYSA-N CCc(cc1)c(C(C(CC2)C#N)N2S(c2ccccc2)(=O)=O)cc1Cl Chemical compound CCc(cc1)c(C(C(CC2)C#N)N2S(c2ccccc2)(=O)=O)cc1Cl PEGHXXGQDVKXGV-UHFFFAOYSA-N 0.000 description 1
- DLUHQAIZNWSTGD-UHFFFAOYSA-N CCc(ccc([ClH]C)c1)c1C#CC(OC)=O Chemical compound CCc(ccc([ClH]C)c1)c1C#CC(OC)=O DLUHQAIZNWSTGD-UHFFFAOYSA-N 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- 108091054872 CK2 family Proteins 0.000 description 1
- SCJNYBYSTCRPAO-LXBQGUBHSA-N CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 Chemical compound CN(C)C\C=C\C(=O)NC1=CC=C(N=C1)C(=O)N[C@@]1(C)CCC[C@H](C1)NC1=NC(C2=CNC3=CC=CC=C23)=C(Cl)C=N1 SCJNYBYSTCRPAO-LXBQGUBHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- YZFKYBPXJZPIAX-UHFFFAOYSA-N Cc(ccc(Cl)c1)c1-c([nH]c(-c1ncnc(N(C)I)c1)c1)c1C(N)=C Chemical compound Cc(ccc(Cl)c1)c1-c([nH]c(-c1ncnc(N(C)I)c1)c1)c1C(N)=C YZFKYBPXJZPIAX-UHFFFAOYSA-N 0.000 description 1
- HCNZGOYXNZLSOT-UHFFFAOYSA-N Cc(ccc(Cl)c1)c1C1=CN(C)CC1C#N Chemical compound Cc(ccc(Cl)c1)c1C1=CN(C)CC1C#N HCNZGOYXNZLSOT-UHFFFAOYSA-N 0.000 description 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RWVHZMFCFYBANX-UHFFFAOYSA-N ClC=1C=CC(=C(N)C1)CC.ClC=1C=CC(=C(C1)N1C=CC=C1)CC Chemical compound ClC=1C=CC(=C(N)C1)CC.ClC=1C=CC(=C(C1)N1C=CC=C1)CC RWVHZMFCFYBANX-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102100021808 Eukaryotic elongation factor 2 kinase Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101100273645 Gallus gallus CCNA2 gene Proteins 0.000 description 1
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101100297762 Gibberella zeae (strain ATCC MYA-4620 / CBS 123657 / FGSC 9075 / NRRL 31084 / PH-1) PKS12 gene Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150017137 Haspin gene Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 description 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 description 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 description 1
- 101000895759 Homo sapiens Eukaryotic elongation factor 2 kinase Proteins 0.000 description 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 description 1
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000600885 Homo sapiens Serine/threonine-protein kinase NIM1 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000637847 Homo sapiens Serine/threonine-protein kinase tousled-like 2 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101150058160 Lyn gene Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- URVLIFSCSOGOJH-UHFFFAOYSA-N N-methyl-2-phenyl-5-pyrrolo[2,1-f][1,2,4]triazin-4-yl-1H-pyrrole-3-carboxamide Chemical compound CNC(=O)C1=C(NC(=C1)C1=NC=NN2C1=CC=C2)C2=CC=CC=C2 URVLIFSCSOGOJH-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- JIFWEKALVILBOB-UHFFFAOYSA-N O.NN.ClC=1C=CC(=C(N)C1)CC Chemical compound O.NN.ClC=1C=CC(=C(N)C1)CC JIFWEKALVILBOB-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100037345 Serine/threonine-protein kinase NIM1 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102100032014 Serine/threonine-protein kinase tousled-like 2 Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000008036 Suppressor of Cytokine Signaling Proteins Human genes 0.000 description 1
- 108010075383 Suppressor of Cytokine Signaling Proteins Proteins 0.000 description 1
- 101150110875 Syk gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123582 Telomerase inhibitor Drugs 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- DRBWRJPFNOBNIO-KOLCDFICSA-N [(2r)-1-[(2r)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid Chemical compound N([C@H](C)C(=O)N1[C@@H](CCC1)B(O)O)C(=O)C1=CC=NC=C1 DRBWRJPFNOBNIO-KOLCDFICSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical class 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000676 alkoxyimino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- OTKPPUXRIADSGD-PPRNARJGSA-N avoparcina Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2C([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C(C=C2)[C@@H](O)[C@H](C(N[C@H](C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@H]1C[C@@H](N)[C@@H](O)[C@H](C)O1 OTKPPUXRIADSGD-PPRNARJGSA-N 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004986 diarylamino group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFXLJWUGRPGMFU-UHFFFAOYSA-N dipropoxyphosphinothioyl n,n-diethylcarbamodithioate;sulfane Chemical compound S.CCCOP(=S)(OCCC)SC(=S)N(CC)CC BFXLJWUGRPGMFU-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
- RPMYYRHJEHHLQI-UHFFFAOYSA-N ethyl 3-(5-chloro-2-methylphenyl)-1h-pyrrole-2-carboxylate Chemical compound N1C=CC(C=2C(=CC=C(Cl)C=2)C)=C1C(=O)OCC RPMYYRHJEHHLQI-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- QBCFSFLLYWKWMJ-UHFFFAOYSA-N ethyl 3-oxo-3-phenylpropanoate 1H-imidazole Chemical compound N1C=NC=C1.O=C(CC(=O)OCC)C1=CC=CC=C1 QBCFSFLLYWKWMJ-UHFFFAOYSA-N 0.000 description 1
- ABSHFAKNVLRGHT-UHFFFAOYSA-N ethyl 5-(6-aminopyrimidin-4-yl)-1-(benzenesulfonyl)-3-(5-chloro-2-ethylphenyl)pyrrole-2-carboxylate Chemical compound CCOC(=O)c1c(cc(-c2cc(N)ncn2)n1S(=O)(=O)c1ccccc1)-c1cc(Cl)ccc1CC ABSHFAKNVLRGHT-UHFFFAOYSA-N 0.000 description 1
- ZDWXQOFSGOMFRO-UHFFFAOYSA-N ethyl 5-(6-aminopyrimidin-4-yl)-3-[2-ethyl-5-(trifluoromethyl)phenyl]-1H-pyrrole-2-carboxylate Chemical compound NC1=CC(=NC=N1)C1=CC(=C(N1)C(=O)OCC)C1=C(C=CC(=C1)C(F)(F)F)CC ZDWXQOFSGOMFRO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- PAEYAKGINDQUCT-UHFFFAOYSA-N ethyl-1H-pyrrole-2-carboxylate Natural products CCOC(=O)C1=CC=CN1 PAEYAKGINDQUCT-UHFFFAOYSA-N 0.000 description 1
- PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000008424 iodobenzenes Chemical class 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AXUCYZGYDJQPOR-UHFFFAOYSA-N methyl 2-(5-chloro-2-ethylphenyl)-1h-pyrrole-3-carboxylate Chemical compound CCC1=CC=C(Cl)C=C1C1=C(C(=O)OC)C=CN1 AXUCYZGYDJQPOR-UHFFFAOYSA-N 0.000 description 1
- BIECSXCXIXHDBC-UHFFFAOYSA-N methyl 2-bromo-5-chlorobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1Br BIECSXCXIXHDBC-UHFFFAOYSA-N 0.000 description 1
- ROEMPTYBFWTSSQ-UHFFFAOYSA-N methyl 2-chloro-5-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(C(F)(F)F)=CC=C1Cl ROEMPTYBFWTSSQ-UHFFFAOYSA-N 0.000 description 1
- PTUFQIQUXAKHOW-UHFFFAOYSA-N methyl 2-ethyl-5-(trifluoromethyl)benzoate Chemical compound CCC1=CC=C(C(F)(F)F)C=C1C(=O)OC PTUFQIQUXAKHOW-UHFFFAOYSA-N 0.000 description 1
- FXRXVKXAJXZKKB-UHFFFAOYSA-N methyl 2-methyl-5-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC(C(F)(F)F)=CC=C1C FXRXVKXAJXZKKB-UHFFFAOYSA-N 0.000 description 1
- DHVIMENUJZOYEM-UHFFFAOYSA-N methyl 5-chloro-2-ethylbenzoate Chemical compound CCC1=CC=C(Cl)C=C1C(=O)OC DHVIMENUJZOYEM-UHFFFAOYSA-N 0.000 description 1
- HMGNABFNVYLVMD-UHFFFAOYSA-N methyl 5-chloro-2-methylbenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1C HMGNABFNVYLVMD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- KFRSWPTXYKWRFY-UHFFFAOYSA-N n-methyl-5-[6-(methylamino)pyrimidin-4-yl]-2-phenyl-1h-pyrrole-3-carboxamide Chemical compound CNC(=O)C=1C=C(C=2N=CN=C(NC)C=2)NC=1C1=CC=CC=C1 KFRSWPTXYKWRFY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- WVUCPRGADMCTBN-UHFFFAOYSA-M potassium;3-ethoxy-3-oxopropanoate Chemical compound [K+].CCOC(=O)CC([O-])=O WVUCPRGADMCTBN-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003858 primary carboxamides Chemical class 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 102200087780 rs77375493 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- YLCPETHKVOFRJD-UHFFFAOYSA-N tert-butyl 2-(5-chloro-2-methylphenyl)-4-iodopyrrole-1-carboxylate Chemical compound Cc1ccc(Cl)cc1-c1cc(I)cn1C(=O)OC(C)(C)C YLCPETHKVOFRJD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DSPYCWLYGXGJNJ-UHFFFAOYSA-N tert-butyl n-prop-2-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCC#C DSPYCWLYGXGJNJ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 102000042287 type II cytokine receptor family Human genes 0.000 description 1
- 108091052254 type II cytokine receptor family Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
Description
上記式中、
W環はピロールであり;
R1は場合により置換されたアリール又はヘテロアリールであり;
R2はCN又はCONR6R7であり、前記式中、R6及びR7は独立して水素、又は直鎖もしくは分岐鎖C1−C6アルキル、直鎖もしくは分岐鎖C2−C6アルケニル、直鎖もしくは分岐鎖C2−C6アルキニル、C3−C7シクロアルキル、シクロアルキルアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり、あるいはR6及びR7はそれらが結合している窒素原子と一緒になり、場合によりN、O及びSから選択される更に1個のヘテロ原子を含む場合により置換された5〜7員ヘテロシクリル基を形成してもよく;
R3は水素、ハロ、又は直鎖もしくは分岐鎖C1−C6アルキル、C3−C7シクロアルキル、シクロアルキルアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり;
R4は
上記式中、R8は水素、又は直鎖もしくは分岐鎖C1−C6アルキル、直鎖もしくは分岐鎖C2−C6アルケニル、直鎖もしくは分岐鎖C2−C6アルキニル、C3−C7シクロアルキル、シクロアルキルアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル及びヘテロシクリルアルキル、COR9、CONR10R11並びにSO2R12から選択される場合により置換された基であり、
上記式中、R9は直鎖もしくは分岐鎖C1−C6アルキル、直鎖もしくは分岐鎖C2−C6アルケニル、直鎖もしくは分岐鎖C2−C6アルキニル、C3−C7シクロアルキル、シクロアルキルアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり;
R10及びR11は独立して水素、又は直鎖もしくは分岐鎖C1−C6アルキル、直鎖もしくは分岐鎖C2−C6アルケニル、直鎖もしくは分岐鎖C2−C6アルキニル、C3−C7シクロアルキル、シクロアルキルアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり、あるいはR10及びR11はそれらが結合している窒素原子と一緒になり、場合によりN、O及びSから選択される更に1個のヘテロ原子を含む場合により置換された5〜7員ヘテロシクリル基を形成してもよく;
R12は直鎖もしくは分岐鎖C1−C6アルキル、直鎖もしくは分岐鎖C2−C6アルケニル、直鎖もしくは分岐鎖C2−C6アルキニル、C3−C7シクロアルキル、シクロアルキルアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり;
R5は水素、ハロ、又は直鎖もしくは分岐鎖C1−C6アルキル、C3−C7シクロアルキル、シクロアルキルアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基である。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボニトリル(化合物9);
1−(5−クロロ−2−メチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボニトリル(化合物63);
1−(5−クロロ−2−エチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボニトリル(化合物68);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボニトリル(化合物72);
3−(5−クロロ−2−メチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物123);
3−(5−クロロ−2−エチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物124);
3−[2−エチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物125);
3−(5−クロロ−2−メチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物129);
3−(5−クロロ−2−エチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物130);
3−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物131);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボキサミド(化合物189);
2−(5−クロロ−2−メチルフェニル)−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物190);
2−(5−クロロ−2−メチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物191);
2−(5−クロロ−2−メチルフェニル)−5−(1H−ピロロ[2,3−b]ピリジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物192);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボキサミド(化合物197);
2−(5−クロロ−2−エチルフェニル)−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物198);
2−(5−クロロ−2−エチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物199);
5−(6−アミノピリミジン−4−イル)−2−[2−クロロ−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物204);
2−[2−クロロ−5−(トリフルオロメチル)フェニル]−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物205);
2−[2−クロロ−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物206);
5−(6−アミノピリミジン−4−イル)−2−[2−メチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物211);
5−[6−(メチルアミノ)ピリミジン−4−イル]−2−[2−メチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物212);
2−[2−メチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物213);
5−(6−アミノピリミジン−4−イル)−2−[2−エチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物218);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物219);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物220);
1−(5−クロロ−2−メチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物229);
1−(5−クロロ−2−メチルフェニル)−4−(6,7−ジヒドロ−5H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物234);
4−(6−アミノピリミジン−4−イル)−1−(5−クロロ−2−エチルフェニル)−1H−ピロール−2−カルボキサミド(化合物235);
1−(5−クロロ−2−エチルフェニル)−4−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−2−カルボキサミド(化合物236);
1−(5−クロロ−2−エチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物237);
1−(5−クロロ−2−エチルフェニル)−4−(ピロロ[2,1−f][1,2,4]トリアジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物240);
1−(5−クロロ−2−エチルフェニル)−4−(6,7−ジヒドロ−5H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物241);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物244);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(9H−プリン−6−イル)−1H−ピロール−2−カルボキサミド(化合物245);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(1H−ピラゾロ[3,4−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物246);
4−(6−アミノピリミジン−4−イル)−1−[2−エチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−2−カルボキサミド(化合物256);
4−(5−クロロ−2−メチルフェニル)−1−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物270);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−N−メチル−1H−ピロール−3−カルボキサミド(化合物301);
2−(5−クロロ−2−エチルフェニル)−N−メチル−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物302);
2−(5−クロロ−2−エチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物303);
2−[2−メチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物318);
5−(6−アミノピリミジン−4−イル)−2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−1H−ピロール−3−カルボキサミド(化合物321);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物322);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物323);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1−(2−ヒドロキシエチル)−1H−ピロール−3−カルボキサミド(化合物331)及び
5−(6−アミノピリミジン−4−イル)−3−(5−クロロ−2−メチルフェニル)−1−(2−ヒドロキシエチル)−1H−ピロール−2−カルボキサミド(化合物335)。
工程1:式(II):
あるいは
工程1a:式(III)
工程2:得られた式(IV):
場合により、式(Ia)の化合物を式(Ia)の別の異なる化合物に変換し、所望により、式(Ia)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Ia)に変換する。
工程4:式(VII):
工程5:得られた式(VIII):
NHR6R7(XI)
(式中、R6及びR7は上記に定義した通りである。)のアミン誘導体との反応によりアミド化し、式(Ia):
場合により、式(Ia)の化合物を式(Ia)の別の異なる化合物に変換し、所望により、式(Ia)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Ia)に変換する。
工程8:式(XII):
工程9:得られた式(XIII):
場合により、式(Ib)の化合物を式(Ib)の別の異なる化合物に変換し、所望により、式(Ib)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Ib)に変換する。
工程10:式(XIV):
場合により、式(Ic)の化合物を式(Ic)の別の異なる化合物に変換し、所望により、式(Ic)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Ic)に変換する。
工程11:式(XV):
工程12:得られた式(XVI):
場合により、式(Id)の化合物を式(Id)の別の異なる化合物に変換し、所望により、式(Id)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Id)に変換する。
工程15:式(XIX):
工程16:得られた式(XX):
場合により、式(Ie)の化合物を式(Ie)の別の異なる化合物に変換し、所望により、式(Ie)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(Ie)に変換する。
変換法1)酸性条件下で加水分解することにより、R2がCNである式(I)の化合物を、R2がCONH2である式(I)の対応する化合物に変換する;
変換法2)式(I)の化合物を十分にtert−ブトキシカルボニル化し、式(XXIII):
NHR6R7(XXIII)
(式中、R6及びR7は上記に定義した通りであるが、両方が水素ではない。)のアミン誘導体で処理し、tert−ブトキシカルボニル保護基を脱保護することにより、R2がCONH2である式(I)の化合物を、R2がCONR6R7(式中、R6及びR7は上記に定義した通りであるが、両方が水素ではない。)である式(I)の対応する化合物に変換する;
変換法3)N,N−ジメチルホルムアミド等の溶媒中、塩基の存在下に室温から還流までの温度にて約30分間から約96時間まで式R5−X(XXIV)又はR3−X(XXV)(式中、R5又はR3は夫々直鎖もしくは分岐鎖C1−C6アルキル、C3−C7シクロアルキル、シクロアルキルアルキル、ヘテロシクリル及びヘテロシクリルアルキルから選択される場合により置換された基であり、Xはハロゲンである。)の場合により置換されたハロゲン化アルキルで処理することにより、R5が水素である式(Ia)の化合物又はR3が水素である(Id)の化合物を、R5又はR3が夫々上記に定義した通りである式(Ia)又は(Id)の対応する化合物に変換する。
場合により医薬的に許容可能な塩の形態である本発明の式(I)の特定の化合物については、実験セクションと特許請求の範囲を参照されたい。以下の実施例に示すように、本願に記載する方法又は当分野で周知の他の方法を使用して本発明の化合物を合成した。
薄層クロマトグラフィーはMerckシリカゲル60 F254プレコートプレートで実施した。カラムクロマトグラフィーは中圧下にシリカ(Merckシリカゲル40〜63μm)で実施するか、又はプレパックシリカゲルカートリッジ(Biotage又はVarian)に接続したBiotage SP1フラッシュ精製システムを使用して実施した。成分を紫外光(λ:254nm)とヨウ素蒸気により可視化した。必要な場合には、996 Waters PDA検出器を装備したWaters分取HPLC 600と、電子スプレーイオン化の正イオンモードに設定したMicromassモデルZMDシングル四重極型質量分析計を使用してWaters Symmetry C18(19×50mm,5μm)カラム又はWaters X Terra RP 18(30×150mm,5μm)カラムで分取HPLCにより化合物を精製した。手法1:A相:0.1%TFA/ACN=95/5;B相:ACN/H2O=95/5。10→90%Bのグラジエント8分間、90%Bに2分間維持;流速20mL/分。手法2:A相:0.05%NH4OH/ACN=95/5;B相:ACN/H2O=95/5。10→100%Bのグラジエント8分間、100%Bに2分間維持;流速20mL/分。
2−クロロ−5−(トリフルオロメチル)安息香酸メチル
1H NMR(500MHz,DMSO−d6)δ 8.08(s,1H),7.86(dd,J=1.6,7.9Hz,1H),7.60(d,J=7.9Hz,1H),3.87(s,3H),2.60(s,3H)。
1H NMR(400MHz,DMSO−d6)δ 8.10(d,J=1.6Hz,1H),8.02(d,J=8.3Hz,1H),7.85(dd,J=2.1,8.4Hz,1H),3.89(s,3H)。
5−クロロ−2−エチル安息香酸メチル
1H NMR(600MHz,DMSO−d6)δ 8.04(d,J=1.10Hz,1H),7.88(dd,J=1.5,8.2Hz,1H),7.62(d,J=8.1Hz,1H),3.87(s,3H),2.97(q,J=7.6Hz,2H),1.18(t,J=7.6Hz,3H)。
5−ブロモ−2−(5−クロロ−2−メチルフェニル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル(III)
−78℃まで冷却したLiHMDS(76mL,1M溶液)のTHF(70mL)溶液にACN(4.1mL,79mmol)を滴下した。溶液を−78℃で1時間撹拌し、5−クロロ−2−メチル安息香酸メチル(7.38g,40mmol)のTHF(20mL)溶液を加えた。反応混合物を16時間かけて室温まで昇温した。次にNH4Cl(110mL,10%水溶液)を加え、混合物をEtOAc(120mL)で抽出した。水層を更にEtOAc(80mL)で抽出し、Na2SO4で乾燥し、蒸発乾涸した。粗生成物である残渣をフラッシュクロマトグラフィー(ヘキサン/EtOAc 85/15)により精製し、標記化合物を得た(6.2g,80%)。
3−(5−クロロ−2−メチルフェニル)−3−オキソプロパンニトリル(4.65g,24mmol)と、2−アミノアセトアルデヒドジエチルアセタール(3.85mL,26.5mmol)と、トルエン(150mL)の混合物を窒素雰囲気下でディーン・スターク装置にて一晩還流下で撹拌した。混合物を減圧蒸発させ、それ以上精製せずに次工程で使用した。
粗生成物である3−(5−クロロ−2−メチルフェニル)−3−[(2,2−ジエトキシエチル)アミノ]プロプ−2−エンニトリルをDCM(10mL)に溶解し、5℃のTFA(20mL)に加えた。室温で30分間撹拌後、反応混合物を濃縮し、次いでEtOAcと飽和NaHCO3溶液で希釈した。有機層を分離し、水とブラインで洗浄し、Na2SO4で乾燥し、濃縮した。シリカゲルカラムクロマトグラフィー(EtOAc/ヘキサン,0%→20%グラジエント溶出)により標記化合物を得た(2.31g,45%,2段階)。
1H NMR(400MHz,DMSO−d6)δ 11.99(br.s.,1H),7.47−7.52(m,1H),7.41−7.46(m,1H),7.31−7.37(m,1H),7.02(t,J=2.81Hz,1H),6.53−6.61(m,1H),2.58(q,J=7.53Hz,2H),0.99(t,J=7.51Hz,3H)。
1H NMR(400MHz,DMSO−d6)δ 12.23(br.s.,1H),7.80−7.96(m,3H),7.12(t,J=2.81Hz,1H),6.65(t,J=2.69Hz,1H)。
1H NMR(500MHz,DMSO−d6)δ 12.08(br.s.,1H),7.74(d,J=7.96Hz,1H),7.65(s,1H),7.62(d,J=8.24Hz,1H),7.08(t,J=2.75Hz,1H),6.62(t,J=2.61Hz,1H),2.36−2.39(m,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.05(br.s.,1H),7.79(dd,J=1.46,8.06Hz,1H),7.66(d,J=8.24Hz,1H),7.61(s,1H),7.06(t,J=2.75Hz,1H),6.61(t,J=2.75Hz,1H),2.69(q,J=7.51Hz,1H),2.07(s,1H),1.11−1.52(m,1H),1.04(t,J=7.51Hz,1H)。
1H NMR(600MHz,DMSO−d6)δ 12.15(br.s.,1H),7.94(dd,J=1.28,8.42Hz,2H),7.76(dd,J=1.28,8.42Hz,2H),7.49−7.54(m,2H),7.36−7.42(m,1H),7.02(t,J=2.84Hz,1H),6.58(dd,J=2.38,2.93Hz,1H)。
2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(1.733g,8.0mmol)の無水THF(25mL)懸濁液に0℃にてNaH(60%鉱油分散物,0.452g,11.3mmol)を加えた。反応液を同温度に20分間維持した後、2−[(クロロメトキシ)エチル](トリメチル)シラン(2.0mL,11.3mmol)を加え、混合物を室温で2時間撹拌した。飽和NaCl溶液(30mL)を0℃で加え、混合物をEtOAc(2×35mL)で抽出した。有機相を分離し、Na2SO4で乾燥し、溶媒を蒸発させ、標記化合物を得た(2.637g,95%)。
2−(5−クロロ−2−メチルフェニル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル(2.5g,7.2mmol)の2/1 MeOH/THF(450mL)溶液に5℃にてNBS(1.281g,7.2mmol)を3時間かけて3回に分けて加えた。添加後毎に混合物を室温で撹拌した。混合物を減圧蒸発させた。飽和NaCl溶液を加え、混合物をEtOAcで抽出した。有機相を分離し、Na2SO4で乾燥し、溶媒を蒸発させ、粗生成物をフラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(2.14g,70%)。
1H NMR(600MHz,DMSO−d6)δ 7.59(dd,J=2.4,8.4Hz,1H),7.47−7.51(m,1H),7.40(d,J=2.4Hz,1H),6.91(s,1H),5.15(d,J=11.2Hz,1H),4.89(d,J=11.2Hz,1H),2.40−2.47(m,1H),2.29−2.36(m,1H),1.05(t,J=7.5Hz,3H),0.65−0.78(m,2H),−0.07(s,9H)。
1H NMR(400MHz,DMSO−d6)δ 8.03(s,1H),7.93−8.01(m,2H),6.98(s,1H),5.23(d,J=11.4Hz,1H),5.06(d,J=11.4Hz,1H),3.27−3.30(m,2H),0.61−0.77(m,2H),−0.11(m,9H)。
1H NMR(600MHz,DMSO−d6)δ 7.80−7.90(m,1H),7.73(s,1H),7.68(d,J=7.9Hz,1H),6.94(s,1H),5.15(d,J=11.2Hz,1H),4.93(d,J=11.2Hz,1H),3.28−3.30(m,2H),2.22(s,3H),0.62−0.75(m,2H),−0.10(s,9H)。
1H NMR(600MHz,DMSO−d6)δ 7.89(dd,J=1.5,8.2Hz,1H),7.71(d,J=8.1Hz,1H),7.69(s,1H),6.94(s,1H),5.14(d,J=11.2Hz,1H),4.88(d,J=11.2Hz,1H),3.28−3.30(m,2H),2.55−2.59(m,1H),2.44(qd,J=7.4,14.7Hz,1H),1.08−1.12(m,3H),0.65−0.76(m,2H),−0.09(s,9H)。
1H NMR(600MHz,DMSO−d6)δ 7.51−7.63(m,5H),6.91(s,1H),5.23(s,2H),3.34−3.38(m,2H),0.71−0.78(m,2H),−0.08(s,9H)。
2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(400mg,1.85mmol)のACN(20mL)溶液に5℃にてNBS(329mg,1.85mmol)を2時間かけて2回に分けて加えた。添加後毎に混合物を室温で撹拌した。混合物を減圧蒸発させ、粗生成物をフラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(379mg,69%)。
1H NMR(400MHz,DMSO−d6)δ 12.73(br.s.,1H),7.51(dd,J=2.20,8.43Hz,1H),7.44(d,J=8.42Hz,1H),7.39(d,J=2.38Hz,1H),6.72(s,1H),2.58(q,J=7.57Hz,2H),1.02(t,J=7.60Hz,3H)。
2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−3−カルボニトリル(II)
2−フェニル−1−(フェニルスルホニル)−1H−ピロール−3−カルボン酸エチル(VII)
安息香酸(5.0g,41mmol)のDMF(50mL)溶液にカルボニルジイミダゾール(7.31g,45mmol)を加えた。混合物を室温で撹拌した。2時間後に塩化マグネシウム(4.68g,49mmol)とモノエチルマロン酸カリウム(14g,82mmol)を加えた。反応が完了するまで混合物を撹拌下に100℃まで加熱後、室温まで冷却し、氷水750mLにゆっくりと加え、固形分を沈澱させた。固形分を濾取して標記化合物(8.66g,81.1%)を得、それ以上精製せずに次工程で使用した。
2,2−ジエトキシエタンアミン(6.43g,48.3mmol)とTEA(6.84g,67.62mmol)のEtOAc(70mL)溶液に室温にて塩化アセチル(4.17g,53.14mmol)を加えた。1時間後にEtOH(0.7mL)を加えた。得られた懸濁液を1時間撹拌後、濾過した。EtOAcを濾液から蒸発させて除去し、N−(2,2−ジエトキシエチル)アセトアミドを油状物として得、それ以上精製せずに次工程で使用した。3−オキソ−3−フェニルプロパン酸エチル−1H−イミダゾール(8.66g,33.26mmol)をTFA(10.6mL)中でN−(2,2−ジエトキシエチル)アセトアミド(48.3mmol)により処理した。反応混合物を60分間60℃に加熱後、TFAを蒸発により除去し、油性残渣をEtOAcに溶解し、水と飽和NaHCO3溶液で2回洗浄した。有機層を回収し、溶媒を蒸発させ、暗色油状物を得た。油状物をEtOH(28mL)と2N NaOH(14mL)で処理し、得られた反応混合物を室温で一晩撹拌した。溶液を氷水にゆっくりと加え、濾過後に標記化合物を得た(6.2g,55.8%)。
アルゴン雰囲気下で5℃にて2−フェニル−1H−ピロール−3−カルボン酸エチル(1.0g,4.65mmol)のDMF(12mL)溶液にNaH(60%油分散物,223mg,5.58mmol)を加えた。反応混合物を1時間撹拌後、ベンゼンスルホニルクロリド(0.653mL,5.11mmol)を滴下した。2時間後に反応混合物を氷水に撹拌下に加えた。EtOAc(150mL)を加え、有機層を分離し、水とブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて油状物を得、Biotage SP1フラッシュクロマトグラフィー(シクロヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(1.24g,75%)。
5−クロロ−2−エチルアニリン
8℃まで冷却した硫酸(96%,63mL)に、温度を10℃未満に維持しながら4−エチルアニリン(10.3mL,82.5mmol)を滴下した。添加後、反応混合物を−5℃まで冷却した後、温度を0℃未満に維持しながら硝酸(100%,4mL)と硫酸(96%,10mL)の混液を加えた。次に反応混合物を同温度で1時間撹拌した。反応混合物を氷(200mL)に注ぎ、沈澱を濾過し、水洗した。固形分を水(100mL)に懸濁し、NH4OH(35%)で中和した。沈澱を濾過し、オーブン乾燥し、薄茶色固体を得た(10.0g,73%)。
4−エチル−3−ニトロアニリン(10g,60mmol)の濃HCl(200mL)溶液を冷却(5℃)し、これに亜硝酸ナトリウム水溶液(4.2g,60mmol,5M,12mL)を滴下し、反応混合物を同温度で1.5時間撹拌した。次にCuCl(9.5g,96mmol)を加え、溶液を室温で1時間、次いで80℃で更に1時間撹拌した。冷却後に反応混合物をDCM(3×100mL)で抽出し、有機層を合わせてNa2SO4で乾燥した。次に粗生成物をフラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を黄色油状物として得た(6.28g,56%)。
ヒドラジン水和物(6.95mL,134.7mmol)のメタノール(50mL)溶液を塩化鉄(III)(547mg,3.4mmol)と活性炭(547mg)の存在下で4−クロロ−1−エチル−2−ニトロベンゼン(6.25g,33.7mmol)のメタノール(120mL)溶液に滴下し、反応混合物を14時間還流下で撹拌した。セライト濾過により固形分を除去し、濾液を濃縮し、フラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を薄いピンク色の油状物として得た(5.09g,97%)。
2−エチル−5−(トリフルオロメチル)アニリン
1−ブロモ−2−ニトロ−4−(トリフルオロメチル)ベンゼン(6.14mL,40.1mmol)を2−プロパノール(200mL)に溶解した。この混合物にTEA(19.8mL,140.3mmol)とカリウムビニルトリフルオロボラート(6.44g,48.1mmol)を加えた。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、PdCl2(dppf)(1.5g,2.0mmol)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、還流まで3時間昇温した。反応混合物を室温まで冷却し、セライトパッドで濾過し、EtOAcで洗浄し、濾液を濃縮後、EtOAcと水で希釈した。2層を分離し、水層をEtOAcで抽出した。有機画分を合わせてブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をフラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(5.6g,64%)。
1−エテニル−2−ニトロ−4−(トリフルオロメチル)ベンゼン(2.2g,10.13mmol)をTHF(150mL)に溶解し、H2(40psi)下で室温にて10% Pd/C(200mg)の存在下で8時間振盪した。反応混合物をセライトパッドで濾過し、EtOAcで洗浄し、濾液を濃縮した。残渣をフラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(1.76g,92%)。
4−ブロモ−1−(5−クロロ−2−エチルフェニル)−1H−ピロール−2−カルボニトリル(XII)
5−クロロ−2−エチルアニリン(10.8g,69.44mmol)と2,5−ジメトキシテトラヒドロフラン(9.87mL,76.38mmol)をAcOH(20mL)中で3時間還流した。反応混合物を蒸発させ、残渣をEtOAcで希釈し、水、飽和NaHCO3溶液、ブラインで洗浄後、Na2SO4で乾燥した。溶媒を蒸発させ、粗生成物をBiotage SP1フラッシュクロマトグラフィー(ヘキサン中0%→15% EtOAcでグラジエント溶出)により精製し、標記化合物を得た(12.52g,88%)。
1−(5−クロロ−2−エチルフェニル)−1H−ピロール(11.8g,57.56mmol)の無水AC(150ml)溶液に0℃にてイソシアン酸クロロスルホニル(5.32mL,61.11mmol)を滴下した。混合物を同温度で30分間撹拌後、この混合物にDMF(12mL)を滴下した。同温度で1時間撹拌後、反応混合物を氷水に注ぎ、10分間撹拌後、EtOAcで希釈した。有機層を分離し、水層をEtOAcで2回抽出した。有機相を合わせてNa2SO4で乾燥し、減圧蒸発させた。粗生成物をBiotage SP1フラッシュクロマトグラフィー(ヘキサン中0%→15% EtOAcでグラジエント溶出)により精製し、標記化合物を得た(10.62g,80%)。
1−(5−クロロ−2−エチルフェニル)−1H−ピロール−2−カルボニトリル(2.307g,10mmol)のTHF(50mL)溶液にNBS(1.87g,10.5mmol)のTHF(50mL)溶液を加えた。混合物を室温で90分間撹拌後、NBS(356mg,2mmol)のTHF(10mL)溶液を加えた。混合物を室温で90分間撹拌後、減圧蒸発させた。飽和NaCl溶液を加え、混合物をEtOAcで抽出した。有機相を分離し、Na2SO4で乾燥し、溶媒を蒸発させ、粗生成物をBiotage SP1フラッシュクロマトグラフィー(ヘキサン中0%→15% EtOAcでグラジエント溶出)により精製し、標記化合物を得た(2.38g,77%)。
1H NMR(400MHz,DMSO−d6)δ 7.66(d,J=1.7Hz,1H),7.63(d,J=2.2Hz,1H),7.55−7.59(m,1H),7.50(d,J=8.5Hz,1H),7.38(d,J=1.7Hz,1H),2.06(s,1H)。
1H NMR(400MHz,DMSO−d6)δ 8.26(s,1H),8.03(d,J=0.7Hz,2H),7.77(d,J=1.8Hz,1H),7.45(d,J=1.7Hz,1H)。
ESI(+)MS:m/z 330(MH+)。
1H NMR(600MHz,DMSO−d6)δ 7.89−7.95(m,2H),7.76(d,J=7.9Hz,1H),7.74(d,J=1.6Hz,1H),7.41(d,J=1.6Hz,1H),2.44(q,J=7.3Hz,2H),1.08(t,J=7.3Hz,3H)。
ESI(+)MS:m/z 248(MH+)。
4−クロロ−2−ヨード−1−エチルベンゼン
1−エチル−2−ヨード−4−(トリフルオロメチル)ベンゼン
水素雰囲気(45psi)下で1−エテニル−4−(トリフルオロメチル)ベンゼン(1.72mL,11.6mmol)のTHF(60mL)溶液をPd/C(10%,400mg)の存在下で7時間撹拌した。固形分をセライト濾過(DCMで洗浄)し、浴の温度を200mmHgで20℃未満に維持しながら濾液を注意深く濃縮した。こうして得られた濃縮溶液をそれ以上操作せずに次工程で使用した。
過ヨウ素酸ナトリウム(3.73g,17.4mmol)とヨウ素(2.95g,11.6mmol)を酢酸(8.45mL)と無水酢酸(4.23mL)の混液に溶解した0℃の溶液に硫酸(96%,1.9mL)を滴下した後、1−エチル−4−(トリフルオロメチル)ベンゼン(2.0g,11.6mmol)を滴下した。反応混合物を24時間撹拌しながら室温まで昇温した。メタ重亜硫酸ナトリウム(10%)の溶液を加えて残留しているヨウ素をクエンチし、引き続いてNaOH(35%)を加えてpH=7とした。水層をDCM(3×50mL)で抽出し、有機層を合わせてNa2SO4で乾燥した。溶媒を除去した後、粗生成物をそれ以上精製せずに次工程で使用した。
4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(XIV)
アルゴン下で−78℃にて4−クロロ−2−ヨード−1−メチルベンゼン(5.0g,19.8mmol)のTHF(40mL)溶液にn−BuLi(2.5Mヘキサン溶液,8.72mL,21.8mmol)をゆっくりと滴下した。混合物を−78℃で1時間撹拌後、DMF(7.7mL,99mmol)を加えた後、室温まで4時間昇温し、1N HCl(5mL)でクエンチした。反応混合物を一晩撹拌し、1N HCl(50mL)とEt2Oで希釈し、有機相を分離し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、蒸発させ、標記化合物(3.14g,94%)を黄色油状物として得た。
反応温度を10℃未満に維持しながら、NaH(60%油分散物,950mg,23.28mmol)の無水THF(43mL)懸濁液にシアノメチルホスホン酸ジエチル(3.67ml,23.28mmol)のTHF(17mL)溶液を5℃にて20分間かけて滴下した。懸濁液を5℃で60分間撹拌した。反応温度を10℃未満に維持しながら、5−クロロ−2−メチルベンズアルデヒド(2.99g,19.4mmol)のTHF(30mL)溶液を20分間かけて滴下した。反応混合物を室温まで昇温し、一晩撹拌した。水を加え、溶媒を蒸発させ、残渣をEtOAcと水に分配した。水層を分離し、EtOAcで抽出し、有機層を合わせて水、ブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させ、標記化合物(3.26g,95%)を淡黄色油状物として得た。
反応温度を5℃未満に維持しながら、NaH(60%油分散物,263mg,6.58mmol)の無水THF(40mL)懸濁液に3−(5−クロロ−2−メチルフェニル)アクリロニトリル(970mg,15.48mmol)と(p−トルエンスルホニル)メチルイソシアニド(1.28g,6.58mmol)のTHF(20mL)溶液をを5℃にて10分間かけて滴下した。反応混合物を室温まで昇温し、一晩撹拌した。水を加え、溶媒を蒸発させ、残渣をDCMと水に分配した。水層を分離し、DCMで抽出し、有機層を合わせて水、ブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させ、粗生成物をBiotage SP1フラッシュクロマトグラフィー(ヘキサン/EtOAc 7/3)により精製し、標記化合物を得た(497mg,42%)。
ESI(+)MS:m/z 231(MH+)。
ESI(+)MS:m/z 271(MH+)。
ESI(+)MS:m/z 251(MH+)。
ESI(+)MS:m/z 265(MH+)。
ESI(+)MS:m/z 169(MH+)。
3−(5−クロロ−2−メチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−2−カルボン酸エチル(XV)
アルゴン雰囲気下で0℃にてメチル−(4−メチルフェニル)スルホン(6.74g,39.6mmol)のTHF(200mL)溶液にn−BuLi(2.5Mヘキサン溶液,34.8mL,87.12mmol)を滴下した。0℃で30分間撹拌後、クロロリン酸ジエチル(5.70mL,39.6mmol)のTHF(30mL)溶液をゆっくりと滴下した。反応混合物を0℃で30分間撹拌後、−78℃まで冷却した後、5−クロロ−2−メチルベンズアルデヒド(6.1g,39.6mmol)のTHF(10mL)溶液を加えた。−78℃で1時間撹拌後、反応混合物の温度を室温まで上げた。水(50mL)を加え、反応混合物を減圧濃縮して沈澱を得、濾過し、水洗し、減圧下でオーブン乾燥し、標記化合物をベージュ色固体として得た(8.24g,68%)。
アルゴン雰囲気下で室温にてNaH(60%油分散物,2.25g,56.19mmol)の無水THF(140mL)懸濁液に[(E)−2−(5−クロロ−2−メチルフェニル)エテニル](4−メチルフェニル)スルホン(8.18g,26.76mmol)とイソシアノ酢酸エチル(5.85mL,53.52 mmoL)のTHF(200mL)溶液を1時間かけて滴下した。反応混合物を2時間撹拌後、水とEtOAcを加えた。有機層を分離し、水とブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて茶色い油状物を得、Biotage SP1フラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(3.44g,49%)。
アルゴン雰囲気下で5℃にて3−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボン酸エチル(526mg,2mmol)のDMF(5mL)溶液にNaH(60%油分散物,96mg,2.4mmol)を加えた。反応混合物を1時間撹拌後、ベンゼンスルホニルクロリド(0.306mL,2.4mmol)を滴下した。室温で2.5時間後に反応混合物を氷水に撹拌下に加えた。EtOAcを加え、有機層を分離し、水とブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて油状物を得、Biotage SP1フラッシュクロマトグラフィー(ヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(783mg,97%)。
1H NMR(600MHz,DMSO−d6)δ 7.94−8.06(m,2H),7.85(d,J=3.30Hz,1H),7.77−7.82(m,1H),7.68−7.73(m,2H),7.34−7.37(m,1H),7.28−7.31(m,1H),7.08(d,J=2.38Hz,1H),6.51(d,J=3.30Hz,1H),3.93(q,J=7.08Hz,2H),2.28−2.40(m,2H),0.94(t,J=7.60Hz,3H),0.78(t,J=7.05Hz,3H)。
ESI(+)MS:m/z 458(MH+)。
ESI(+)MS:m/z 438(MH+)。
1H NMR(600MHz,DMSO−d6)δ 8.04(dd,J=1.19,8.52Hz,2H),7.89(d,J=3.11Hz,1H),7.79−7.82(m,1H),7.69−7.73(m,2H),7.66(d,J=8.06Hz,1H),7.52(d,J=8.06Hz,1H),7.35(s,1H),6.57(d,J=3.30Hz,1H),3.88(q,J=7.02Hz,2H),2.43−2.49(m,2H),0.98(t,J=7.51Hz,3H),0.71(t,J=7.14Hz,3H)。
ESI(+)MS:m/z 356(MH+)。
2−(5−クロロ−2−メチルフェニル)−4−ヨード−1H−ピロール−1−カルボン酸tert−ブチル(XIX)
ESI(+)MS:m/z 432(MH+)。
ESI(+)MS:m/z 472(MH+)。
ESI(+)MS:m/z 452(MH+)。
ESI(+)MS:m/z 466(MH+)。
ESI(+)MS:m/z 370(MH+)。
4−クロロ−7−(4−メトキシベンジル)−6,7−ジヒドロ−5H−ピロロ[2,3−d]ピリミジン(V)
2−(4,6−ジクロロピリミジン−5−イル)エタノール(470mg,2.43mmol)のEtOH(10mL)溶液にDIPEA(592μL,2.9mmol)と4−メトキシベンジルアミン(380μL,3.40mmol)を加えた。溶液を5時間還流した。溶媒を減圧除去し、残渣をEtOAcで希釈し、水洗し、Na2SO4で乾燥し、濾過し、減圧濃縮し、標記化合物を油状物として得た(520mg,73%)。
2−{4−クロロ−6−[(4−メトキシベンジル)アミノ]ピリミジン−5−イル}エタノール(293mg,1mmol)をトルエン(5mL)中でSOCl2(145μL,2mmol)により処理した。反応混合物を1時間還流後、濃縮し、標記化合物を油状物として得た。粗生成物を精製せずに後続反応で使用した。
6−クロロ−5−(2−クロロエチル)−N−(4−メトキシベンジル)ピリミジン−4−アミンのDMF(5ml)溶液にK2CO3(414mg,3mmol)を加えた後、110℃まで2時間昇温した。反応混合物を水で希釈し、EtOAcで抽出し、Na2SO4で乾燥し、濾過し、減圧濃縮し、標記化合物を油状物として得た(261mg,95%)。
2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−3−カルボン酸メチル(VII)
4−クロロ−1−エチル−2−ヨードベンゼン(2.66g,10mmol)とプロピオール酸メチル(1.79mL,20mmol)のDMF(20mL)溶液にCu2O(1.43g,10mmol)を加えた。反応液を機械的撹拌下に110℃(油浴温度)まで20時間加熱した。反応液をセライトプラグで濾過し、プラグをEtOAc(100mL)で洗浄し、濾液を先ず水洗した後、ブラインで洗浄した。有機相を硫酸ナトリウムで乾燥し、蒸発させ、粗生成物をシリカゲルクロマトグラフィー(ヘプタン/Et2O 95/5)により精製し、標記化合物を油状物として得た(1.29g,58%)。
3−(5−クロロ−2−エチルフェニル)プロプ−2−イン酸メチル(500mg,2.25mmol)をDMF(4.5mL)中で2,2−ジエトキシエタンアミン(0.368mL,2.48mmol)により処理し、110℃(油浴温度)まで18時間加熱した。揮発分を減圧蒸発させ、粗生成物を無水酢酸(9mL)中で加熱還流した。10時間後に反応を完了し、揮発分を減圧除去し、標記化合物を得、それ以上精製せずに次工程で利用した。
3−[アセチル(2,2−ジエトキシエチル)アミノ]−3−(5−クロロ−2−エチルフェニル)プロプ−2−エン酸メチル(2.25mmol)のDCM(0.350mL)溶液を塩化マグネシウム(43mg,0.45mmol)のTFA(0.6mL)溶液に加え、65℃(油浴温度)まで加熱した。30分後に反応液を蒸発させ、粗生成物をシリカゲルクロマトグラフィー(ヘキサン:EtOAc 8:2)により単離し、標記化合物を黄色い結晶固体として得た(142mg,24%)。
アルゴン雰囲気下で5℃にて2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボン酸メチル(0.2g,0.76mmol)のDMF(3mL)溶液にNaH(60%油分散物,36mg,0.91mmol)を加えた。反応混合物を1時間撹拌後、ベンゼンスルホニルクロリド(0.106mL,0.83mmol)を滴下した。2時間後に反応混合物を氷水に撹拌下に加えた。EtOAc(30mL)を加え、有機層を分離し、水とブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて油状物を得、Biotage SP1フラッシュクロマトグラフィー(シクロヘキサン/EtOAc 9/1)により精製し、標記化合物を得た(248mg,81%)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(化合物1)
工程1a:2−(5−クロロ−2−メチルフェニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル(IV)
アルゴン下で−78℃にて5−ブロモ−2−(5−クロロ−2−メチルフェニル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル(948mg,2.23mmol)のTHF(10mL)溶液に2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.683mL,3.35mmol)を加えた。−78℃にてn−BuLi(2.5Mヘキサン溶液,1.95mL,5.025mmol)をゆっくりと滴下した。混合物を−78℃で1時間撹拌した。MeOH(1.5mL)を加え、得られた混合物をゆっくりと昇温後に室温で撹拌した。NH4Cl溶液(10mL)を加え、混合物をEtOAc(30mL)で抽出し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮し、それ以上精製せずに次工程で使用した。
50mL容丸底フラスコに撹拌棒、冷却器及びアルゴンと真空に接続した三方弁を装着し、室温で前工程からの2−(5−クロロ−2−メチルフェニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル、6−ヨードピリミジン−4−アミン(740mg,3.35mmol)、2M Na2CO3(3.35mL,6.70mmol)及びジオキサン(22mL)を仕込んだ。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、PdCl2(dppf)(182mg,0.223mmol)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、110℃まで1時間昇温した。反応混合物を室温まで冷却し、セライトパッドで濾過し、EtOAcで洗浄し、濾液を濃縮後、EtOAc(30mL)と水(10mL)で希釈した。2層を分離し、水層をEtOAc(25mL)で抽出した。有機画分を合わせてブライン水溶液(2×20mL)で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 97/2/1)により精製し、標記化合物を得た(343mg,35%,2段階)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1−{[2−(トリメチルシリル)エトキシ]メチル}−1H−ピロール−3−カルボニトリル(61mg,0.14mmol)の無水DCM(2.8mL)溶液にTFA(1.4mL)を加え、室温で4時間撹拌した。溶媒除去後、残渣をEtOH(3mL)と33% NH4OH(0.4mL)で処理し、30分間撹拌した。溶媒を蒸発乾涸し、残渣をフラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 93/7/0.7)により精製し、標記化合物を固体として得た(28mg,65%)。
ESI(+)MS:m/z 324(MH+)。
ESI(+)MS:m/z 334(MH+)。
1H NMR(400MHz,DMSO−d6)δ 12.94(br.s.,1H),12.21(br.s.,1H),8.75(s,1H),7.70(br.s.,1H),7.64(dd,J=2.5,3.4Hz,1H),7.45−7.52(m,2H),7.39−7.43(m,1H),7.09(dd,J=1.7,3.5Hz,1H),2.32(s,3H)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 334(MH+)。
ESI(+)MS:m/z 336(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.71(br.s.,1H),8.36(d,J=0.9Hz,1H),7.48−7.53(m,1H),7.44(d,J=8.4Hz,1H),7.41(d,J=2.4Hz,1H),7.22(s,1H),6.89(s,2H),6.73(d,J=1.1Hz,1H),2.61(q,J=7.6Hz,2H),1.01(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.78(br.s.,1H),8.54(br.s.,1H),8.19(br.s.,1H),7.52−7.61(m,1H),7.42−7.52(m,3H),6.90(br.s.,1H),2.89(br.s.,3H),2.61(q,J=7.6Hz,2H),1.01(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.96(br.s.,1H),12.21(br.s.,1H),8.73(s,1H),7.71(s,1H),7.60−7.66(m,1H),7.50−7.55(m,1H),7.40−7.47(m,2H),7.09(d,J=2.0Hz,1H),2.65(q,J=7.5Hz,2H),1.03(t,J=7.5Hz,3H)。
ESI(+)MS:m/z 349(MH+)。
ESI(+)MS:m/z 349(MH+)。
ESI(+)MS:m/z 348(MH+)。
ESI(+)MS:m/z 350(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.90(br.s.,1H),8.38(d,J=1.1Hz,1H),7.96(s,1H),7.84−7.92(m,2H),7.28(s,1H),6.94(s,2H),6.75(d,J=1.28Hz,1H)。
1H NMR(600MHz,DMSO−d6)δ 12.53−13.20(m,1H),8.44(br.s.,1H),7.72−8.05(m,3H),7.23−7.56(m,1H),6.82(br.s.,1H),2.84(d,J=3.5Hz,3H)。
ESI(+)MS:m/z 388(MH+)。
ESI(+)MS:m/z 389(MH+)。
ESI(+)MS:m/z 389(MH+)。
ESI(+)MS:m/z 388(MH+)。
ESI(+)MS:m/z 390(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.77(br.s.,1H),8.37(d,J=0.9Hz,1H),7.76(d,J=8.0Hz,1H),7.71(s,1H),7.62(d,J=8.0Hz,1H),7.25(s,1H),6.91(s,2H),6.74(d,J=1.1Hz,1H),2.41(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.76(br.s.,1H),8.42(br.s.,1H),7.76(d,J=7.9Hz,1H),7.72(s,1H),7.63(d,J=7.9Hz,1H),7.35(br.s.,2H),6.81(br.s.,1H),2.83(d,J=4.21Hz,3H),2.41(s,3H)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 370(MH+)。
ESI(+)MS:m/z 358(MH+)。
ESI(+)MS:m/z 372(MH+)。
1H NMR(600MHz,DMSO−d6)δ 13.05(br.s.,1H),12.22(br.s.,1H),8.74(s,1H),7.82(d,J=8.6Hz,1H),7.74(s,1H),7.72(s,1H),7.67(d,J=8.0Hz,1H),7.62−7.66(m,J=2.7Hz,1H),7.10(d,J=2.4Hz,1H),2.76(q,J=7.6Hz,2H),1.08(t,J=7.5Hz,3H)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 384(MH+)。
ESI(+)MS:m/z 262(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.64(br.s.,1H),8.54(br.s.,1H),7.79−7.88(m,1H),7.57(t,J=7.7Hz,1H),7.47−7.51(m,1H),7.35−7.41(m,1H),6.93(br.s.,1H),2.90(d,J=4.40Hz,3H)。
ESI(+)MS:m/z 286(MH+)。
ESI(+)MS:m/z 286(MH+)。
ESI(+)MS:m/z 288(MH+)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボニトリル(化合物9)
工程1:2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−3−カルボニトリル(IV)
アルゴン下で−78℃にて2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−3−カルボニトリル(1.02g,2.77mmol)と2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.791mL,3.88mmol)のTHF(8.5mL)溶液にLDA(2M THF/ヘプタン/エチルベンゼン溶液,4.6mL,9.15mmol)をゆっくりと滴下した。50分後にMeOH(4mL)を加え、昇温し、NH4Cl溶液(20mL)を室温で滴下した。次に反応液を水で希釈し、Et2Oで抽出し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて標記化合物を得、それ以上精製せずに使用した。
2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−3−カルボニトリル(2.77mmol)、6−ヨードピリミジン−4−アミン(918mg,4.16mmol)、PdCl2(dppf)(226mg,0.277mmol)及びCs2CO3(2.71g,8.31mmol)を脱気し、アルゴンを再充填した後、窒素下でジオキサン(20mL)と水(4mL)に溶解した。反応混合物を室温で一晩撹拌後、EtOAcで希釈し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 95/5/0.5)により精製し、標記化合物を得た(540mg,39%,2段階)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−3−カルボニトリル(299mg,0.647mmol)のTHF(6.5mL)溶液を水(3mL)中でLiOH・H2O(109mg,2.59mmol)により処理し、2日間加熱還流した。冷却後、残渣を水(20mL)で希釈し、Et2O(20mL)で洗浄した。水相を1N HCl(7mL)の氷水(70mL)溶液に撹拌下にゆっくりと加え、白色固体を濾取し、50℃で減圧乾燥後に標記化合物を得た(157mg,70%)。
5−(6−アミノピリミジン−4−イル)−2−フェニル−1H−ピロール−3−カルボキサミド(化合物38)
工程4:2−フェニル−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−3−カルボン酸エチル(VIII)
アルゴン下で−78℃にて2−フェニル−1−(フェニルスルホニル)−1H−ピロール−3−カルボン酸エチル(440mg,1.24mmol)と2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.303mL,1.2mmol)のTHF(1.9mL)溶液にLDA(2M THF/ヘプタン/エチルベンゼン溶液,1.61mL,3.22mmol)をゆっくりと滴下した。50分後にMeOH(1mL)を加え、昇温し、室温でNH4Cl溶液(2mL)を滴下した。反応液を水で希釈し、Et2Oで抽出し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて標記化合物を得、それ以上精製せずに使用した。
2−フェニル−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−3−カルボン酸エチル(1.24mmol)、6−ヨードピリミジン−4−アミン(411mg,1.86mmol)、PdCl2(dppf)(101mg,0.124mmol)及びNa2CO3(394mg,3.72mmol)を脱気し、アルゴンを再充填した後、窒素下でジオキサン(12mL)と水(1.9mL)に溶解した。反応混合物を室温で一晩撹拌後、EtOAcで希釈し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 95/5/0.5)により精製し、標記化合物を得た(240mg,43%,2段階)。
5−(6−アミノピリミジン−4−イル)−2−フェニル)−1−(フェニルスルホニル)−1H−ピロール−3−カルボン酸エチル(290mg,0.647mmol)のTHF(6.5mL)溶液をLiOH・H2O(109mg,2.59mmol)の水(3mL)溶液で処理し、2日間加熱還流した。冷却後、残渣を水(20mL)で希釈し、Et2O(20mL)で洗浄した。水相を1N HCl(7mL)の氷水(70mL)溶液に撹拌下にゆっくりと加え、白色固体を濾取し、50℃で減圧乾燥後に標記化合物を得た(153mg,85%)。
5−(6−アミノピリミジン−4−イル)−2−フェニル−1H−ピロール−3−カルボン酸(40mg,0.143mmol)をDMF(0.5mL)とDIPEA(99μL,0.571mmol)に溶解した溶液を0℃で撹拌した。EDCI(55mg,0.286mmol)とHOBT・NH3(44mg,0.286mmol)を加え、反応混合物を室温で一晩撹拌した。混合物を飽和NaHCO3溶液(20mL)で希釈し、EtOAc(50mL)で抽出し、Na2SO4で乾燥し、濾過した。溶媒を減圧蒸発させ、粗生成物をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 9/1/0.1)により精製し、標記化合物を得た(35mg,89%)。
1H NMR(600MHz,DMSO−d6)δ 11.77(br.s.,1H),8.36(br.s.,1H),7.62−7.65(m,2H),7.37−7.42(m,2H),7.32−7.36(m,1H),7.30(br.s.,1H),7.26(br.s.,1H),7.18(br.s.,1H),6.80(br.s.,2H),2.82(d,J=4.58Hz,3H)。
ESI(+)MS:m/z 304(MH+)。
1H NMR(600MHz,DMSO−d6)δ 11.77(br.s.,1H),8.33(d,J=0.9Hz,1H),7.83(q,J=4.2Hz,1H),7.60−7.67(m,2H),7.35−7.40(m,2H),7.28−7.34(m,1H),7.14(s,1H),6.76(s,2H),6.73(d,J=1.1Hz,1H),2.67(d,J=4.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 11.78(br.s.,1H),8.37(br.s.,1H),7.83(d,J=4.58Hz,1H),7.59−7.66(m,2H),7.37−7.41(m,2H),7.33(d,J=7.33Hz,1H),7.21(br.s.,2H),6.81(br.s.,1H),2.83(d,J=4.58Hz,3H),2.67(d,J=4.58Hz,3H)。
ESI(+)MS:m/z 318(MH+)。
4−(6−アミノピリミジン−4−イル)−1−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボニトリル(化合物44)
工程8:1−(5−クロロ−2−メチルフェニル)−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボニトリル(XIII)
アルゴン下で−78℃にて4−ブロモ−1−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボニトリル(591mg,2.0mmol)のTHF(10mL)溶液に2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.446mL,2.2mmol)を加えた。n−BuLi(2.5Mヘキサン溶液,0.88mL,2.2mmol)を−78℃でゆっくりと滴下した。混合物を−78℃で1時間撹拌した。MeOH(1.0mL)を加え、得られた混合物をゆっくりと昇温した後に室温で撹拌した。NH4Cl溶液(10mL)を加え、混合物をEtOAc(3×30mL)で抽出し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、減圧蒸留し、それ以上精製せずに次工程で使用した。
50mL容丸底フラスコに撹拌棒、冷却器及びアルゴンと真空に接続した三方弁を装着し、室温で前工程からの1−(5−クロロ−2−メチルフェニル)−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボニトリル、6−ヨードピリミジン−4−アミン(663mg,3.0mmol)、2M Na2CO3(3.0mL,6.0mmol)及びジオキサン(20mL)を仕込んだ。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、PdCl2(dppf)(163mg,0.2mmol)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、110℃まで1時間昇温した。反応混合物を室温まで冷却し、セライトパッドで濾過し、EtOAcで洗浄し、濾液を濃縮後、EtOAcと水で希釈した。2層を分離し、水層をEtOAcで抽出した。有機画分を合わせてブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 95/5/0.5)により精製し、標記化合物を得た(291mg,47%,2段階)。
1H NMR(600MHz,DMSO−d6)δ 8.38(br.s.,1H),8.01(br.s.,1H),7.71(br.s.,1H),7.66(d,J=2.0Hz,1H),7.58(dd,J=2.2,8.4Hz,1H),7.52(d,J=8.4Hz,1H),7.25(br.s.,1H),6.72(br.s.,1H),2.82(d,J=4.4Hz,3H),2.10(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.52(s,1H),8.49(d,J=1.6Hz,1H),8.11(dd,J=1.3,2.6Hz,1H),8.07(d,J=1.8Hz,1H),7.77(d,J=2.3,1H),7.62(dd,J=2.3,8.3Hz,1H),7.56(d,J=8.3Hz,1H),7.50(dd,J=1.3,4.8Hz,1H),7.03−7.09(m,1H),2.14(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.33(s,1H),7.97(d,J=1.5Hz,1H),7.65(s,1H),7.61−7.64(m,1H),7.55(d,J=8.4Hz,1H),6.81(s,2H),6.65(s,1H)2.39(q,J=7.3Hz,2H),1.04(t,J=7.3Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.38(br.s.,1H),8.02(br.s.,1H),7.71(br.s.,1H),7.66(d,J=2.0Hz,1H),7.63(dd,J=2.2,8.4Hz,1H),7.56(d,J=8.4Hz,1H),7.25(br.s.,1H),6.72(br.s.,1H),2.82(d,J=4.4Hz,3H),2.39(q,J=7.33Hz,2H),1.04(t,J=7.3Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.52(s,1H),8.51(d,J=1.8Hz,1H),8.11(dd,J=1.3,2.6Hz,1H),8.07(d,J=1.6Hz,1H),7.77(d,J=2.2Hz,1H),7.67(dd,J=2.2,8.4Hz,1H),7.59(d,J=8.4Hz,1H),7.49(d,J=4.8Hz,1H),7.06(dd,J=2.6,4.8Hz,1H),2.39−2.46(q,J=7.1Hz,2H),1.06(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.34(d,J=0.9Hz,1H),8.27(s,1H),8.07(d,J=1.8Hz,1H),7.94−8.06(m,2H),7.72(d,J=1.6Hz,1H),6.84(br.s.,2H),6.67(d,J=1.1Hz,1H)。
1H NMR(600MHz,DMSO−d6)δ 8.39(br.s.,1H),8.26(br.s.,1H),8.10(br.s.,1H),8.03(br.s.,2H),7.77(br.s.,1H),7.28(br.s.,1H),6.73(br.s.,1H),2.82(d,J=4.4Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.62(d,J=1.6Hz,1H),8.54(s,1H),8.40(s,1H),8.10−8.14(m,2H),8.08(br.s.,2H),7.45−7.50(m,1H),7.08(dd,J=2.56,4.58Hz,1H)。
ESI(+)MS:m/z 344(MH+)。
ESI(+)MS:m/z 358(MH+)。
工程8で4−ブロモ−1−[2−エチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−2−カルボニトリルから出発した以外はこの手順に従い、以下の化合物を製造した。
1H NMR(600MHz,DMSO−d6)δ 8.31−8.36(m,1H),8.03(d,J=1.65Hz,1H),7.87−7.96(m,2H),7.78(d,J=8.61Hz,1H),7.68(d,J=1.65Hz,1H),6.82(s,2H),6.66(d,J=1.10Hz,1H),2.52(q,J=7.3Hz,2H),1.08(t,J=7.3Hz,3H)。
ESI(+)MS:m/z 372(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 262(MH+)。
ESI(+)MS:m/z 276(MH+)。
ESI(+)MS:m/z 286(MH+)。
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(9H−プリン−6−イル)−1H−ピロール−2−カルボニトリル(化合物62)
工程8:1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボニトリル(XIII)
アルゴン下で−78℃にて4−ブロモ−1−[2−クロロ−5−(トリフルオロメチル)フェニル]−1H−ピロール−2−カルボニトリル(349mg,1.0mmol)のTHF(4mL)溶液に2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.230mL,1.1mmol)を加えた。−78℃にてn−BuLi(2.5Mヘキサン溶液,0.440mL,1.1mmol)をゆっくりと滴下した。混合物を−78℃で1時間撹拌した。MeOH(0.5mL)を加え、得られた混合物をゆっくりと昇温後に室温で撹拌した。NH4Cl溶液(5mL)を加え、混合物を水で希釈し、EtOAc(30mL)で抽出し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、減圧蒸留し、それ以上精製せずに次工程で使用した。
50mL容丸底フラスコに撹拌棒、冷却器及びアルゴンと真空に接続した三方弁を装着し、室温で前工程からの1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボニトリル、6−クロロ−9−(4−メトキシベンジル)−9H−プリン(412mg,1.5mmol)、2M Na2CO3(1.5mL,3.0mmol)及びジオキサン(8mL)を仕込んだ。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、PdCl2(dppf)(81.6mg,0.1mmol)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、110℃まで2時間昇温した。反応混合物を室温まで冷却し、セライトパッドで濾過し、EtOAcで洗浄し、濾液を濃縮後、EtOAcと水で希釈した。2層を分離し、水層をEtOAcで抽出した。有機画分を合わせてブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(ヘキサン中30%→50% EtOAcでグラジエント溶出)により精製し、1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−[9−(4−メトキシベンジル)−9H−プリン−6−イル]−1H−ピロール−2−カルボニトリルを得た(178mg,35%,2段階)。
1H NMR(400MHz,DMSO−d6)δ 12.13(br.s.,1H),8.72(br.s.,1H),8.32(d,J=1.7Hz,1H),8.01(d,J=1.7Hz,1H),7.72(d,J=2.2Hz,1H),7.51−7.65(m,3H),7.09(dd,J=1.6,3.6Hz,1H),2.14(s,3H)。
ESI(+)MS:m/z 333(MH+)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 336(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.13(br.s.,1H),8.72(s,1H),8.33(d,J=1.8Hz,1H),8.01(d,J=1.65Hz,1H),7.73(d,J=2.2Hz,1H),7.63−7.67(m,1H),7.56−7.61(m,3H),7.08(dd,J=1.6,3.6Hz,1H),2.43(q,J=7.3Hz,2H),1.06(t,J=7.5Hz,3H)。
ESI(+)MS:m/z 349(MH+)。
ESI(+)MS:m/z 349(MH+)。
ESI(+)MS:m/z 350(MH+)。
1H NMR(400MHz,DMSO−d6)δ 12.15(br.s.,1H),8.73(s,1H),8.45(d,J=1.7Hz,1H),8.36(d,J=0.8Hz,1H),8.03−8.09(m,3H),7.61(dd,J=2.4,3.5Hz,1H),7.07(dd,J=1.7,3.6Hz,1H)。
ESI(+)MS:m/z 389(MH+)。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 369(MH+)。
ESI(+)MS:m/z 369(MH+)。
ESI(+)MS:m/z 370(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 383(MH+)。
ESI(+)MS:m/z 383(MH+)。
ESI(+)MS:m/z 384(MH+)。
ESI(+)MS:m/z 286(MH+)。
ESI(+)MS:m/z 287(MH+)。
ESI(+)MS:m/z 287(MH+)。
ESI(+)MS:m/z 288(MH+)。
1−(6−アミノピリミジン−4−イル)−4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(化合物87)
反応温度を10℃未満に維持しながら、NaH(60%油分散物,60mg,1.5mmol)の無水THF(4mL)懸濁液に4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(216mg,1mmol)のTHF(4mL)溶液を5℃にて20分間かけて滴下した。懸濁液を5℃で60分間撹拌した。反応温度を10℃未満に維持しながら、4,6−ジクロロピリミジン(179mg,1.2mmol)のTHF(4mL)溶液を10分間かけて滴下した。反応混合物を室温まで昇温し、一晩撹拌した。反応混合物をNH4Cl溶液に注ぎ、EtOAc(2×30mL)で抽出した。有機層を合わせて水、ブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させた。残渣をBiotage SP1フラッシュクロマトグラフィー(ヘキサン/EtOAc 8/2)により精製し、4−(5−クロロ−2−メチルフェニル)−1−(6−クロロピリミジン−4−イル)−1H−ピロール−3−カルボニトリルを得た(203mg,62%)。
1H NMR(600MHz,DMSO−d6)δ 8.79(d,J=2.2Hz,1H),8.10(d,J=2.2Hz,1H),7.45(s,1H),7.41(s,2H),2.32(s,3H)。
ESI(+)MS:m/z 324(MH+)。
HRMS(ESI)C18H16ClN5+H+の計算値338.1167,実測値338.1169。
HRMS(ESI)C16H9ClF3N5+H+の計算値364.0572,実測値364.0575。
HRMS(ESI)C17H11ClF3N5+H+の計算値378.0728,実測値378.0731。
ESI(+)MS:m/z 344(MH+)。
ESI(+)MS:m/z 358(MH+)。
HRMS(ESI)C18H14F3N5+H+の計算値358.1274,実測値358.1270。
ESI(+)MS:m/z 372(MH+)。
ESI(+)MS:m/z 262(MH+)。
ESI(+)MS:m/z 276(MH+)。
4−(5−クロロ−2−メチルフェニル)−1−(ピロロ[2,1−f][1,2,4]トリアジン−4−イル)−1H−ピロール−3−カルボニトリル(化合物99)
反応温度を10℃未満に維持しながら、NaH(60%油分散物,60mg,1.5mmol)の無水THF(4mL)懸濁液に4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(216mg,1mmol)のTHF(4mL)溶液を5℃にて20分間かけて滴下した。懸濁液を5℃で60分間撹拌した。4−クロロピロロ[2,1−f][1,2,4]トリアジン(183mg,1.2mmol)を加え、反応液を2時間還流下で撹拌した。反応混合物をNH4Cl溶液に注ぎ、EtOAc(2×30mL)で抽出した。有機層を合わせて水、ブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させた。残渣をBiotage SP1フラッシュクロマトグラフィー(ヘキサン/EtOAc 85/15)により精製し、標記化合物を得た(183mg,55%)。
HRMS(ESI)C19H14ClN5+H+の計算値348.1011,実測値348.1013。
HRMS(ESI)C18H9ClF3N5+H+の計算値388.0572,実測値388.0568。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 286(MH+)。
4−(5−クロロ−2−メチルフェニル)−1−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボニトリル(化合物105)
4−クロロ−7−{[2−(トリメチルシリル)エトキシ]メチル}−7H−ピロロ[2,3−d]ピリミジン(157mg,0.55mmol)、Cs2CO3(223mg,0.69mmol)、4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(100mg,0.46mmol)及び無水トルエン(2.5mL)を室温で仕込んだ。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、Pd2(dba)3(10mg,0.011mmol)とトリ−tert−ブチルホスフィン(23μL,0.023mmol,1.0Mトルエン溶液)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、100℃まで6時間昇温した。反応混合物を濃縮し、Biotage SP1フラッシュクロマトグラフィー(ヘキサン中10%→20% EtOAcでグラジエント溶出)により精製し、4−(5−クロロ−2−メチルフェニル)−1−(7−{[2−(トリメチルシリル)エトキシ]メチル}−7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボニトリルを得た(110mg,51%)。
ESI(+)MS:m/z 333(MH+)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 335(MH+)。
ESI(+)MS:m/z 336(MH+)。
HRMS(ESI)C19H14ClN5+H+の計算値348.1011,実測値348.1015。
ESI(+)MS:m/z 350(MH+)。
HRMS(ESI)C18H9ClF3N5+H+の計算値388.0572,実測値388.0575。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 370(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 384(MH+)。
ESI(+)MS:m/z 286(MH+)。
ESI(+)MS:m/z 288(MH+)。
5−(6−アミノピリミジン−4−イル)−3−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボキサミド(化合物120)
工程11:3−(5−クロロ−2−メチルフェニル)−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボン酸エチル(XVI)
アルゴン下で−78℃にて3−(5−クロロ−2−メチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−2−カルボン酸エチル(403mg,1.0mmol)のTHF(5mL)溶液にLDA(2M THF/ヘプタン/エチルベンゼン溶液,0.55mL,1.1mmol)をゆっくりと滴下した。30分後に、2−イソプロポキシ−4,4,5,5−テトラメチル−1,3,2−ジオキシボロラン(0.230mL,1.1mmol)を−78℃で混合物に加え、1時間撹拌した。MeOH(0.5mL)を加え、得られた混合物をゆっくりと昇温後に室温で撹拌し、水で希釈し、EtOAc(30mL×3)で抽出し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させて標記化合物を得、それ以上精製せずに使用した。
3−(5−クロロ−2−メチルフェニル)−1−(フェニルスルホニル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−2−カルボン酸エチル、6−ヨードピリミジン−4−アミン(221mg,1mmol)及びNa2CO3(318mg,3mmol)をジオキサン/水(3/1,10mL)に溶解した。得られた反応混合物を3回脱気し、その都度アルゴンを再充填した後、PdCl2(dppf)(81mg,0.1mmol)を加えた。得られた反応混合物を4回脱気し、その都度アルゴンを再充填した後、110℃まで30分間昇温した。反応混合物を室温まで冷却し、セライトパッドで濾過し、EtOAcで洗浄した。濾液を濃縮後、EtOAcで希釈し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、減圧濃縮した。残渣をBiotage SP1フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 98/2/0.2)により精製し、標記化合物を得た(198mg,40%)。
1H NMR(600MHz,DMSO−d6)δ 8.78(s,1H),8.35(dd,J=1.19,8.52Hz,2H),7.80−7.85(m,2H),7.70−7.78(m,2H),7.35−7.40(m,1H),7.32−7.34(m,1H),7.31(d,J=2.20Hz,1H),7.09(s,1H),6.88(d,J=3.66Hz,1H),6.27(s,2H),4.09(q,J=7.14Hz,2H),2.17(s,3H),1.11(s,9H),0.92(t,J=7.05Hz,3H)。
ESI(+)MS:m/z 511(MH+)。
1H NMR(600MHz,DMSO−d6)δ 8.79(s,1H),8.33(dd,J=1.01,8.52Hz,2H),7.80−7.85(m,2H),7.70−7.78(m,2H),7.39−7.44(m,1H),7.31−7.38(m,1H),7.27(d,J=2.20Hz,1H),7.09(s,1H),6.83(d,J=3.66Hz,1H),6.27(s,2H),3.99−4.10(m,2H),1.11(s,9H),1.02−1.07(m,3H),0.88(t,J=7.14Hz,3H)。
ESI(+)MS:m/z 545(MH+)。
1H NMR(600MHz,DMSO−d6)δ 8.79(s,1H),8.28−8.45(m,2H),7.81−7.87(m,2H),7.73−7.78(m,2H),7.72(d,J=8.0Hz,1H),7.58(d,J=8.0Hz,1H),7.54(s,1H),7.14(s,1H),6.84(d,J=3.6Hz,1H),6.27(s,2H),4.02(q,J=6.9Hz,2H),2.61(q,J=7.6Hz,2H),1.11(s,9H),1.06−1.10(m,3H),0.81(t,J=7.0Hz,3H)。
マイクロ波装置で150℃に15分間加熱下に、5−(6−アミノピリミジン−4−イル)−3−(5−クロロ−2−メチルフェニル)−1−(フェニルスルホニル)−1H−ピロール−2−カルボン酸エチル(80mg,0.161mmol)をTHF(0.5mL)中でLiOH・H2O(27mg,0.644mmol)により処理した。冷却後、残渣を濃縮し、1N HCl(300μL)で処理し、飽和炭酸水素ナトリウム溶液で中和し、得られた沈澱を濾取し、標記化合物を得た(52mg,98%)。
ESI(+)MS:m/z 343(MH+)。
ESI(+)MS:m/z 377(MH+)。
ESI(+)MS:m/z 353(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.42−12.89(m,1H),12.24(br.s.,1H),11.39(br.s.,1H),8.79(s,1H),7.62(dd,J=2.47,3.39Hz,1H),7.29−7.36(m,1H),7.25(d,J=2.01Hz,1H),7.19(s,1H),7.01(dd,J=1.65,3.48Hz,1H),2.52−2.56(m,2H),1.00−1.05(m,3H)。
ESI(+)MS:m/z 401(MH+)。
5−(6−アミノピリミジン−4−イル)−3−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボン酸(52mg,0.158mmol)をDMF(1.0mL)とDIPEA(55μL,0.634mmol)に溶解した溶液を0℃にて撹拌した。EDCI(60mg,0.317mmol)とHOBT・NH3(48mg,0.317mmol)を加え、反応混合物を室温で3時間撹拌した。混合物を5℃にて飽和炭酸水素ナトリウム溶液で希釈し、30分間撹拌し、得られた沈澱を濾取し、標記化合物を得た(42mg,80%)。
ESI(+)MS:m/z 342(MH+)。
ESI(+)MS:m/z 376(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.16(br.s.,1H),12.04(br.s.,1H),8.78(s,1H),7.63−7.76(m,1H),7.58(dd,J=2.38,3.48Hz,1H),7.24−7.27(m,2H),7.22(d,J=1.28Hz,1H),7.14−7.18(m,1H),7.12(s,1H),7.01(dd,J=1.74,3.57Hz,1H),2.14(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.17(br.s.,1H),12.03(br.s.,1H),8.78(s,1H),7.64(br.s.,1H),7.58(dd,J=2.38,3.48Hz,1H),7.26−7.33(m,2H),7.19(d,J=2.02Hz,1H),7.14(br.s.,1H),7.12(d,J=2.20Hz,1H),6.99(dd,J=1.83,3.66Hz,1H),1.01(t,J=7.51Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.17(br.s.,1H),12.14(br.s.,1H),8.79(s,1H),7.79(br.s.,1H),7.60(dd,J=1.28,8.06Hz,1H),7.58(dd,J=2.56,3.48Hz,1H),7.49(d,J=8.06Hz,1H),7.45(d,J=1.28Hz,1H),7.17(d,J=1.65Hz,1H),7.13(br.s.,1H),7.01(dd,J=1.74,3.57Hz,1H),2.60(q,J=7.51Hz,2H),1.05(t,J=7.51Hz,3H)。
ESI(+)MS:m/z 342(MH+)。
ESI(+)MS:m/z 356(MH+)。
ESI(+)MS:m/z 390(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.16(br.s.,1H),12.03(br.s.,1H),8.77(s,1H),8.29(q,J=4.15Hz,1H),7.58(dd,J=2.47,3.39Hz,1H),7.22−7.28(m,2H),7.21(d,J=1.65Hz,1H),7.13(d,J=2.01Hz,1H),7.01(dd,J=1.65,3.48Hz,1H),2.70(d,J=4.58Hz,3H),2.13(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.16(br.s.,1H),12.03(br.s.,1H),8.78(s,1H),8.27(q,J=4.33Hz,1H),7.57(dd,J=2.38,3.48Hz,1H),7.29−7.32(m,1H),7.26−7.28(m,1H),7.17(d,J=2.20Hz,1H),7.13(d,J=2.20Hz,1H),6.99(dd,J=1.65,3.66Hz,1H),2.69(d,J=4.58Hz,3H),2.45−2.48(m,1H),1.00(t,J=7.60Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.16(br.s.,1H),12.12(br.s.,1H),8.78(s,1H),8.38(q,J=4.03Hz,1H),7.59(dd,J=1.37,8.15Hz,1H),7.57(dd,J=2.47,3.39Hz,1H),7.49(d,J=8.06Hz,1H),7.44(d,J=1.10Hz,1H),7.17(d,J=1.65Hz,1H),7.01(dd,J=1.74,3.57Hz,1H),2.69(d,J=4.40Hz,3H),2.58(q,J=7.51Hz,2H),1.04(t,J=7.60Hz,3H)。
ESI(+)MS:m/z 342(MH+)。
ESI(+)MS:m/z 352(MH+)。
ESI(+)MS:m/z 354(MH+)。
ESI(+)MS:m/z 356(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 396(MH+)。
ESI(+)MS:m/z 406(MH+)。
ESI(+)MS:m/z 406(MH+)。
ESI(+)MS:m/z 408(MH+)。
ESI(+)MS:m/z 362(MH+)。
ESI(+)MS:m/z 376(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 388(MH+)。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
ESI(+)MS:m/z 280(MH+)。
ESI(+)MS:m/z 294(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 306(MH+)。
ESI(+)MS:m/z 356(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 368(MH+)。
ESI(+)MS:m/z 380(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 396(MH+)。
ESI(+)MS:m/z 410(MH+)。
ESI(+)MS:m/z 420(MH+)。
ESI(+)MS:m/z 420(MH+)。
ESI(+)MS:m/z 422(MH+)。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 404(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
ESI(+)MS:m/z 404(MH+)。
ESI(+)MS:m/z 414(MH+)。
ESI(+)MS:m/z 416(MH+)。
ESI(+)MS:m/z 294(MH+)。
ESI(+)MS:m/z 306(MH+)。
ESI(+)MS:m/z 318(MH+)。
ESI(+)MS:m/z 318(MH+)。
ESI(+)MS:m/z 320(MH+)。
4−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−N−メチル−1H−ピロール−1−カルボキサミド(化合物180)
工程15:2−(5−クロロ−2−メチルフェニル)−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−1−カルボン酸tert−ブチル(XX)
アルゴン下で−78℃にて2−(5−クロロ−2−メチルフェニル)−4−ヨード−1H−ピロール−1−カルボン酸tert−ブチル(442mg,1.06mmol)と4,4,5,5−テトラメチル−2−(プロパン−2−イルオキシ)−1,3,2−ジオキサボロラン(217mg,1.16mmol)を無水THF(1.6mL)中でn−BuLi(2Mヘキサン溶液,0.58mL,1.6mmol)により処理し、反応混合物を−78℃で撹拌した。2時間後にMeOH(1mL)を加え、昇温し、室温でNH4Cl溶液(2mL)を滴下した。溶液をジエチルエーテルで希釈し、水とブラインで順次洗浄した。有機層を無水Na2SO4で乾燥し、蒸発させて標記化合物を得、それ以上精製せずに後続反応で使用した。
粗生成物である2−(5−クロロ−2−メチルフェニル)−4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)−1H−ピロール−1−カルボン酸tert−ブチル(392mg,0.94mmol)、Na2CO3(250mg,2.36mmol)、PdCl2(dppf)(77mg,0.094mmol)及び6−ヨードピリミジン−4−アミン(311mg,1.41mmol)を脱気し、アルゴンパージし、脱気した1,4−ジオキサン(3mL)と水(1mL)に懸濁した。反応混合物を110℃(油浴温度)まで2時間加熱した。溶液をEtOAcで希釈し、水洗した。無水Na2SO4で乾燥後、有機層を蒸発させた。粗生成物をシリカゲルクロマトグラフィー(ヘキサン/EtOAc 8:2)により精製し、標記化合物を得た(220mg,58%)。
4−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−1−カルボン酸tert−ブチル(210mg,0.55mmol)をDCM(11mL)中でTFA(5.5mL)により処理した。反応混合物を室温で3日間撹拌した。揮発分を蒸発させ、得られた固形分をEtOHに懸濁し、pH9〜10になるまで30%水酸化アンモニウムで処理した。溶液をEtOAcで希釈し、先ず10%水酸化アンモニウム、次いでブラインで洗浄し、無水Na2SO4で乾燥後、有機層を蒸発させ、残った標記化合物をそれ以上精製せずに次工程で利用した。
トリホスゲン(97.5mg,0.325mmol)のDCM(7mL)溶液に6−[5−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−イル]ピリミジン−4−アミン(156mg,0.55mmol)のDCM(10mL)溶液を加えた後、DIPEA(373μL,2.15mmol)を加えた。3時間後にメチルアミン(2Mテトラヒドロフラン溶液,430μL,0.86mmol)とDIPEA(97μL,0.56mmol)のDCM(4mL)溶液を加えた。反応液を室温で一晩撹拌した。溶液をブラインで洗浄し、有機相をNa2SO4で乾燥し、濃縮した。粗生成物をフラッシュクロマトグラフィー(DCM/MeOH 90/10)により精製し、標記化合物を得た(120mg,64%,2段階)。
ESI(+)MS:m/z 356(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 356(MH+)。
ESI(+)MS:m/z 370(MH+)。
ESI(+)MS:m/z 380(MH+)。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 404(MH+)。
ESI(+)MS:m/z 414(MH+)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボキサミド(化合物189)
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(59mg,0.19mmol)のTFA(0.90mL)溶液に高効率撹拌下に水(0.11mL)と96%硫酸(0.22mL)を順次加えた。混合物を70℃で5時間撹拌後、水(1.5mL)を滴下して希釈した。撹拌下に30%アンモニア水を添加することにより反応混合物を塩基性(pH10〜12)にした。沈澱した固形分を濾取し、水洗し、最後に真空オーブンで50℃にて乾燥し、標記化合物をオフホワイト固体として得た(42mg,68%)。
1H NMR(400MHz,DMSO−d6)δ 11.91(br.s.,1H),8.35(s,1H),7.10−7.39(m,5H),6.52−6.78(m,2H),2.81(d,J=4.5Hz,3H),2.12(m,3H)。
1H NMR(400MHz,DMSO−d6)δ 12.16(br.s.,1H),12.08(br.s.,1H),8.66(s,1H),7.71(s,1H),7.61(dd,J=2.5,3.3Hz,1H),7.47(br.s.,1H),7.29−7.36(m,1H),7.21−7.28(m,1H),7.11(dd,J=1.6,3.5Hz,1H),6.79(br.s.,1H),2.14(s,3H)。
1H NMR(400MHz,DMSO−d6)δ 11.85(br.s.,1H),11.65(br.s.,1H),8.16(d,J=5.0Hz,1H),7.53(d,J=3.3Hz,1H),7.44(s,2H),7.39(d,J=5.1Hz,1H),7.27−7.38(m,4H),7.02(d,J=3.5Hz,1H),6.74(br.s.,1H),2.17(s,3H)。
1H NMR(500MHz,DMSO−d6)δ 12.21(br.s.,1H),8.78(s,1H),8.59(s,1H),7.99(d,J=2.20Hz,1H),7.33−7.38(m,1H),7.21−7.33(m,3H),6.82(br.s.,1H),2.16(s,3H)。
1H NMR(400MHz,DMSO−d6)δ 14.00(s,1H),12.47(br.s.,1H),8.82(s,1H),8.78(s,1H),7.93−7.98(m,1H),7.49(br.s.,1H),7.22−7.39(m,3H),6.90(br.s.,1H),2.14(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 11.67(s,1H),8.41(s,1H),8.02(dd,J=1.3,2.5Hz,1H),7.91(s,1H),7.54(br.s.,1H),7.47(dd,J=1.3,4.7Hz,1H),7.27−7.37(m,1H),7.16−7.27(m,2H),7.05(dd,J=2.5,4.6Hz,1H),6.85(br.s.,1H),2.10(s,3H)。
ESI(+)MS:m/z 354(MH+)。
1H NMR(600MHz,DMSO−d6)δ 11.94(br.s.,1H),8.31(d,J=0.9Hz,1H),7.37(dd,J=2.4,8.2Hz,1H),7.30(d,J=8.2Hz,1H),7.28(s,1H),7.21(d,J=2.4Hz,1H),7.16(br.s.,1H),6.76(s,1H),6.68(br.s.,1H),6.66(d,J=1.1Hz,1H),2.46(q,J=7.7Hz,2H),0.96(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 11.94(br.s.,1H),8.35(br.s.,1H),7.39(dd,J=2.3,8.3Hz,1H),7.34(br.s.,1H),7.31(d,J=8.2Hz,1H),7.23(d,J=2.0Hz,1H),7.17(br.s.,2H),6.73(br.s.,1H),6.68(br.s.,1H),2.80(br.s.,3H),2.46(q,J=7.6Hz,2H),0.97(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.17(br.s.,1H),12.08(br.s.,1H),8.65(s,1H),7.71(s,1H),7.61(dd,J=2.2,3.3Hz,1H),7.42(br.s.,1H),7.37(dd,J=2.3,8.4Hz,1H),7.29(d,J=8.4Hz,1H),7.23(d,J=2.3Hz,1H),7.00−7.14(m,1H),6.76(br.s.,1H),2.45(q,J=7.5Hz,2H),0.98(t,J=7.5Hz,3H)。
ESI(+)MS:m/z 367(MH+)。
ESI(+)MS:m/z 367(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 368(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.17(br.s.,1H),8.34(s,1H),7.65−7.81(m,3H),7.43(br.s.,1H),7.31(s,1H),6.89(br.s.,2H),6.76(br.s.,1H),6.66(s,1H)。
1H NMR(400MHz,DMSO−d6)δ 12.13(br.s.,1H),8.38(s,1H),7.62−7.87(m,3H),7.40(br.s.,1H),7.34(br.s.,1H),7.26(br.s.,1H),6.74(br.s.,1H),6.70(s,1H),2.82(d,J=4.39Hz,3H)。
HRMS(ESI)C18H11ClF3N5O+H+の計算値406.0677,実測値406.0679。
1H NMR(500MHz,DMSO−d6)δ 12.51(br.s.,1H),8.80(s,1H),8.60(s,1H),8.03(d,J=1.9Hz,1H),7.68−7.81(m,3H),7.56(br.s.,1H),6.83(br.s.,1H)。
1H NMR(500MHz,DMSO−d6)δ 14.08(br.s.,1H),12.74(br.s.,1H),8.86(s,1H),8.79(s,1H),8.01(s,1H),7.69−7.82(m,3H),7.62(br.s.,1H),6.97(br.s.,1H)。
ESI(+)MS:m/z 406(MH+)。
ESI(+)MS:m/z 408(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.00(br.s.,1H),8.32(d,J=0.9Hz,1H),7.61(d,J=8.1Hz,1H),7.51(s,1H),7.47(d,J=7.9Hz,1H),7.32(br.s.,1H),7.30(s,1H),6.78(br.s.,1H),6.72(br.s.,1H),6.66(d,J=1.1Hz,1H),2.23(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 11.96(br.s.,1H),8.34(br.s.,1H),7.60(d,J=8.2Hz,1H),7.50(s,1H),7.44−7.48(m,1H),7.33(br.s.,1H),7.29(br.s.,1H),7.20(br.s.,1H),6.70(br.s.,2H),2.78(br.s.,3H),2.20(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.27(br.s.,1H),12.10(br.s.,1H),8.67(s,1H),7.75(s,1H),7.58−7.64(m,2H),7.55(br.s.,1H),7.54(s,1H),7.47(d,J=8.1Hz,1H),7.12(d,J=2.6Hz,1H),6.81(br.s.,1H),2.25(s,3H)。
ESI(+)MS:m/z 387(MH+)。
ESI(+)MS:m/z 387(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 388(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.00(br.s.,1H),8.31(d,J=1.10Hz,1H),7.64−7.68(m,1H),7.51(d,J=8.06Hz,1H),7.47(s,1H),7.31(s,1H),7.28(br.s.,1H),6.77(br.s.,2H),6.68(br.s.,1H),6.66(d,J=1.10Hz,1H),2.56(q,J=7.63Hz,2H),1.00(t,J=7.63Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.00(br.s.,1H),8.35(br.s.,1H),7.68(d,J=7.51Hz,1H),7.52(d,J=8.24Hz,1H),7.49(s,1H),7.36(br.s.,1H),7.27(br.s.,1H),7.20(br.s.,1H),6.70(br.s.,1H),6.68(br.s.,1H),2.81(br.s.,3H),2.56(q,J=7.60Hz,2H),1.01(t,J=7.60Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.27(br.s.,1H),12.09(br.s.,1H),8.66(s,1H),7.75(d,J=0.55Hz,1H),7.66(dd,J=1.28,8.24Hz,1H),7.62(d,J=3.11Hz,1H),7.44−7.55(m,2H),7.12(d,J=3.48Hz,1H),6.78(br.s.,1H),2.59(q,J=7.61Hz,2H),1.02(t,J=7.61Hz,3H)。
ESI(+)MS:m/z 401(MH+)。
ESI(+)MS:m/z 401(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.09(br.s.,1H),11.99(br.s.,1H),8.70(s,1H),7.66−7.73(m,2H),7.59−7.62(m,2H),7.53(br.s.,1H),7.36−7.41(m,2H),7.30−7.35(m,1H),7.09(dd,J=1.74,3.57Hz,1H),6.87(br.s.,1H)。
ESI(+)MS:m/z 306(MH+)。
4−(6−アミノピリミジン−4−イル)−1−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボキサミド(化合物227)
4−(6−アミノピリミジン−4−イル)−1−(5−クロロ−2−メチルフェニル)−1H−ピロール−2−カルボニトリル(32mg,0.103mmol)のTFA(0.512mL)溶液に高効率撹拌下に水(64μL)と95%硫酸(128μL)を順次加えた。混合物を70℃で4時間撹拌後、水(1.5mL)を滴下して希釈した。撹拌下に30%アンモニア水を添加することにより反応混合物を塩基性(pH10〜12)にした。沈澱した固形分を濾取し、水洗し、最後に真空オーブンで50℃にて乾燥し、標記化合物をオフホワイト固体として得た(18mg,53%)。
1H NMR(600MHz,DMSO−d6)δ 8.35(br.s.,1H),7.70(br.s.,1H),7.51(br.s.,1H),7.35−7.40(m,1H),7.26−7.35(m,2H),7.15(br.s.,1H),6.92(br.s.,1H),6.62(s,1H),2.81(d,J=3.8Hz,3H),1.94(s,3H)。
1H NMR(400MHz,DMSO−d6)δ 12.16(br.s.,1H),12.08(br.s.,1H),8.66(s,1H),7.71(s,1H),7.61(dd,J=2.5,3.3Hz,1H),7.47(br.s.,1H),7.29−7.36(m,1H),7.21−7.28(m,1H),7.11(dd,J=1.6,3.5Hz,1H),6.79(br.s.,1H),2.14(s,3H)。
ESI(+)MS:m/z 351(MH+)。
ESI(+)MS:m/z 353(MH+)。
1H NMR(400MHz,DMSO−d6)δ 13.97(s,1H),8.85(s,1H),8.80(s,1H),8.06(d,J=1.8Hz,1H),7.95(d,J=1.8Hz,1H),7.85(br.s.,1H),7.41−7.45(m,1H),7.40(d,J=2.0Hz,1H),7.36(d,J=8.2Hz,1H),7.06(br.s.,1H),1.98(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.46(s,1H),8.05(dd,J=1.3,2.5Hz,1H),8.02(d,J=1.8Hz,1H),7.90(d,J=1.8Hz,1H),7.88(br.s.,1H),7.48(dd,J=1.1,4.6Hz,1H),7.41−7.45(m,1H),7.40(d,J=2.0Hz,1H),7.36(d,J=8.4Hz,1H),7.06(br.s.,1H),7.02(dd,J=2.5,4.6Hz,1H),1.97(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.16(s,1H),7.75(br.s.,1H),7.54(d,J=1.6Hz,1H),7.36−7.42(m,1H),7.34(d,J=1.6Hz,1H),7.32(d,J=8.4Hz,1H),7.30(d,J=2.0Hz,2H),6.92(br.s.,1H),3.59(t,J=8.6Hz,2H),3.20(t,J=8.6Hz,2H),1.94(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.30(d,J=1.0Hz,1H),7.71(br.s.,1H),7.49(d,J=1.8Hz,1H),7.47(d,J=1.8Hz,1H),7.40−7.45(m,1H),7.33−7.38(m,1H),7.29(d,J=2.2Hz,1H),6.91(br.s.,1H),6.71(s,2H),6.57(d,J=1.1Hz,1H),2.25(dq,J=0.73,7.53Hz,1H),0.97(t,J=7.63Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.35(br.s.,1H),7.69(br.s.,1H),7.57(br.s.,1H),7.51(br.s.,1H),7.43(dd,J=2.3,8.3Hz,1H),7.36(d,J=8.2Hz,1H),7.30(d,J=2.2Hz,1H),7.15(br.s.,1H),6.91(br.s.,1H),6.62(s,1H),2.81(d,J=4.0Hz,3H),2.25(dq,J=2.5,7.5Hz,2H),0.98(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.03(br.s.,1H),8.66(s,1H),7.87(d,J=1.8Hz,1H),7.83(d,J=1.6Hz,2H),7.55(dd,J=2.6,3.5Hz,1H),7.45(dd,J=2.2,8.4Hz,1H),7.38(d,J=8.4Hz,1H),7.36(d,J=2.2Hz,1H),7.07(dd,J=1.6,3.5Hz,1H),6.96(br.s.,1H),2.29(dq,J=2.5,7.5Hz,2H),1.00(t,J=7.5Hz,3H)。
ESI(+)MS:m/z 367(MH+)。
ESI(+)MS:m/z 367(MH+)。
1H NMR(600MHz,DMSO−d6)δ 8.46(s,1H),7.98−8.10(m,2H),7.90(d,J=1.8Hz,1H),7.88(br.s.,1H),7.44−7.51(m,2H),7.34−7.41(m,2H),7.04(br.s.,1H),7.02(dd,J=2.6,4.6Hz,1H),2.21−2.34(m,2H),1.00(t,J=7.5Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.41(br.s.,1H),7.81(br.s.,1H),7.60(br.s.,1H),7.44−7.52(m,2H),7.39(d,J=8.4Hz,1H),7.32(d,J=2.2Hz,1H),7.09(s,1H),3.79(br.s.,2H),2.18−2.32(m,2H),0.98(t,J=7.6Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 8.31(d,J=1.1Hz,1H),7.87(s,1H),7.81−7.84(m,2H),7.79(br.s.,1H),7.63(d,J=1.6Hz,1H),7.53(d,J=1.6Hz,1H),6.96(br.s.,1H),6.75(br.s.,2H),6.59(d,J=1.1Hz,1H)。
1H NMR(600MHz,DMSO−d6)δ 8.36(br.s.,1H),7.88(s,1H),7.80−7.84(m,1H),7.76(br.s.,1H),7.60(br.s.,1H),7.57(br.s.,1H),7.19(br.s.,1H),6.96(br.s.,1H),6.63(s,1H),2.81(d,J=3.5Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.07(br.s.,1H),8.68(s,1H),7.99(d,J=1.6Hz,1H),7.92−7.97(m,2H),7.91(br.s.,1H),7.78−7.87(m,2H),7.57(dd,J=2.5,3.3Hz,1H),7.08(dd,J=1.6,3.6Hz,1H),7.04(br.s.,1H)。
1H NMR(500MHz,DMSO−d6)δ 12.51(br.s.,1H),8.80(s,1H),8.60(s,1H),8.03(d,J=1.9Hz,1H),7.68−7.81(m,3H),7.56(br.s.,1H),6.83(br.s.,1H)。
1H NMR(500MHz,DMSO−d6)δ 14.02(s,1H),8.87(s,1H),8.80(s,1H),8.23(d,J=1.4Hz,1H),8.00(s,2H),7.92(br.s.,1H),7.81−7.89(m,2H),7.12(br.s.,1H)。
1H NMR(500MHz,DMSO−d6)δ 8.48(d,J=2.0Hz,1H),8.19(d,J=1.6Hz,1H),8.06(d,J=1.1Hz,1H),7.98(s,1H),7.96(d,J=1.6Hz,1H),7.94(br.s.,1H),7.82−7.88(m,2H),7.46−7.49(m,1H),7.09(br.s.,1H),7.04(dd,J=2.4,4.4Hz,1H)。
ESI(+)MS:m/z 408(MH+)。
ESI(+)MS:m/z 362(MH+)。
MS:m/z 376(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 387(MH+)。
ESI(+)MS:m/z 387(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 388(MH+)。
1H NMR(600MHz,DMSO−d6)δ 8.36(br.s.,1H),7.77(br.s.,1H),7.74(dd,J=1.28,7.88Hz,1H),7.57−7.64(m,2H),7.55(s,1H),7.51(d,J=1.83Hz,1H),6.95(br.s.,3H),6.61(s,1H),2.29−2.38(m,2H),1.02(t,J=7.60Hz,3H)。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 401(MH+)。
ESI(+)MS:m/z 401(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
ESI(+)MS:m/z 280(MH+)。
ESI(+)MS:m/z 294(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 306(MH+)。
1−(6−アミノピリミジン−4−イル)−4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボキサミド(化合物268)
1−(6−アミノピリミジン−4−イル)−4−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボニトリル(80mg,0.258mmol)のTFA(1.3mL)溶液に高効率撹拌下に水(0.16mL)と95%硫酸(0.32mL)を順次加えた。混合物を70℃で8時間撹拌後、水(2.0mL)を滴下して希釈した。撹拌下に30%アンモニア水を添加することにより反応混合物を塩基性(pH10〜12)にした。沈澱した固形分を濾取し、水洗し、最後に真空オーブンで50℃にて乾燥した。フラッシュクロマトグラフィー(DCM/MeOH 95/5)により精製し、標記化合物を得た(47mg,55%)。
1H NMR(600MHz,DMSO−d6)δ 8.35(br.s.,2H),7.73(br.s.,1H),7.43−7.56(m,1H),7.32(br.s.,1H),7.24−7.26(m,2H),7.21(s,1H),7.19(d,J=1.6Hz,1H),6.84(br.s.,1H),6.63(br.s.,1H),2.85(br.s.,3H),2.11−2.15(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.47(br.s.,1H),8.66(s,1H),8.47(d,J=2.2Hz,1H),7.78(d,J=2.2Hz,1H),7.71(br.s.,1H),7.61(br.s.,1H),7.21−7.29(m,3H),7.17(d,J=3.3Hz,1H),6.91(br.s.,1H),2.17(s,3H)。
ESI(+)MS:m/z 351(MH+)。
ESI(+)MS:m/z 353(MH+)。
HRMS(ESI)m/z C17H13ClN6O+H+の計算値353.0912,実測値353.0909。
1H NMR(600MHz,DMSO−d6)δ 8.48(s,1H),8.46(d,J=2.2Hz,1H),8.25(d,J=1.3Hz,1H),7.80(d,J=2.2Hz,1H),7.68(br.s.,1H),7.62(d,J=4.2Hz,1H),7.26−7.29(m,1H),7.21−7.26(m,2H),7.15(dd,J=2.7,4.6Hz,1H),7.00(br.s.,1H),2.16(s,3H)。
HRMS(ESI)m/z C18H16ClN5O+H+の計算値354.1116,実測値354.1120。
HRMS(ESI)C17H16ClN5O+H+の計算値342.1116,実測値342.1113。
HRMS(ESI)C18H15ClN5O+H+の計算値356.1273,実測値356.1267。
HRMS(ESI)C19H16ClN5O+H+の計算値366.1116,実測値366.1119。
HRMS(ESI)C19H16ClN5O+H+の計算値366.1116,実測値366.1111。
HRMS(ESI)C19H18ClN5O+H+の計算値368.1273,実測値368.1277。
HRMS(ESI)C16H11ClF3N5O+H+の計算値382.0677,実測値382.0681。
HRMS(ESI)C17H13ClF3N5O+H+の計算値396.0834,実測値396.0838。
HRMS(ESI)C18H11ClF3N5O+H+の計算値406.0677,実測値406.0674。
HRMS(ESI)C17H10ClF3N6O+H+の計算値406.0677,実測値406.0676。
ESI(+)MS:m/z 408(MH+)。
ESI(+)MS:m/z 362(MH+)。
ESI(+)MS:m/z 376(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 386(MH+)。
ESI(+)MS:m/z 388(MH+)。
HRMS(ESI)C18H16F3N5O+H+の計算値376.1380,実測値376.1385。
ESI(+)MS:m/z 390(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
ESI(+)MS:m/z 280(MH+)。
ESI(+)MS:m/z 294(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 304(MH+)。
ESI(+)MS:m/z 306(MH+)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−N−メチル−1H−ピロール−3−カルボキサミド(化合物301)
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボキサミド(341mg,1.0mmol)をDMF(0.3mL)とTHF(6mL)に溶解した溶液を二炭酸ジ−tert−ブチル(1.309g,6mmol)とDMAP(15.8mg,0.13mmol)で処理した。室温で3時間後に反応混合物を水で希釈し、EtOAcで抽出した。有機層を合わせてブラインで洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させた。残渣をTHF(2mL)に溶解し、メチルアミン(2M THF溶液,2mL,4mmol)で処理し、室温で一晩撹拌した。反応混合物を濃縮し、DCM(5mL)に溶解し、TFA(5mL)で処理した。室温で3時間後に反応混合物を濃縮し、EtOAcで希釈し、10%アンモニアで洗浄した。有機相を分離し、ブライン水溶液で洗浄し、Na2SO4で乾燥し、濾過し、溶媒を減圧蒸発させた。フラッシュクロマトグラフィー(DCM/MeOH/MeOH中7N NH3 98/2/0.2)により精製し、標記化合物を得た(220mg,62%)。
1H NMR(600MHz,DMSO−d6)δ 11.96(br.s.,1H),8.36(br.s.,1H),7.75(d,J=4.76Hz,1H),7.39(dd,J=1.92,8.15Hz,1H),7.31(d,J=8.24Hz,2H),7.23(d,J=1.65Hz,2H),6.74(br.s.,1H),2.81(br.s.,3H),2.61(d,J=4.58Hz,4H),2.44(q,J=7.63Hz,2H),0.96(t,J=7.60Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.18(br.s.,1H),12.09(br.s.,1H),8.66(s,1H),7.93(q,J=4.21Hz,1H),7.68(d,J=1.10Hz,1H),7.60−7.64(m,J=2.93Hz,1H),7.36(dd,J=2.29,8.33Hz,1H),7.29(d,J=8.24Hz,1H),7.22(d,J=2.20Hz,1H),7.07(d,J=3.30Hz,1H),2.67(d,J=4.58Hz,3H),2.46(q,J=7.57Hz,2H),0.97(t,J=7.60Hz,3H)。
ESI(+)MS:m/z 380(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 342(MH+)。
ESI(+)MS:m/z 364(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 382(MH+)。
ESI(+)MS:m/z 396(MH+)。
ESI(+)MS:m/z 410(MH+)。
ESI(+)MS:m/z 420(MH+)。
ESI(+)MS:m/z 420(MH+)。
ESI(+)MS:m/z 422(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.00(br.s.,1H),8.32(d,J=1.10Hz,1H),7.85(q,J=4.40Hz,1H),7.58−7.63(m,1H),7.51(s,1H),7.47(d,J=8.24Hz,1H),7.28(d,J=1.10Hz,1H),6.79(s,2H),6.66(d,J=1.10Hz,1H),2.61(d,J=4.52Hz,3H),2.20(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 11.99(br.s.,1H),8.36(br.s.,1H),7.84(q,J=4.85Hz,1H),7.63(d,J=7.88Hz,1H),7.53(s,1H),7.44−7.50(m,1H),7.33(br.s.,1H),7.22(br.s.,1H),6.72(br.s.,1H),2.81(br.s.,3H),2.62(d,J=4.71Hz,3H),2.21(s,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.27(br.s.,1H),12.11(br.s.,1H),8.67(s,1H),8.01(q,J=4.46Hz,1H),7.71(d,J=1.28Hz,1H),7.64(dd,J=2.56,3.48Hz,1H),7.61(dd,J=1.37,8.15Hz,1H),7.54(s,1H),7.46(d,J=7.88Hz,1H),7.09(dd,J=1.83,3.48Hz,1H),2.69(d,J=4.40Hz,3H),2.23(s,3H)。
ESI(+)MS:m/z 400(MH+)。
ESI(+)MS:m/z 402(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.01(br.s.,1H),8.31(d,J=1.10Hz,1H),7.82(q,J=4.52Hz,1H),7.66(dd,J=1.56,8.15Hz,1H),7.50(d,J=8.24Hz,1H),7.47(s,1H),7.28(s,1H),6.78(s,2H),6.66(d,J=1.10Hz,1H),2.61(d,J=4.58Hz,3H),2.54(q,J=7.57Hz,2H),0.99(t,J=7.60Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.00(br.s.,1H),8.35(br.s.,1H),7.83(d,J=4.58Hz,1H),7.68(d,J=8.24Hz,1H),7.52(d,J=8.24Hz,1H),7.49(s,1H),7.33(br.s.,1H),7.20(br.s.,1H),6.72(br.s.,1H),2.81(br.s.,3H),2.61(d,J=4.58Hz,3H),2.55(q,J=7.63Hz,2H),1.00(t,J=7.60Hz,3H)。
1H NMR(600MHz,DMSO−d6)δ 12.27(br.s.,1H),12.11(br.s.,1H),8.66(s,1H),7.99(q,J=4.40Hz,1H),7.72(s,1H),7.66(dd,J=1.56,7.97Hz,1H),7.63−7.64(m,1H),7.51(br.s.,1H),7.49(br.s.,1H),7.08(dd,J=1.83,3.48Hz,1H),2.68(s,3H),2.57(q,J=7.51Hz,2H),1.01(t,J=7.60Hz,3H)。
ESI(+)MS:m/z 414(MH+)。
ESI(+)MS:m/z 416(MH+)。
1H NMR(600MHz,DMSO−d6)δ 12.10(br.s.,1H),11.99(br.s.,1H),8.70(s,1H),7.99(q,J=4.76Hz,1H),7.66−7.73(m,2H),7.61(dd,J=2.38,3.48Hz,1H),7.55(s,1H),7.36−7.40(m,2H),7.30−7.34(m,1H),7.06(dd,J=1.74,3.57Hz,1H),2.73(d,J=4.58Hz,3H)。
ESI(+)MS:m/z 320(MH+)。
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1−メチル−1H−ピロール−3−カルボキサミド(化合物328)
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボキサミド(98mg,0.3mmol)のDMF(1mL)溶液にCs2CO3(107mg,0.33mmol)とMeI(28μL,0.43mmol)を加えた。混合物を室温で3時間撹拌後、溶媒を除去した。残渣にEtOAcと水を加え、層分離し、水層をEtOAcで抽出し、有機層を合わせて水洗し、Na2SO4で乾燥し、濾過し、濃縮した。粗生成物をフラッシュクロマトグラフィー(DCM/MeOH/MeOH中NH3 95/5/0.5)により精製し、標記化合物を得た(43mg,42%)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 410(MH+)。
ESI(+)MS:m/z 372(MH+)。
ESI(+)MS:m/z 342(MH+)。
ESI(+)MS:m/z 366(MH+)。
ESI(+)MS:m/z 410(MH+)。
ESI(+)MS:m/z 372(MH+)。
JAKキナーゼ活性の阻害剤の生化学アッセイ
一般原理−33P−γ−ATPをトレーサとしてATPの存在下で特定のJAK2、JAK1又はJAK3ペプチド基質をJAKキナーゼによりトランスリン酸化する。リン酸化反応後に、未反応の未標識及び放射性標識ATPは過剰のダウエックスイオン交換樹脂に捕捉され、最終的に樹脂は重力により反応プレートの底に沈降する。その後、上清を回収し、計数用プレートに注入後、β線計数により評価する。
酵素−予めリン酸化せずに線形反応速度を示した市販のJAK2キナーゼドメイン(Invitrogen,Eugene,OR)を使用してアッセイを実施した。
酵素−JAK1キナーゼドメイン(UniProtKB/Swiss−Protデータベースのアクセッション番号P23458である1154アミノ酸長全長配列の残基861〜1152)を使用してアッセイを実施した。
酵素−予めリン酸化せずに線形反応速度を示したJAK3キナーゼドメイン(UniProtKB/Swiss−Protデータベースのアクセッション番号P52333である1124アミノ酸長全長配列の残基781〜1124)を使用してアッセイを実施した。
酵素−予めリン酸化せずに線形反応速度を示したTYK2キナーゼドメイン(UniProtKB/Swiss−Protデータベースのアクセッション番号P29597である1187アミノ酸長全長配列の残基833〜1187)を使用してアッセイを実施した。
細胞株:10%ウシ胎仔血清(FBS)を加えたRPMI−1640培地−Glutamax(Gibco BRL,Gaithesburg,MD,米国)でJAK2依存性ヒト巨核芽球性白血病細胞株SET−2(DSMZ,Braunschweig,ドイツ)とJAK2非依存性ヒト慢性骨髄性白血病細胞株K562(ECACC,Wiltshire,英国)を37℃、5%CO2下に培養した。IL−2依存性ヒトT細胞性リンパ腫細胞株DERL−7(DSMZ,Braunschweig,ドイツ)を使用し、IL−2により活性化されたJAK1/JAK3キナーゼに対する細胞中の化合物の活性を試験した。DERL−7細胞株は20% FBSと20ng/mlヒトIL−2(Sigma−Aldrich,St.Louis,MO,米国)を加えたRPMI−1640培地−Glutamax(Gibco BRL,Gaithesburg,MD,米国)で培養した。
予めγ線照射(200Radγ線全身照射)しておいた5〜6週齢雌性重症複合型免疫不全症(SCID)マウス(Charles River)に急性巨核芽球性白血病細胞株SET−2(細胞107個)を皮下接種した。触知可能な腫瘍(100〜200mm3)をもつマウスに溶媒(0.5% Methocel)又は式(I)の化合物を1日2回10日間投与した。ノギスを使用して定期的に腫瘍サイズを測定し、腫瘍増殖阻害率(TGI)を計算した。
Claims (9)
- 3−(5−クロロ−2−メチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物123);
3−(5−クロロ−2−エチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物124);
3−[2−エチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物125);
3−(5−クロロ−2−メチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物129);
3−(5−クロロ−2−エチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物130);
3−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物131);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1H−ピロール−3−カルボキサミド(化合物189);
2−(5−クロロ−2−メチルフェニル)−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物190);
2−(5−クロロ−2−メチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物191);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−1H−ピロール−3−カルボキサミド(化合物197);
2−(5−クロロ−2−エチルフェニル)−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物198);
2−(5−クロロ−2−エチルフェニル)−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物199);
5−(6−アミノピリミジン−4−イル)−2−[2−クロロ−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物204);
2−[2−クロロ−5−(トリフルオロメチル)フェニル]−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物205);
2−[2−クロロ−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物206);
5−(6−アミノピリミジン−4−イル)−2−[2−メチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物211);
5−[6−(メチルアミノ)ピリミジン−4−イル]−2−[2−メチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物212);
2−[2−メチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物213);
5−(6−アミノピリミジン−4−イル)−2−[2−エチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−3−カルボキサミド(化合物218);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物219);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物220);
1−(5−クロロ−2−メチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物229);
1−(5−クロロ−2−メチルフェニル)−4−(6,7−ジヒドロ−5H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物234);
4−(6−アミノピリミジン−4−イル)−1−(5−クロロ−2−エチルフェニル)−1H−ピロール−2−カルボキサミド(化合物235);
1−(5−クロロ−2−エチルフェニル)−4−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−2−カルボキサミド(化合物236);
1−(5−クロロ−2−エチルフェニル)−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物237);
1−(5−クロロ−2−エチルフェニル)−4−(6,7−ジヒドロ−5H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物241);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物244);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(9H−プリン−6−イル)−1H−ピロール−2−カルボキサミド(化合物245);
1−[2−クロロ−5−(トリフルオロメチル)フェニル]−4−(1H−ピラゾロ[3,4−d]ピリミジン−4−イル)−1H−ピロール−2−カルボキサミド(化合物246);
4−(6−アミノピリミジン−4−イル)−1−[2−エチル−5−(トリフルオロメチル)フェニル]−1H−ピロール−2−カルボキサミド(化合物256);
4−(5−クロロ−2−メチルフェニル)−1−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物270);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−エチルフェニル)−N−メチル−1H−ピロール−3−カルボキサミド(化合物301);
2−(5−クロロ−2−エチルフェニル)−N−メチル−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物302);
2−(5−クロロ−2−エチルフェニル)−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物303);
2−[2−メチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物318);
5−(6−アミノピリミジン−4−イル)−2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−1H−ピロール−3−カルボキサミド(化合物321);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−[6−(メチルアミノ)ピリミジン−4−イル]−1H−ピロール−3−カルボキサミド(化合物322);
2−[2−エチル−5−(トリフルオロメチル)フェニル]−N−メチル−5−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1H−ピロール−3−カルボキサミド(化合物323);
5−(6−アミノピリミジン−4−イル)−2−(5−クロロ−2−メチルフェニル)−1−(2−ヒドロキシエチル)−1H−ピロール−3−カルボキサミド(化合物331)及び
5−(6−アミノピリミジン−4−イル)−3−(5−クロロ−2−メチルフェニル)−1−(2−ヒドロキシエチル)−1H−ピロール−2−カルボキサミド(化合物335)
から成る群から選択される化合物又はその医薬的に許容可能な塩。 - 請求項1に記載の式(I)の化合物又はその医薬的に許容可能な塩の製造方法であって、
工程4:式(VII):
工程5:得られた式(VIII):
工程6:得られた式(IX):
工程7:得られた式(X):
NHR6R7(XI)
(式中、R6及びR7は請求項1に定義した通りである。)のアミン誘導体との反応によりアミド化し、式(Ia):
あるいは
工程11:式(XV):
工程12:得られた式(XVI):
工程13:得られた式(XVII):
工程14:得られた式(XVIII):
あるいは
工程15:式(XIX):
工程16:得られた式(XX):
工程17:得られた式(XXI):
工程18:得られた式(XXII):
場合により、
R2がCONH 2 である式(I)の化合物を、十分にtert−ブトキシカルボニル化し、式(XXIII):
NHR6R7 (XXIII)
(式中、R6及びR7は請求項1に定義した通りであるが、両方が水素ではない。)のアミン誘導体で処理し、tert−ブトキシカルボニル保護基を脱保護することにより、R2がCONR6R7(式中、R6及びR7は上記に定義した通りであるが、両方が水素ではない。)である式(I)の対応する化合物に変換:
;及び
所望により、式(I)の化合物をその医薬的に許容可能な塩に変換するか又は塩を遊離化合物(I)に変換する工程
を含むことを特徴とする方法。 - 治療有効量の請求項1に記載の式(I)の化合物又はその医薬的に許容可能な塩と、少なくとも1種の医薬的に許容可能な賦形剤、担体及び/又は希釈剤を含む医薬組成物。
- 1種以上の化学療法剤を更に含む、請求項4に記載の医薬組成物。
- JAKファミリーキナーゼ蛋白質活性のインビトロ阻害方法であって、前記蛋白質を有効量の請求項1に記載の式(I)の化合物と接触させる工程を含む方法。
- 抗癌療法で同時、別個又は順次使用するための併用製剤として、請求項1に記載の式(I)の化合物又はその医薬的に許容可能な塩と、1種以上の化学療法剤を含む製剤。
- 医薬用としての請求項1に記載の式(I)の化合物又はその医薬的に許容可能な塩。
- 抗癌活性を有する医薬の製造における請求項1に記載の式(I)の化合物又はその医薬的に許容可能な塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12178946 | 2012-08-02 | ||
EP12178946.5 | 2012-08-02 | ||
PCT/EP2013/065598 WO2014019908A2 (en) | 2012-08-02 | 2013-07-24 | Substituted pyrroles active as kinases inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015530980A JP2015530980A (ja) | 2015-10-29 |
JP6276762B2 true JP6276762B2 (ja) | 2018-02-07 |
Family
ID=48874299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015524721A Active JP6276762B2 (ja) | 2012-08-02 | 2013-07-24 | キナーゼ阻害剤として活性な置換ピロール類 |
Country Status (10)
Country | Link |
---|---|
US (4) | US9688661B2 (ja) |
EP (1) | EP2880025B1 (ja) |
JP (1) | JP6276762B2 (ja) |
CN (1) | CN104507923B (ja) |
BR (1) | BR112015002152B1 (ja) |
DK (1) | DK2880025T3 (ja) |
ES (1) | ES2726833T3 (ja) |
HK (1) | HK1208459A1 (ja) |
RU (1) | RU2666538C2 (ja) |
WO (1) | WO2014019908A2 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
BR112015002152B1 (pt) | 2012-08-02 | 2021-04-27 | Nerviano Medical Sciences S.R.L. | Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos |
CN106661002B (zh) | 2014-08-04 | 2021-06-29 | 纽韦卢森公司 | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物 |
MX2018000577A (es) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. |
TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
CN109310694A (zh) | 2016-04-04 | 2019-02-05 | 洛克索肿瘤学股份有限公司 | 治疗儿科癌症的方法 |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MA44610A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
HUE053643T2 (hu) | 2016-05-18 | 2021-07-28 | Loxo Oncology Inc | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése |
US10683292B2 (en) * | 2016-07-25 | 2020-06-16 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
RU2019108280A (ru) | 2016-08-24 | 2020-09-25 | Аркьюл, Инк. | Аминопирролопиримидиноновые соединения и способы их применения |
IT201600092469A1 (it) * | 2016-09-14 | 2018-03-14 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Blonanserina |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
GB201708457D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Inhibitors of metallo-beta-lactamases |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CN109020860B (zh) * | 2018-09-25 | 2021-06-22 | 宝鸡文理学院 | 一种2-芳基-3-酯基多取代吡咯类化合物及其合成精制方法 |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
AU2021212770A1 (en) * | 2020-01-30 | 2022-08-18 | Shangpharma Innovation Inc. | Strad-binding agents and uses thereof |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519603A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
WO2022055963A1 (en) | 2020-09-10 | 2022-03-17 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
CN116981669A (zh) * | 2021-02-05 | 2023-10-31 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
JP2024513040A (ja) | 2021-04-02 | 2024-03-21 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換されたピロールカルボサミド、それの製造方法及びそれのキナーゼ阻害薬としての使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407962B2 (en) * | 2003-02-07 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors or protein kinases |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US20110144128A1 (en) * | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
EP2348023B9 (en) * | 2005-12-13 | 2017-03-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
EP1968568A4 (en) * | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
NZ572202A (en) * | 2006-03-27 | 2012-05-25 | Nerviano Medical Sciences Srl | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
PE20090054A1 (es) * | 2007-01-23 | 2009-01-26 | Palau Pharma Sa | Derivados de purina |
UA101493C2 (ru) * | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
BR112015002152B1 (pt) | 2012-08-02 | 2021-04-27 | Nerviano Medical Sciences S.R.L. | Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos |
-
2013
- 2013-07-24 BR BR112015002152-2A patent/BR112015002152B1/pt active IP Right Grant
- 2013-07-24 EP EP13740288.9A patent/EP2880025B1/en active Active
- 2013-07-24 RU RU2015106787A patent/RU2666538C2/ru active
- 2013-07-24 CN CN201380040898.9A patent/CN104507923B/zh active Active
- 2013-07-24 WO PCT/EP2013/065598 patent/WO2014019908A2/en active Application Filing
- 2013-07-24 ES ES13740288T patent/ES2726833T3/es active Active
- 2013-07-24 JP JP2015524721A patent/JP6276762B2/ja active Active
- 2013-07-24 US US14/418,555 patent/US9688661B2/en active Active
- 2013-07-24 DK DK13740288.9T patent/DK2880025T3/en active
-
2015
- 2015-09-18 HK HK15109201.9A patent/HK1208459A1/xx unknown
-
2017
- 2017-05-18 US US15/598,976 patent/US10071986B2/en active Active
- 2017-05-18 US US15/599,025 patent/US10479778B2/en active Active
-
2018
- 2018-08-06 US US16/055,396 patent/US10479779B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10479778B2 (en) | 2019-11-19 |
BR112015002152B1 (pt) | 2021-04-27 |
US20150166512A1 (en) | 2015-06-18 |
WO2014019908A2 (en) | 2014-02-06 |
US10071986B2 (en) | 2018-09-11 |
US20180339978A1 (en) | 2018-11-29 |
US9688661B2 (en) | 2017-06-27 |
US20170253579A1 (en) | 2017-09-07 |
RU2015106787A (ru) | 2016-09-20 |
CN104507923B (zh) | 2018-02-09 |
ES2726833T3 (es) | 2019-10-09 |
US10479779B2 (en) | 2019-11-19 |
EP2880025B1 (en) | 2018-12-05 |
JP2015530980A (ja) | 2015-10-29 |
CN104507923A (zh) | 2015-04-08 |
WO2014019908A3 (en) | 2014-03-27 |
DK2880025T3 (en) | 2019-03-18 |
BR112015002152A2 (pt) | 2017-11-07 |
HK1208459A1 (en) | 2016-03-04 |
EP2880025A2 (en) | 2015-06-10 |
US20170253578A1 (en) | 2017-09-07 |
RU2666538C2 (ru) | 2018-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6276762B2 (ja) | キナーゼ阻害剤として活性な置換ピロール類 | |
JP6016915B2 (ja) | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール | |
RU2621732C2 (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
US11833153B2 (en) | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors | |
JP5998223B2 (ja) | キナーゼ阻害剤としての置換3,4−ジヒドロピロロ[1,2−a]ピラジン−1(2H)−オン誘導体 | |
JP2014503566A (ja) | 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用 | |
EP2702055A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160720 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170823 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6276762 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |